



US007351562B2

(12) **United States Patent**
Chatterjee et al.

(10) **Patent No.:** **US 7,351,562 B2**
(45) **Date of Patent:** **Apr. 1, 2008**

(54) **RIBULOSE 1,5-BISPHOSPHATE
CARBOXYLASE/OXYGENASE
POLYPEPTIDES AND RELATED
POLYNUCLEOTIDES**

(75) Inventors: **Ranjini Chatterjee**, Belmont, CA (US);
Michelle M. Chen, Belmont, CA (US);
Ranjan Patnaik, San Jose, CA (US);
Stephen L. Schmidt, Belmont, MA
(US)

(73) Assignee: **Codexis, Inc.**, Redwood City, CA (US)

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 265 days.

(21) Appl. No.: **10/425,332**

(22) Filed: **Apr. 28, 2003**

(65) **Prior Publication Data**

US 2004/0038262 A1 Feb. 26, 2004

Related U.S. Application Data

(60) Provisional application No. 60/375,910, filed on Apr.
26, 2002.

(51) **Int. Cl.**
C12N 9/12 (2006.01)
C12N 15/00 (2006.01)
C12P 21/06 (2006.01)
C07H 21/04 (2006.01)

(52) **U.S. Cl.** **435/189**; 435/69.1; 435/320.1;
536/23.2

(58) **Field of Classification Search** 435/183,
435/69.1, 252.1, 320.1; 536/23.1, 234
See application file for complete search history.

(56) **References Cited**

OTHER PUBLICATIONS

Andrews et al., Kinetics and subunit interactions of ribulose
bisphosphate carboxylase-oxygenase from cyanobacterium,
Synechococcus sp. JBC 256(16): 8445-8451, 1981.*

Shinozaki et al., Molecular cloning and sequence analysis of the
cyanobacterial gene for the large subunit of ribulose-1,5-
biphosphate carboxylase/oxygenase. PNAS., 1983, vol. 80: 4050-
4054.*

Shinozaki et al., Genes for the large and small subunits of ribulose-
1,5-biphosphate carboxylase/oxygenase constitute a single operon
in a cyanobacterium *Anacystis nidulans* 6301. Mol. Gen Genet.,
1985, vol. 200: 27-32.*

Shinozaki et al., Molecular cloning and sequence analysis of the
cyanobacterial gene for the large subunit of ribulose-1,5-
biphosphate carboxylase/oxygenase. PNAS., 1983, vol. 80: 4050-
4054.*

Broun et al., Catalytic plasticity of fatty acid modification enzymes
underlying chemical diversity of plant lipids. Science, 1998, vol.
282: 1315-1317.*

Witkowski et al., Conversion of b-ketoacyl synthase to a malonyl
decarboxylase by replacement of the active-site cysteine with
glutamine. Biochemistry, 1999, vol. 38: 11643-11650.*

Seffernick et al., Melamine deaminase and Atrazine
chlorohydrolase: 98 percent identical but functionally different. J.
Bacteriol., 2001, vol. 183 (8): 2405-2410.*

Whisstock et al., Prediction of protein function from protein
sequence and structure. Q. Rev. Biophys., 2003, vol. 36(3): 307-
340.*

Andrews et al., 1984, "Active-site Carbamate Formation and Reaction-
Intermediate-Analog Binding by Ribulosebisphosphate
Carboxylase/Oxygenase in the Absence of its Small Subunits,"
Proc. Natl. Acad. Sci. 81:3660-3664.

Badger et al., 1985, "A Model for HCO₃ Accumulation and Pho-
tosynthesis in the Cyanobacterium *Synechococcus* sp.," *Plant
Physiol.* 77:465-471.

Badger et al., 1982, "Photosynthesis and Inorganic Carbon Usage
by the Marine Cyanobacterium, *Synechococcus* sp.," *Plant Physiol.*
70:517-523.

Blanchard et al., 2003, "Current State of the Data in the
Cyanobacterium *Synechococcus* prepared for the DOE Genomes to
Life Project. Carbon Sequestration in *Synechococcus* Sp.: From
Molecular Machines to Hierarchical Modeling," *NGCR* pp. 1-9.

Crosbie et al., 2003, "Dispersal and Phylogenetic Diversity of
Nonmarine Picocyanobacteria, Inferred from 16S rRNA Gene and
cpcBA-Interhenic Spacer Sequence Analyses," *Applied and Envi-
ronmental Microbiology* 69(9):5716-5721.

Fuller et al., 2003, "Clade-Specific 16S Ribosomal DNA
Oligonucleotides Reveal the Predominance of a Single Marine
Synechococcus Clade throughout a Stratified Water Column in the
Red Sea," *Applied and Environmental Microbiology* 69(5):2430-
2443.

Giovannoni et al., 1988, "Evolutionary Relationships among
Cyanobacteria and Green Chloroplasts," *Journal of Bacteriology*
170(8):3584-3592.

Golden et al., 1989, "Genetic Relationship of Two Highly Studied
Synechococcus Strains Designed *Anacystis nidulans*," *Journal of
Bacteriology* 171(1):24-29.

Holtman et al., 2005, "High-Throughput Functional Analysis of the
Synechococcus elongates PCC 7942 Genome," *DNA Research*
12:103-115.

Honda et al., 1999, "Detection of Seven Major Evolutionary Lin-
eages in Cyanobacteria Based on the 16S rRNA Gene Sequence
Analysis with New Sequences of Five Marine *Synechococcus*
Strains," *J. Mol. Evol.* 48:723-739.

(Continued)

Primary Examiner—Rebecca E. Prouty
Assistant Examiner—Ganapathirama Raghu
(74) *Attorney, Agent, or Firm*—Dechert LLP

(57) **ABSTRACT**

The present invention relates to novel ribulose-1,5-bispho-
sphate carboxylase/oxygenase polypeptides and the poly-
nucleotides that encode them. The invention also provides
related host cells and methods.

9 Claims, 4 Drawing Sheets

OTHER PUBLICATIONS

- Ong et al., 1991, "Phycocerythins of Marine Unicellular Cyanobacteria," *J. Biol. Chem.* 266(15):9515-9527.
- Rasmussen et al., 1998, "Fingerprinting of Cyanobacteria Based on PCR with Primers Derived from Short and Long Tandemly Repeated Repetitive Sequences," *Applied and Environmental Microbiology* 64(1):265-272.
- Robertson et al., 2001, "Phylogenetic analyses of *Synechococcus* strains (cyanobacteria) using sequences of 16S rDNA . . ." *International Journal of Systematic and Evolutionary Microbiology* 51:861-871.
- Seo et al., 2003, "The Phylogenetic Relationships of Cyanobacteria inferred from 16S rRNA, gyrB, rpoC1 and rpoD1 gene sequences," *J. Gen. Appl. Microbiol.* 49:191-203.
- Shestakov, 2002, "Gene-Targeted and Site-Directed Mutagenesis of Photosynthesis Genes in Cyanobacteria," *Photosynthesis Research* 73:279-284.
- Shinozaki et al., 1983, "Molecular Cloning and Sequence Analysis of the Cyanobacterial Gene for the Large Subunit of Ribulose-1,5-bisphosphate carboxylase/oxygenase," *Proc. Natl. Acad. Sci.* 80:4050-4054.
- Stanier et al., 1971, "Purification and Properties of Unicellular Blue-Green Algae (Order Chroococcales)," *Bacteriological Reviews* 35(2):171-205.
- ATCC Product Description for *Synechococcus* sp.pp. 1-14, 2006.
- Ting et al., "Cyanobacterial Photosynthesis in the Oceans: the Origins and Significance of Divergent Light-Harvesting Strategies," *TRENDS in Microbiology* 10(3):134-142.
- Turner et al., "Molecular Phylogeny of Nitrogen-Fixing Unicellular Cyanobacteria," *Bol. Bull. Acad. Sin.* 42:181-186.
- Genebank Accession No. BAA03076 [gi:485794], Apr. 14, 2005.
- Genebank Accession No. CAE08233 [gi:33639225], Apr. 17, 2005.
- Genebank Accession No. ABB57456 [gi:81169116], Nov. 8, 2005.
- Genebank Accession No. Q8DIS5 [gi:81742950], Apr. 18, 2006.
- Genebank Accession No. P27568 [gi:132028], Apr. 18, 2006.
- Genebank Accession No. P00879 [gi:20141627], Jun. 27, 2006.
- Genebank Accession No. Q44176 [gi:3183143], Apr. 18, 2006.
- Genebank Accession No. P00880 [gi:59802957], Jun. 27, 2006.

* cited by examiner




Figure 1





Figure 2

Gene replacement vector 1 (pGR-1)

Synechocystis PCC 6803 rbc Replacement Vector



*Afl III generates compatible end with Nco I (both 5' and 3' flanking sequences contain Nco I site)

Figure 3

Whole Cell CO₂ Fixation Assay




FIGURE 4

1

**RIBULOSE 1,5-BISPHOSPHATE
CARBOXYLASE/OXYGENASE
POLYPEPTIDES AND RELATED
POLYNUCLEOTIDES**

CROSS-REFERENCE TO RELATED
APPLICATIONS

This application claims the benefit under 35 U.S.C. § 119(e) of U.S. Ser. No. 60/375,910, filed Apr. 26, 2002, which is incorporated herein in its entirety.

COPYRIGHT NOTIFICATION

A portion of the disclosure of this patent document contains material which is subject to copyright protection. The copyright owner has no objection to the facsimile reproduction by anyone of the patent document or patent disclosure, as it appears in the Patent and Trademark Office patent file or records, but otherwise reserves all copyright rights whatsoever.

FIELD OF THE INVENTION

The present invention relates to novel ribulose-1,5-bisphosphate carboxylase/oxygenase polypeptides and the polynucleotides that encode them.

BACKGROUND OF THE INVENTION

Carbon fixation, or the conversion of CO₂ to reduced forms amenable to cellular biochemistry, occurs by several metabolic pathways in diverse organisms. The most familiar of these is the Calvin Cycle (or "Calvin-Benson" cycle), which is present in cyanobacteria and their plastid derivatives (i.e., chloroplasts), as well as in proteobacteria. The Calvin cycle in these organisms utilizes the enzyme, ribulose-1,5-bisphosphate carboxylate/oxygenase ("Rubisco"). See, e.g., the world wide web at blc.Arizona.edu/courses/181gh/rick/photosynthesis/Calvin.html; Raven, et al. (1981) *The Biology of Plants*, 3rd Edition, Worth Publishers, Inc., NY, N.Y. Rubisco exists in at least two forms: Form I Rubisco, which is found in proteobacteria, cyanobacteria, and plastids; and Form II Rubisco, which is found in proteobacteria. Form I Rubisco is encoded by two genes encoding large and small subunits (rbcL and rbcS), and may exist as an octo-dimer composed of eight large subunits (rbcL) and eight small subunits (rbcS). Form II Rubisco is a dimeric form of the enzyme. Form II Rubisco has clear similarities to the large subunit of Form I Rubisco, and is encoded by a single gene, also referred to as rbcL. The evolutionary origin of the small subunit of Form I Rubisco remains uncertain; it is less highly conserved than the large subunit, and may have cryptic homology to a portion of the Form II protein.

All photosynthetic organisms catalyze the fixation of atmospheric CO₂ by the bifunctional enzyme Rubisco. Significant variations in kinetic properties of this enzyme are found among various phylogenetic groups. Because of the abundance and fundamental importance of Rubisco, the enzyme has been extensively studied. Well over 1,000 different Rubisco homologues are available in the public literature and the crystal structure of Rubisco has been solved for several variants of the protein.

Rubisco contains two competing enzymatic activities: an oxygenase and a carboxylase activity. The oxygenation reaction catalyzed by Rubisco is considered a "wasteful"

2

process because it competes with, and significantly reduces the net amount of carbon fixed by an organism. The Rubisco enzyme species encoded in various photosynthetic organisms have been selected by natural evolution to provide higher plants with a Rubisco enzyme that is substantially more efficient at carboxylation in the presence of atmospheric oxygen.

The creation of plants and other photosynthetic organisms having improved Rubisco biosynthetic pathways can provide increased yields of certain types of foodstuffs, enhanced biomass energy sources, and may alter the types and amounts of nutrients present in certain foodstuffs, among other desirable phenotypes. The development of technologies for effective biological fixation of CO₂ on a global scale can mitigate the effects of atmospheric greenhouse gas emission. Cyanobacterial aquaculture ("cyanofarming") offers one of the most productive solutions for global greenhouse gas control, as compared to other biological alternatives aimed at CO₂ abatement technology for global use. However, it would be desirable to improve biomass productivity of cyanofarming by 10 to 20 fold over current production levels. Thus, a need exists for improved Rubisco enzymes.

BRIEF SUMMARY OF THE INVENTION

The present invention provides novel ribulose 1,5-bisphosphate carboxylase/oxygenase ("Rubisco") polypeptides, including the large and small subunits. In particular, the present invention provides an isolated or recombinant Rubisco large subunit polypeptide comprising an amino acid sequence selected from the group consisting of:

- (a) an amino acid sequence that is at least 99% identical to SEQ ID NO: 5;
- (b) an amino acid sequence that is at least 95% identical to SEQ ID NO: 8;
- (c) an amino acid sequence that is at least 97% identical to SEQ ID NO: 35; and
- (d) an amino acid sequence that is at least 99% identical to SEQ ID NO: 11.

Specific Rubisco large subunit polypeptides of the present invention comprise an amino acid sequence selected from the group consisting of SEQ ID NO: 5, SEQ ID NO: 8, SEQ ID NO: 1, SEQ ID NO: 14, SEQ ID NO: 20, SEQ ID NO: 29, SEQ ID NO: 32, SEQ ID NO: 35, SEQ ID NO: 38, SEQ ID NO: 41, SEQ ID NO: 47, SEQ ID NO: 50, and SEQ ID NO: 53.

Certain large subunit Rubisco polynucleotides encode large subunit Rubisco polypeptides having at least one amino residue from the set of (a)-(bd) residues listed below. The amino acid residue positions refer to the position in the encoded amino acid sequence when it is optimally aligned with reference sequence SEQ ID NO: 5, 8, 35, or 11. The present invention further provides Rubisco large subunit polypeptides that have at least one amino acid residue selected from the group consisting of: (a) V at position 84; (b) D at position 92; (c) F at position 93; (d) L at position 113; (e) L at position 116; (f) L at position 117; (g) L at position 127; (h) A at position 129; (i) V at position 137; (j) I at position 139; (k) Y at position 141; (l) L at position 142; (m) S at position 149; (n) G at position 154; (o) K at position 158; (p) L at position 166; (q) M at position 209; (r) Q at position 219; (s) E at position 220; (t) E at position 223; (u) A at position 225 (v) T at position 232; (w) Q at position 246; (x) E at position 249; (y) A at position 252; (z) I at position

257; (aa)T at position 259; (ab) G at position 269; (ac) S at position 276; (ad) Y at position 280; (ae) L at position 286; (af) A at position 297; (ag) K at position 303; (ah) T at position 304; (ai) M at position 317; (aj) Q at position 322; (ak) T at position 325; (al) R at position 336; (am) Q at position 337; (an) T at position 338; (ao) I at position 343; (ap) Q at position 345; (aq) L at position 346; (ar) S at position 349; (as) F at position 350; (at)P at position 352; (au) E at position 353; (av) N or T at position 356; (aw) N at position 359; (ax) D at position 362; (ay) G at position 366; (az) F at position 372; (ba) A at position 373; (bb) A at position 389; (bc) I at position 415; (bd) R at position 450; and (be) I at position 454.

The present invention also provides Rubisco small subunit polypeptides that comprise an amino acid sequence corresponding to SEQ ID NO: 3 and having one or more substitutions selected from the group consisting of: (a) D23N; (b) M33T; (c) K66N; (d) S67G; (e) S102G; and (f) P108S. The present invention provides specific Rubisco small subunit polypeptides selected from the group consisting of: SEQ ID NO: 12, SEQ ID NO: 18, SEQ ID NO: 24, SEQ ID NO: 27, SEQ ID NO: 30, SEQ ID NO: 39, SEQ ID NO: 45, SEQ ID NO: 48, and SEQ ID NO: 54.

The present invention further provides Rubisco polypeptides having both large and small subunits and that exhibit ribulose 1,5-bisphosphate carboxylase/oxygenase ("Rubisco") activity,

wherein the polypeptide comprises a large subunit and a small subunit,

wherein the large subunit comprises an amino acid sequence selected from the group consisting of:

(a) an amino acid sequence that is at least 99% identical to SEQ ID NO: 5;

(b) an amino acid sequence that is at least 95% identical to SEQ ID NO: 8;

(c) an amino acid sequence that is at least 97% identical to SEQ ID NO: 35;

(d) an amino acid sequence that is at least 99% identical to SEQ ID NO: 11; and

(e) an amino acid sequence corresponding to SEQ ID NO: 2; and

wherein the small subunit comprises an amino acid sequence selected from the group consisting of:

(f) SEQ ID NO:3; and

(g) SEQ ID NO: 3 having one or more substitutions selected from the group consisting of: (i) D23N; (ii) M33T; (iii) K66N; (iv) S67G; (v) S103G; and (vi) P108S; and

wherein the polypeptide does not comprise (e) and (f) together.

The present invention also provides additional Rubisco polypeptides, as well as the Rubisco polynucleotides that encode them, related vectors, host cells, and methods, all of which are provided in more detail below.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 depicts the Calvin-Benson Cycle

FIG. 2 depicts Vector pCK110700-I-Bla.

FIG. 3 depicts Vector pGR-1.

FIG. 4 provides a schematic description of the Whole Cell CO₂ fixation assay described in Example 6.

DETAILED DESCRIPTION

The present invention provides novel ribulose 1,5-bisphosphate carboxylase/oxygenase polypeptides and the polynucleotides that encode them. As used herein, the terms "ribulose 1,5-bisphosphate carboxylase/oxygenase" and "Rubisco" are used interchangeably herein to refer to a polypeptide that, in nature, is made up of two subunits, a large subunit and a small subunit. The large subunit of Rubisco is also referred to as "rbcL" and the small subunit of Rubisco is also referred to as "rbcS". Both subunits together are referred to herein as "rbcLS." The term "Rubisco activity" refers herein to the ability to catalyze the conversion of ribulose 1,5-bisphosphate ("RuBP") to 3-phosphoglycerate ("PG") in the presence of carbon dioxide. This reaction takes place as part of the Calvin-Benson cycle, and is depicted as step "A" of FIG. 1.

The present invention provides Rubisco large subunit polypeptides and polynucleotides, Rubisco small subunit polypeptides and polynucleotides, as well as Rubisco large/small subunit (i.e., having both large and small subunits together in a single polypeptide) polypeptides and polynucleotides (collectively referred to herein as "Rubisco polypeptides" and "Rubisco polynucleotides"). The terms "Rubisco large subunit polypeptide" and "Rubisco rbcL polypeptide" are used interchangeably herein to refer to a polypeptide corresponding to the large subunit of Rubisco. The terms "Rubisco small subunit polypeptide" and "Rubisco rbcS polypeptide" are used interchangeably herein to refer to a polypeptide corresponding to the small subunit of Rubisco. The terms "Rubisco large/small subunit polypeptide" and "Rubisco rbcLS polypeptide" are used interchangeably herein to refer herein to a polypeptide that corresponds to both large and small subunits of Rubisco. Similarly, the terms "Rubisco large subunit polynucleotide" and "Rubisco rbcL polynucleotide" are used interchangeably herein to refer to a polynucleotide that encodes a Rubisco large subunit polypeptide. The terms "Rubisco small subunit polynucleotide" and "Rubisco rbcS polynucleotide" are used interchangeably herein to refer to a polynucleotide that encodes a Rubisco small subunit polypeptide. As used herein, the terms "Rubisco large and small subunit polypeptide" and "Rubisco rbcLS polynucleotide" are used interchangeably herein to refer to a polynucleotide that encodes both a Rubisco large subunit polypeptide and a Rubisco small subunit polypeptide.

Rubisco Polypeptides

Rubisco polypeptides of the present invention include Rubisco large subunit polypeptides ("rbcL"), Rubisco small subunit polypeptides ("rbcS"), and Rubisco large/small polypeptides ("rbcLS"). The terms "protein" and "polypeptide" are used interchangeably herein to refer to a polymer of amino acids. The term "amino acid sequence" refers to the order of amino residues in the protein or polypeptide. Large and small subunits of the present invention may be combined in different combinations with each other together in a single enzyme having Rubisco specific activity. Alternatively, the large and small subunits of the present invention may be combined with the large large and small subunits from a wild type Rubisco polypeptides (i.e., invention Rubisco large subunit combined with wild type Rubisco small subunit, or wild type Rubisco large subunit combined with invention Rubisco small subunit) to form a polypeptide having Rubisco activity.

5

Rubisco rbcLS polypeptides of the present invention exhibit a detectable level of Rubisco specific activity as measured in the assay described in Example 3.

Rubisco Large Subunit Polypeptides

The present invention provides an isolated or recombinant Rubisco large subunit Rubisco polypeptide that comprises an amino acid sequence selected from the group consisting of:

(a) an amino acid sequence that is at least 99% identical to SEQ ID NO: 5;

(b) an amino acid sequence that is at least 95% identical to SEQ ID NO: 8;

(c) an amino acid sequence that is at least 97% identical to SEQ ID NO: 35; and

(d) an amino acid sequence that is at least 99% identical to SEQ ID NO: 11.

As used herein, the term “isolated” refers to a nucleic acid, polynucleotide, polypeptide, protein, or other component that is partially or completely separated from components with which it is normally associated (other proteins, nucleic acids, cells, synthetic reagents, etc.). A nucleic acid or polypeptide is “recombinant” when it is artificial or engineered, or derived from an artificial or engineered protein or nucleic acid. For example, a polynucleotide that is inserted into a vector or any other heterologous location, e.g. in a genome of a recombinant organism, such that it is not associated with nucleotide sequences that normally flank the polynucleotide as it is found in nature is a recombinant polynucleotide. A protein expressed in vitro or in vivo from a recombinant polynucleotide is an example of a recombinant polypeptide. Likewise, a polynucleotide sequence that does not appear in nature, for example a variant of a naturally occurring gene, is recombinant.

Specific Rubisco large subunit polypeptides of the present invention include those selected from the group consisting of SEQ ID NO: 5, SEQ ID NO: 8, SEQ ID NO: 11, SEQ ID NO: 14, SEQ ID NO: 20, SEQ ID NO: 29, SEQ ID NO: 32, SEQ ID NO: 35, SEQ ID NO: 38, SEQ ID NO: 41, SEQ ID NO: 47, SEQ ID NO: 50, and SEQ ID NO: 53.

The terms “percent identity,” “% identity,” “percent identical,” and “% identical” are used interchangeably herein to refer to the percent amino acid sequence identity that is obtained by ClustalW analysis (version W 1.8 available from European bioinformatics Institute, Cambridge, UK), counting the number of identical matches in the alignment and dividing such number of identical matches by the length of the reference sequence, and using the following default ClustalW parameters to achieve slow/accurate pairwise alignments—Gap Open Penalty:10; Gap Extension Penalty: 0.10; Protein weight matrix:Gonnet series; DNA weight matrix:IUB; Toggle Slow/Fast pairwise alignments=SLOW or FULL Alignment.

When optimally aligned with reference sequence SEQ ID NO: 5, 8, 35, or 11, certain Rubisco large subunit polypeptides of the present invention are characterized by having at least one amino acid residue selected from the group consisting of: (a) V at position 84; (b) D at position 92; (c) F at position 93; (d) L at position 113; (e) L at position 116; (f) L at position 117; (g) L at position 127; (h) A at position 129; (i) V at position 137; (j) I at position 139; (k) Y at position 141; (l) L at position 142; (m) S at position 149; (n) G at position 154; (o) K at position 158; (p) L at position 166; (q) M at position 209; (r) Q at position 219; (s) E at position 220; (t) E at position 223; (u) A at position 225 (v) T at

6

position 232; (w) Q at position 246; (x) E at position 249; (y) A at position 252; (z) I at position 257; (aa) T at position 259; (ab) G at position 269; (ac) S at position 276; (ad) Y at position 280; (ae) L at position 286; (af) A at position 297; (ag) K at position 303; (ah) T at position 304; (ai) M at position 317; (aj) Q at position 322; (ak) T at position 325; (al) R at position 336; (am) Q at position 337; (an) T at position 338; (ao) I at position 343; (ap) Q at position 345; (aq) L at position 346; (ar) S at position 349; (as) F at position 350; (at) P at position 352; (au) E at position 353; (av) N or T at position 356; (aw) N at position 359; (ax) D at position 362; (ay) G at position 366; (az) F at position 372; (ba) A at position 373; (bb) A at position 389; (bc) I at position 415; (bd) R at position 450; and (be) I at position 454.

Two sequences are “optimally aligned” when they are aligned for similarity scoring using a defined amino acid substitution matrix (e.g., BLOSUM62), gap existence penalty and gap extension penalty so as to arrive at the highest core possible for that pair of sequences. Amino acid substitution matrices and their use in quantifying the similarity between two sequences are well-known in the art. See e.g., Dayhoff et al. (1978), “A model of evolutionary change in proteins”; “Atlas of Protein Sequence and Structure,” Vol. 5, Suppl. 3 (Ed. M. O. Dayhoff), pp. 345-352, *Natl. Biomed. Res. Round.*, Washington, D.C.; Henikoff et al. (1992) *Proc. Natl. Acad. Sci. USA*, 89:10915-10919. The BLOSUM62 matrix is often used as a default scoring substitution matrix in sequence alignment protocols such as Gapped BLAST 2.0. The gap existence penalty is imposed for the introduction of a single amino acid gap in one of the aligned sequences, and the gap extension penalty is imposed for each additional empty amino acid position inserted into an already opened gap. The alignment is defined by the amino acids position of each sequence at which the alignment begins and ends, and optionally by the insertion of a gap or multiple gaps in one or both sequences so as to arrive at the highest possible score. While optimal alignment begins and ends, and optionally by the insertion of a gap or multiple gaps in one or both sequences, so as to arrive at the highest possible score. While optimal alignment and scoring can be accomplished manually, the process is facilitated by the use of a computer-implemented alignment algorithm, e.g., gapped BLAST 2.0, described in Altschul, et al. (1997) *Nucleic Acids Res.*, 25:3389-3402, and made available to the public at the National Center for Biotechnology Information Website (the world wide web at ncbi.nlm.nih.gov). Optimal alignments, including multiple alignments can be prepared using readily available programs such as PSI-BLAST, which is described by Altschul, et al. (1997) *Nucleic Acids Res.*, 25:3389-3402.

With respect to an amino acid sequence that is optimally aligned with a reference sequence, an amino acid residue “corresponds to” the position in the reference sequence with which the residue is paired in the alignment. The “position” is denoted by a number that sequentially identifies each amino acid in the reference sequence based on its position relative to the N-terminus. Owing to deletions, insertions, truncations, fusions, etc. that must be taken into account when determining an optimal alignment, in general the amino acid residue number in a test sequence is determined by simply counting from the N-terminal will not necessarily be the same as the number of its corresponding position in the reference sequence. For example, in a case where there is a deletion in an aligned test sequence, there will be no amino acid that corresponds to a position in the reference sequence at the site of deletion. Where there is an insertion

in an aligned reference sequence, that insertion will not correspond to any amino acid position in the reference sequence. In the case of truncations or fusions there can be stretches of amino acids in either the reference or aligned sequence that do not correspond to any amino acid in the corresponding sequence.

Rubisco large subunit polypeptides having an amino acid sequence at least 99% identical to SEQ ID NO: 5 typically comprise at least two amino acid residues selected from the group consisting of: I at position 257, T at position 259, M at position 317, A at position 389, and I at position 454.

Rubisco large subunit polypeptides that have an amino acid sequence at least 95% identical to SEQ ID NO: 8 typically comprise at least two amino acid residues selected from the group consisting of: L at position 113, L at position 117, L at position 127, A at position 129, V at position 137, I at position 139, Y at position 141, L at position 142, Q at position 322, T at position 325, R at position 336, Q at position 337, T at position 338, I at position 343, Q at position 345, L at position 346, S at position 349, F at position 350, P at position 352, E at position 353, T at position 356, N at position 359, D at position 362, G at position 366, F at position 372, and A at position 373.

Rubisco large subunit polypeptides having an amino acid sequence at least 97% identical to SEQ ID NO: 35 typically comprise at least two amino acid residues selected from the group consisting of: S at position 149, M at position 209, Q at position 219, E at position 220, E at position 223, A at position 225, Q at position 246, E at position 249, A at position 252, I at position 257, T at position 259, G at position 269, S at position 276, Y at position 280, L at position 286, K at position 303, T at position 304, and A at position 389.

Rubisco large subunit polypeptides having an amino acid sequence at least 99% identical to SEQ ID NO: 11 typically comprise at least two amino acid residues selected from the group consisting of: V at position 84, K at position 158, L at position 166, M at position 317, and I at position 415.

The present invention also provides an isolated or recombinant Rubisco large subunit polypeptide that comprises an amino acid sequence corresponding to SEQ ID NO: 2 and having one of more substitutions selected from the group consisting of: (a) V at position 84; (b) D at position 92; (c) F at position 93; (d) L at position 113; (e) L at position 116; (f) L at position 117; (g) L at position 127; (h) A at position 129; (i) V at position 137; (j) I at position 139; (k) Y at position 141; (l) L at position 142; (m) S at position 149; (n) G at position 154; (o) K at position 158; (p) L at position 166; (q) M at position 209; (r) Q at position 219; (s) E at position 220; (t) E at position 223; (u) A at position 225; (v) T at position 232; (w) Q at position 246; (x) E at position 249; (y) A at position 252; (z) I at position 257; (aa) T at position 259; (ab) G at position 269; (ac) S at position 276; (ad) Y at position 280; (ae) L at position 286; (af) A at position 297; (ag) K at position 303; (ah) T at position 304; (ai) M at position 317; (aj) Q at position 322; (ak) T at position 325; (al) R at position 336; (am) Q at position 337; (an) T at position 338; (ao) I at position 343; (ap) Q at position 345; (aq) L at position 346; (ar) S at position 349; (as) F at position 350; (at) P at position 352; (au) E at position 353; (av) N or T at position 356; (aw) N at position 359; (ax) D at position 362; (ay) G at position 366; (az) F at position 372; (ba) A at position 373; (bb) A at position 389; (bc) I at position 415; (bd) R at position 450; and (be) I at position 454.

The present invention also provides an isolated or recombinant Rubisco large subunit polypeptide that comprises an

amino acid sequence encoded by a polynucleotide comprising a nucleic acid selected from the group consisting of:

(a) a nucleic acid that hybridizes under stringent conditions over substantially the entire length of a nucleotide sequence that encodes an amino acid sequence selected from the group consisting of:

(i) SEQ ID NO: 5, wherein the nucleic acid encodes an amino acid sequence that, when optimally aligned with SEQ ID NO: 5, comprises at least two amino acid residues selected from the group consisting of: I at position 257, T at position 259, M at position 317, A at position 389, and I at position 454;

(ii) SEQ ID NO: 8, wherein the nucleic acid encodes an amino acid sequence that, when optimally aligned with SEQ ID NO: 8, comprises at least two amino acid residues selected from the group consisting of: L at position 113, L at position 117, L at position 127, A at position 129, V at position 137, I at position 139, Y at position 141, L at position 142, Q at position 322, T at position 325, R at position 336, Q at position 337, T at position 338, I at position 343, Q at position 345, L at position 346, S at position 349, F at position 350, P at position 352, E at position 353, T at position 356, N at position 359, D at position 362, G at position 366, F at position 372, and A at position 373;

(iii) SEQ ID NO: 35, wherein the nucleic acid encodes an amino acid sequence that, when optimally aligned with SEQ ID NO: 35, comprises at least two amino acid residues selected from the group consisting of: S at position 149, M at position 209, Q at position 219, E at position 220, E at position 223, A at position 225, Q at position 246, E at position 249, A at position 252, I at position 257, T at position 259, G at position 269, S at position 276, Y at position 280, L at position 286, K at position 303, T at position 304, and A at position 389;

(iv) SEQ ID NO: 11, wherein the nucleic acid encodes an amino acid sequence that, when optimally aligned with SEQ ID NO: 11, comprises at least two amino acid residues selected from the group consisting of: V at position 84, K at position 158, L at position 166, M at position 317, and I at position 415; and

(b) a complementary nucleic acid that is complementary to the nucleic acid of (a).

Nucleic acids "hybridize" when they associate, typically in solution. Nucleic acids hybridize due to a variety of well-characterized physico-chemical forces, such as hydrogen bonding, solvent exclusion, base stacking and the like. An extensive guide to the hybridization of nucleic acids is found in Tijssen (1993) "Laboratory Techniques in Biochemistry and Molecular Biology-Hybridization with Nucleic Acid Probes," Part I, Chapter 2 (Elsevier, N.Y.).

As used herein, the term "stringent hybridization wash conditions" in the context of nucleic acid hybridization experiments, such as Southern and northern hybridizations, are sequence dependent, and are different under different environmental parameters. An extensive guide to the hybridization of nucleic acids is found in Tijssen (1993) "Laboratory Techniques in Biochemistry and Molecular Biology-Hybridization with Nucleic Acid Probes," Part I, Chapter 2 (Elsevier, N.Y.).

For purposes of the present invention, "highly stringent" hybridization and wash conditions are generally selected to be about 5° C. or less lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength and pH (as noted below, highly stringent conditions can also be referred to in comparative terms). The T_m is the temperature

(under defined ionic strength and pH) at which 50% of the test sequence hybridizes to a perfectly matched probe. Very stringent conditions are selected to be equal to the T_m for a particular probe.

The T_m of a nucleic acid duplex indicates the temperature at which the duplex is 50% denatured under the given conditions and it represents a direct measure of the stability of the nucleic acid hybrid. Thus, the T_m corresponds to the temperature corresponding to the midpoint in transition from helix to random coil; it depends on length, nucleotide composition, and ionic strength for long stretches of nucleotides.

After hybridization, unhybridized nucleic acid material can be removed by a series of washes, the stringency of which can be adjusted depending upon the desired results. Low stringency washing conditions (e.g., using higher salt and lower temperature) increase sensitivity, but can produce nonspecific hybridization signals and high background signals. Higher stringency conditions (e.g., using lower salt and higher temperature that is closer to the hybridization temperature) lowers the background signal, typically with only the specific signal remaining. See Rapley, R. and Walker, J. M. Eds., "Molecular Biometrics Handbook" (Humana Press, Inc.1998).

The T_m of a DNA-DNA duplex can be estimated using Equation 1 as follows:

$$T_m (^{\circ} \text{C.}) = 81.5^{\circ} \text{C.} + 16.6(\log_{10} M) + 0.41 (\%G+C) - 0.72(\%f) - 500/n,$$

where M is the molarity of the monovalent cations (usually Na+), (%G+C) is the percentage of guanosine (G) and cytosine (C) nucleotides, (%f) is the percentage of formalin and n is the number of nucleotide bases (i.e., length) of the hybrid. See id.

The T_m of an RNA-DNA duplex can be estimated by using Equation 2 as follows:

$$T_m (^{\circ} \text{C.}) = 79.8^{\circ} \text{C.} + 18.5(\log_{10} M) + 0.58(\%G+C) - 11.8 (\%G+C)^2 - 0.56(\%f) - 820/n,$$

where M is the molarity of the monovalent cations (usually Na+), (%G+C) is the percentage of guanosine (G) and cytosine (C) nucleotides, (%f) is the percentage of formamide and n is the number of nucleotide bases (i.e., length) of the hybrid. Id.

Equations 1 and 2 are typically accurate only for hybrid duplexes longer than about 100-200 nucleotides. Id.

The T_m of nucleic acid sequences shorter than 50 nucleotides can be calculated as follows:

$$T_m (^{\circ} \text{C.}) = 4(G+C) + 2(A+T),$$

where A (adenine), C, T (thymine), and G are the numbers of the corresponding nucleotides.

An example of stringent hybridization conditions for hybridization of complementary nucleic acids which have more than 100 complementary residues on a filter in a Southern or northern blot is 50% formalin with 1 mg of heparin at 42° C., with the hybridization being carried out overnight. An example of stringent wash conditions is a 0.2xSSC wash at 65° C. for 15 minutes (see Sambrook, et al., Molecular Cloning—A Laboratory Manual" (1989) Cold Spring Harbor Laboratory (Cold Spring Harbor, N.Y.) for a description of SSC buffer). Often the high stringency wash is preceded by a low stringency wash to remove background probe signal. An example low stringency wash is 2xSSC at 40° C. for 15 minutes.

In general, a signal to noise ratio of 2.5x-5x (or higher) than that observed for an unrelated probe in the particular hybridization assay indicates detection of a specific hybrid-

ization. Detection of at least stringent hybridization between two sequences in the context of the present invention indicates relatively strong structural similarity or homology to, e.g., the nucleic acids of the present invention provided in the sequence listings herein.

As noted, "highly stringent" conditions are selected to be about 5° C. or less lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength and pH. Target sequences that are closely related or identical to the nucleotide sequence of interest (e.g., "probe") can be identified under highly stringent conditions. Lower stringency conditions are appropriate for sequences that are less complementary.

One measure of stringent hybridization is the ability to hybridize to a nucleic acid that encodes an amino acid sequence selected from SEQ ID NO: 5, SEQ ID NO: 8, SEQ ID NO: 35, and SEQ ID NO: 11, or complementary polynucleotide sequence thereof, under highly stringent conditions (or very stringent conditions, or ultra-high stringency hybridization conditions, or ultra-ultra high stringency hybridization conditions). Stringent hybridization (as well as highly stringent, ultra-high stringency, or ultra-ultra high stringency hybridization conditions) and wash conditions can be readily determined empirically for any test nucleic acid. For example, in determining highly stringent hybridization and wash conditions, the hybridization and wash conditions are gradually increased (e.g., by increasing temperature, decreasing salt concentration, increasing detergent concentration and/or increasing the concentration of organic solvents, such as formalin, in the hybridization or wash), until a selected set of criteria are met. For example, the stringency of hybridization and wash conditions are gradually increased until a probe comprising one or more nucleic acid sequences encoding an amino acid sequence selected from SEQ ID NO: 5, SEQ ID NO: 8, SEQ ID NO: 35, and SEQ ID NO: 11, binds to a perfectly matched complementary target. A test nucleic acid is said to specifically hybridize to a probe nucleic acid when it hybridizes at least 1/2 as well to the probe as to the perfectly matched complementary target, i.e., with a signal to noise ratio at least 1/2 as high as hybridization of the probe to the target under conditions in which the perfectly matched probe binds to the perfectly matched complementary target.

Ultra high-stringency hybridization and wash conditions are those in which the stringency of hybridization and wash conditions are increased until the signal to noise ratio for binding of the probe to the perfectly matched complementary target nucleic acid is at least 10x. A target nucleic acid which hybridizes to a probe under such conditions, with a signal to noise ratio of at least 1/2 that of the perfectly matched complementary target nucleic acid is said to bind to the probe under ultra-high stringency conditions.

Similarly, even higher levels of stringency can be determined by gradually increasing the stringency of hybridization and/or wash conditions of the relevant hybridization assay. For example, those in which the stringency of hybridization and wash conditions are increased until the signal to noise ratio for binding of the probe to the perfectly matched complementary target nucleic acid is at least 10x, 20x, 50x, 100x, or 500x. A target nucleic acid which hybridizes to a probe under such conditions, with a signal to noise ratio of at least 1/2 that of the perfectly matched complementary target nucleic acid is said to bind to the probe under ultra-ultra-high stringency conditions.

The present invention includes the following target nucleic acids that hybridize under high, ultra-high and ultra-ultra high stringency conditions: (1) target nucleic

acids which hybridize to nucleic acids that encode amino acid sequence SEQ ID NO: 5, and which encode an amino acid sequence that comprises at least two amino acid residues selected from the group consisting of: I at position 257, T at position 259, M at position 317, A at position 389, and I at position 454; (2) target nucleic acids which hybridize to nucleic acids that encode SEQ ID NO: 8, and which encode an amino acid sequence that comprises at least two amino acid residues selected from the group consisting of: L at position 113, L at position 117, L at position 127, A at position 129, V at position 137, I at position 139, Y at position 141, L at position 142, Q at position 322, T at position 325, R at position 336, Q at position 337, T at position 338, I at position 343, Q at position 345, L at position 346, S at position 349, F at position 350, P at position 352, E at position 353, T at position 356, N at position 359, D at position 362, G at position 366, F at position 372, and A at position 373; (3) target nucleic acids which hybridize to nucleic acids that encode SEQ ID NO: 35, and which encode an amino acid sequence that comprises at least two amino acid residues selected from the group consisting of: S at position 149, M at position 209, Q at position 219, E at position 220, E at position 223, A at position 225, Q at position 246, E at position 249, A at position 252, I at position 257, T at position 259, G at position 269, S at position 276, Y at position 280, L at position 286, K at position 303, T at position 304, and A at position 389; and (4) target nucleic acids which hybridize to nucleic acids that encode SEQ ID NO: 11, and which encode an amino acid sequence that comprises at least two amino acid residues selected from the group consisting of: V at position 84, K at position 158, L at position 166, M at position 317, and I at position 415; and (5) a complementary nucleic acid that is complementary to any one of (1)-(5).

The present invention also provides Rubisco large subunit polypeptides that comprise at least one of a group of certain specific amino acid residues at positions determined upon optimum alignment with the amino acid sequence corresponding to SEQ ID NO: 5, 8, 35, or 11. These residues are: (a) I at position 454; (b) V at position 84; (c) K at position 158; (d) L at position 166; and (e) M at position 317.

A Rubisco large subunit polypeptide having the amino acid residue I at position 454 of the large subunit appeared to be associated with higher k_{cat} for RuBP as determined by the method described in Example 4. The residues V at position 84, K at position 158, L at position 166, and M at position 317 appeared to confer a lower K_M as determined by the method described in Example 4.

Rubisco Small Subunit Polypeptides

The present invention provides an isolated or recombinant small subunit Rubisco polypeptide that comprises an amino acid sequence corresponding to SEQ ID NO: 3, and having one or more substitutions selected from the group consisting of: (a) D23N; (b) M33T; (c) K66N; (d) S67G; (e) S102G; and (f) P108S.

Exemplary Rubisco small subunit polypeptides of the present invention include those having an amino acid sequence corresponding to SEQ ID NO: 12, SEQ ID NO: 18, SEQ ID NO: 24, SEQ ID NO: 27, SEQ ID NO: 30, SEQ ID NO: 39, SEQ ID NO: 45, SEQ ID NO: 48, and SEQ ID NO: 54.

The invention further provides Rubisco small subunit polypeptides of the present invention that are encoded by an isolated or recombinant polynucleotide comprising:

(a) a nucleic acid that hybridizes under stringent conditions over substantially the entire length of a nucleotide sequence that encodes an amino acid sequence selected from the group consisting of:

- (i) SEQ ID NO: 12, wherein the nucleic acid encodes an amino acid sequence that, when optimally aligned with SEQ ID NO: 12, comprises at position 23, amino acid residue N;
- (ii) SEQ ID NO: 18, wherein the nucleic acid encodes an amino acid sequence that, when optimally aligned with SEQ ID NO: 18, comprises at position 67, amino acid residue G;
- (iii) SEQ ID NO: 24, wherein the nucleic acid encodes an amino acid sequence that, when optimally aligned with SEQ ID NO: 24, comprises at position 108, amino acid residue S;
- (iv) SEQ ID NO: 27, wherein the nucleic acid encodes an amino acid sequence that, when optimally aligned with SEQ ID NO: 27, comprises at position 66, amino acid residue N;
- (v) SEQ ID NO: 30, wherein the nucleic acid encodes an amino acid sequence that, when optimally aligned with SEQ ID NO: 30, comprises at position 102, amino acid residue G; and
- (vi) SEQ ID NO: 39, wherein the nucleic acid encodes an amino acid sequence that, when optimally aligned with SEQ ID NO: 39, comprises at position 33, amino acid residue T; or

(b) a complementary nucleic acid that is complementary to the nucleic acid of (a).

The present invention also provides Rubisco small subunit polypeptides that comprise N at position 23, where position 23 is determined by optimum alignment with the amino acid sequence corresponding to SEQ ID NO: 3, 12, 18, 24, 27, 30, or 39. This residue appears to be associated with lower K_M .

Rubisco Large and Small Subunit (rbcLS) Polypeptides

The present invention provides an isolated or recombinant polypeptide having Rubisco specific activity (as determined by the method of Example 3),

wherein the polypeptide comprises a large subunit and a small subunit,

wherein the large subunit comprises an amino acid sequence selected from the group consisting of:

- (a) an amino acid sequence that is at least 99% identical to SEQ ID NO: 5;
 - (b) an amino acid sequence that is at least 95% identical to SEQ ID NO: 8;
 - (c) an amino acid sequence that is at least 97% identical to SEQ ID NO: 35;
 - (d) an amino acid sequence that is at least 99% identical to SEQ ID NO: 11; and
 - (e) an amino acid sequence corresponding to SEQ ID NO: 2; and
- wherein the small subunit comprises an amino acid sequence selected from the group consisting of:
- (f) SEQ ID NO:3; and

(g) SEQ ID NO: 3 having one or more substitutions selected from the group consisting of: (i) D23N; (ii) M33T; (iii) K66N; (iv) S67G; (v) S102G; and (vi) P108S; and

wherein the polypeptide does not comprise (e) and (f) together.

The present invention also provides an isolated or recombinant Rubisco rbcLS polypeptide having Rubisco specific activity,

wherein the polypeptide comprises a large subunit and a small subunit,

wherein the large subunit comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 5, SEQ ID NO: 8, SEQ ID NO: 14, SEQ ID NO: 20, SEQ ID NO: 29, SEQ ID NO: 32, SEQ ID NO: 35, SEQ ID NO: 38, SEQ ID NO: 41, and SEQ ID NO: 40, and

wherein the small subunit comprises an amino acid sequence corresponding to SEQ ID NO: 3.

The present invention further provides an isolated or recombinant Rubisco rbcLS polypeptide having Rubisco specific activity and comprising a combination of large and small subunit amino acid sequences selected from the group consisting of:

- (a) SEQ ID NO: 11 and SEQ ID NO: 12;
- (b) SEQ ID NO: 29 and SEQ ID NO: 30;
- (c) SEQ ID NO: 38 and SEQ ID NO: 39;
- (d) SEQ ID NO: 47 and SEQ ID NO: 48; and
- (e) SEQ ID NO: 53 and SEQ ID NO: 54.

Rubisco rbcLS polypeptides of the present invention also include an isolated or recombinant polypeptide having ribulose 1,5-bisphosphate carboxylase/oxygenase activity,

wherein the polypeptide comprises a large subunit and a small subunit,

wherein the large subunit comprises an amino acid sequence corresponding to SEQ ID NO: 3, and

wherein the small subunit comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 18, SEQ ID NO: 24, SEQ ID NO: 27, and SEQ ID NO: 45.

Rubisco Polypeptide Variants

Variants of Rubisco large and small subunit polypeptides of the present invention may be generated using methods that are well known to those having ordinary skill in the art. Libraries of these variants may be generated and screened using the methods described in Example 4 hereinbelow to identify those having Rubisco specific activity.

For example, mutagenesis and directed evolution methods are well known in the art. See, e.g., Ling, et al., "Approaches to DNA mutagenesis: an overview," *Anal. Biochem.*, 254 (2):157-78 (1997); Dale, et al., "Oligonucleotide-directed random mutagenesis using the phosphorothioate method," *Methods Mol. Biol.*, 57:369-74 (1996); Smith, "In vitro mutagenesis," *Ann. Rev. Genet.*, 19:423-462 (1985); Botstein, et al., "Strategies and applications of in vitro mutagenesis," *Science*, 229:1193-1201 (1985); Carter, "Site-directed mutagenesis," *Biochem. J.*, 237:1-7 (1986); Kramer, et al., "Point Mismatch Repair," *Cell*, 38:879-887 (1984); Wells, et al., "Cassette mutagenesis: an efficient method for generation of multiple mutations at defined sites," *Gene*, 34:315-323 (1985); Minshull, et al., "Protein evolution by molecular breeding," *Current Opinion in Chemical Biology*, 3:284-290 (1999); Christians, et al., "Directed evolution of thymidine kinase for AZT phosphorylation using DNA family shuffling," *Nature Biotechnology*, 17:259-264 (1999); Cramer, et al., "DNA shuffling of a family of genes from diverse species accelerates directed evolution," *Nature*, 391:288-291; Cramer, et al., "Molecular evolution of an arsenate detoxification pathway by DNA shuffling," *Nature Biotechnology*, 15:436-438 (1997); Zhang, et al., "Directed evolution of an effective fucosidase from a galactosidase by DNA shuffling and screening," *Proceedings of the National Academy of Sciences. U.S.A.*, 94:45-4-4509; Cramer, et al.,

"Improved green fluorescent protein by molecular evolution using DNA shuffling," *Nature Biotechnology* 14:315-319 (1996); Stemmer, "Rapid evolution of a protein in vitro by DNA shuffling," *Nature*, 370:389-391 (1994); Stemmer, "DNA shuffling by random fragmentation and reassembly: In vitro recombination for molecular evolution," *Proceedings of the National Academy of Sciences, U.S.A.*, 91:10747-10751 (1994); WO 95/22625; WO 97/0078; WO 97/35966; WO 98/27230; WO 00/42651; and WO 01/75767.

10 Rubisco Polynucleotides

Rubisco Large Subunit Polynucleotides

The present invention provides an isolated or recombinant Rubisco large subunit polynucleotide that comprises a nucleic acid having a nucleotide sequence selected from the group consisting of:

- (a) a nucleotide sequence encoding an amino acid sequence that is at least 99% identical to SEQ ID NO: 5;
- (b) a nucleotide sequence encoding an amino acid sequence that is at least 95% identical to SEQ ID NO: 8;
- (c) a nucleotide sequence encoding an amino acid sequence that is at least 97% identical to SEQ ID NO: 35;
- (d) a nucleotide sequence encoding an amino acid sequence that is at least 99% identical to SEQ ID NO: 11; and
- (e) a nucleotide sequence that is complementary to any one of (a) through (d).

The terms "polynucleotide" and "nucleic acid" are used interchangeably herein to refer to a polymer of nucleotides (A, C, T, U, G, etc. or naturally occurring or artificial nucleotide analogues), e.g., DNA or RNA, or a representation thereof. The terms "polynucleotide sequence" and "nucleic acid sequence" are used interchangeably herein to refer to the order of nucleotides in the polynucleotide or nucleic acid. A complementary polynucleotide can be readily determined from any specified polynucleotide sequence.

Specific large subunit Rubisco polynucleotides of the present invention comprise a polynucleotide sequence that encodes an amino acid sequence selected from the group consisting of SEQ ID NO: 5, SEQ ID NO: 8, SEQ ID NO: 11, SEQ ID NO: 14, SEQ ID NO: 20, SEQ ID NO: 29, SEQ ID NO: 32, SEQ ID NO: 35, SEQ ID NO: 38, SEQ ID NO: 41, SEQ ID NO: 47, SEQ ID NO: 50, and SEQ ID NO: 53.

Certain Rubisco large subunit polynucleotides encode Rubisco large subunit polypeptides having at least one amino residue from the set of (a)-(bd) residues listed below. The amino acid residue positions refer to the position in the encoded amino acid sequence when it is optimally aligned with reference sequence SEQ ID NO: 5, 8, 35, or 11. The polypeptides encoded by the large subunit Rubisco polynucleotides typically have at least one amino acid residue selected from the group consisting of: (a) V at position 84; (b) D at position 92; (c) F at position 93; (d) L at position 113; (e) L at position 116; (f) L at position 117; (g) L at position 127; (h) A at position 129; (i) V at position 137; (j) I at position 139; (k) Y at position 141; (l) L at position 142; (m) S at position 149; (n) G at position 154; (o) K at position 158; (p) L at position 166; (q) M at position 209; (r) Q at position 219; (s) E at position 220; (t) E at position 223; (u) A at position 225 (v) T at position 232; (w) Q at position 246; (x) E at position 249; (y) A at position 252; (z) I at position 257; (aa) T at position 259; (ab) G at position 269; (ac) S at position 276; (ad) Y at position 280; (ae) L at position 286; (af) A at position 297; (ag) K at position 303; (ah) T at

position 304; (ai) M at position 317; (aj) Q at position 322; (ak) T at position 325; (al) R at position 336; (am) Q at position 337; (an) T at position 338; (ao) I at position 343; (ap) Q at position 345; (aq) L at position 346; (ar) S at position 349; (as) F at position 350; (at)P at position 352; (au) E at position 353; (av) N or T at position 356; (aw) N at position 359; (ax) D at position 362; (ay) G at position 366; (az) F at position 372; (ba) A at position 373; (bb) A at position 389; (bc) I at position 415; (bd) R at position 450; and (be) I at position 454.

When the amino acid sequence encoded by the Rubisco large subunit polynucleotide is at least 99% identical to SEQ ID NO: 5, it typically comprises at least two amino acid residues selected from the group consisting of: I at position 257, T at position 259, M at position 317, A at position 389, and I at position 454. When the amino acid sequence encoded by the Rubisco large subunit polynucleotide is at least 95% identical to SEQ ID NO: 8, it typically comprises at least two amino acid residues selected from the group consisting of: L at position 113, L at position 117, L at position 127, A at position 129, V at position 137, I at position 139, Y at position 141, L at position 142, Q at position 322, T at position 325, R at position 336, Q at position 337, T at position 338, I at position 343, Q at position 345, L at position 346, S at position 349, F at position 350, P at position 352, E at position 353, T at position 356, N at position 359, D at position 362, G at position 366, F at position 372, and A at position 373. Rubisco large subunit polynucleotides encoding an amino acid sequence that is at least 97% identical to SEQ ID NO: 35 typically encode an amino acid sequence that comprises at least two amino acid residues selected from the group consisting of: S at position 149, M at position 209, Q at position 219, E at position 220, E at position 223, A at position 225, Q at position 246, E at position 249, A at position 252, I at position 257, T at position 259, G at position 269, S at position 276, Y at position 280, L at position 286, K at position 303, T at position 304, and A at position 389. position 450; and (bd) I at position 454. When the amino acid sequence encoded by the Rubisco large subunit polynucleotide is at least 99% identical to SEQ ID NO: 11, it typically comprises at least two amino acid residues selected from the group consisting of: V at position 84, K at position 158, L at position 166, M at position 317, and I at position 415.

The present invention also provides an isolated or recombinant Rubisco large subunit polynucleotides comprising a nucleotide sequence encoding an amino acid sequence corresponding to SEQ ID NO: 2 and having one of more substitutions selected from the group consisting of: (a) V at position 84; (b) D at position 92; (c) F at position 93; (d) L at position 113; (e) L at position 116; (f) L at position 117; (g) L at position 127; (h) A at position 129; (i) V at position 137; (j) I at position 139; (k) Y at position 141; (l) L at position 142; (m) S at position 149; (n) G at position 154; (o) K at position 158; (p) L at position 166; (q) M at position 209; (r) Q at position 219; (s) E at position 220; (t) E at position 223; (u) A at position 225 (v) T at position 232; (w) Q at position 246; (x) E at position 249; (y) A at position 252; (z) I at position 257; (aa)T at position 259; (ab) G at position 269; (ac) S at position 276; (ad) Y at position 280; (ae) L at position 286; (af) A at position 297; (ag) K at position 303; (ah) T at position 304; (ai) M at position 317; (aj) Q at position 322; (ak) T at position 325; (al) R at position 336; (am) Q at position 337; (an) T at position 338; (ao) I at position 343; (ap) Q at position 345; (aq) L at position 346; (ar) S at position 349; (as) F at position 350;

(at)P at position 352; (au) E at position 353; (av) N or T at position 356; (aw) N at position 359; (ax) D at position 362; (ay) G at position 366; (az) F at position 372; (ba) A at position 373; (bb) A at position 389; (bc) I at position 415; (bd) R at position 450; and (be) I at position 454.

The present invention also provides an isolated or recombinant Rubisco large subunit polynucleotide comprising:

(a) a nucleic acid that hybridizes under stringent conditions over substantially the entire length of a nucleotide sequence that encodes an amino acid sequence selected from the group consisting of:

(i) SEQ ID NO: 5, wherein the nucleic acid encodes an amino acid sequence that, when optimally aligned with SEQ ID NO: 5, comprises at least two amino acid residues selected from the group consisting of: I at position 257, T at position 259, M at position 317, A at position 389, and I at position 454;

(ii) SEQ ID NO: 8, wherein the nucleic acid encodes an amino acid sequence that, when optimally aligned with SEQ ID NO: 8, comprises at least two amino acid residues selected from the group consisting of: L at position 113, L at position 117, L at position 127, A at position 129, V at position 137, I at position 139, Y at position 141, L at position 142, Q at position 322, T at position 325, R at position 336, Q at position 337, T at position 338, I at position 343, Q at position 345, L at position 346, S at position 349, F at position 350, P at position 352, E at position 353, T at position 356, N at position 359, D at position 362, G at position 366, F at position 372, and A at position 373;

(iii) SEQ ID NO: 35, wherein the nucleic acid encodes an amino acid sequence that, when optimally aligned with SEQ ID NO: 35, comprises at least two amino acid residues selected from the group consisting of: S at position 149, M at position 209, Q at position 219, E at position 220, E at position 223, A at position 225, Q at position 246, E at position 249, A at position 252, I at position 257, T at position 259, G at position 269, S at position 276, Y at position 280, L at position 286, K at position 303, T at position 304, and A at position 389;

(iv) SEQ ID NO: 11, wherein the nucleic acid encodes an amino acid sequence that, when optimally aligned with SEQ ID NO: 11, comprises at least two amino acid residues selected from the group consisting of: V at position 84, K at position 158, L at position 166, M at position 317, and I at position 415; and

(b) a complementary nucleic acid that is complementary to the nucleic acid of (a).

Specific isolated and recombinant Rubisco large subunit polynucleotides of the present invention correspond in sequence to positions 1 through 1419, inclusive, of a polynucleotide sequence selected from the group consisting of: SEQ ID NO: 4, SEQ ID NO: 7, SEQ ID NO: 10, SEQ ID NO: 13, SEQ ID NO: 19, SEQ ID NO: 28, SEQ ID NO: 31, SEQ ID NO: 34, SEQ ID NO: 37, SEQ ID NO: 40, SEQ ID NO: 46, SEQ ID NO 49, and SEQ ID NO: 52, and SEQ ID NO: 55.

Rubisco Small Subunit Polynucleotides

The present invention provides an isolated or recombinant Rubisco small subunit polynucleotide comprising a nucleotide sequence that encodes an amino acid sequence corresponding to SEQ ID NO: 3 that has one or more substitutions selected from the group consisting of: (a) D23N; (b) M33T; (c) K66N; (d) S67G; (e) S102G; and (f) P108S. Specific Rubisco small subunit polynucleotides of the

present invention comprise a polynucleotide sequence that encodes an amino acid sequence that is selected from the group consisting of SEQ ID NO: 12, SEQ ID NO: 18, SEQ ID NO: 24, SEQ ID NO: 27, SEQ ID NO: 30, and SEQ ID NO: 39.

The present invention also provides an isolated or recombinant Rubisco small subunit polynucleotide comprising a nucleic acid selected from the group consisting of:

(a) a nucleic acid that hybridizes under stringent conditions over substantially the entire length of a nucleotide sequence that encodes an amino acid sequence selected from the group consisting of:

(i) SEQ ID NO: 12, wherein the nucleic acid encodes an amino acid sequence that, when optimally aligned with SEQ ID NO: 12, comprises at position 23, amino acid residue N;

(ii) SEQ ID NO: 18, wherein the nucleic acid encodes an amino acid sequence that, when optimally aligned with SEQ ID NO: 18, comprises at position 67, amino acid residue G;

(iii) SEQ ID NO: 24, wherein the nucleic acid encodes an amino acid sequence that, when optimally aligned with SEQ ID NO: 24, comprises at position 108, amino acid residue S;

(iv) SEQ ID NO: 27, wherein the nucleic acid encodes an amino acid sequence that, when optimally aligned with SEQ ID NO: 27, comprises at position 66, amino acid residue N;

(v) SEQ ID NO: 30, wherein the nucleic acid encodes an amino acid sequence that, when optimally aligned with SEQ ID NO: 30, comprises at position 102, amino acid residue G; and

(vi) SEQ ID NO: 39, wherein the nucleic acid encodes an amino acid sequence that, when optimally aligned with SEQ ID NO: 39, comprises at position 33, amino acid residue T; or

(b) a complementary nucleic acid that is complementary to the nucleic acid of (a).

Specific Rubisco small subunit polynucleotides of the present invention comprise a polynucleotide sequence corresponding to positions 1510 through 1845 inclusive, of a polynucleotide sequence selected from the group consisting of: SEQ ID NO: 10, SEQ ID NO: 16, SEQ ID NO: 22, SEQ ID NO: 28, SEQ ID NO: 37, SEQ ID NO: 55.

Rubisco Large and Small Subunit Polynucleotides

The present invention provides an isolated or recombinant rbcLS polynucleotide comprising a nucleic acid that encodes a Rubisco large subunit polypeptide and a nucleic acid encoding a Rubisco small subunit polypeptide,

wherein the nucleic acid encoding the Rubisco large subunit polypeptide is selected from the group consisting of:

(a) a nucleotide sequence encoding an amino acid sequence that is at least 99% identical to SEQ ID NO: 5;

(b) a nucleotide sequence encoding an amino acid sequence that is at least 95% identical to SEQ ID NO: 8;

(c) a nucleotide sequence encoding an amino acid sequence that is at least 97% identical to SEQ ID NO: 35;

(d) a nucleotide sequence encoding an amino acid sequence that is at least 99% identical to SEQ ID NO: 11; and

(e) a nucleotide sequence that is complementary to any one of (a) through (d); and

wherein the nucleic acid encoding the Rubisco small subunit polypeptide encodes an amino acid sequence having a sequence selected from the group consisting of:

(a) SEQ ID NO:3; and

(b) SEQ ID NO: 3 having one or more substitutions selected from the group consisting of: (i) D23N; (ii) M33T; (iii) K66N; (iv) S67G; (v) S103G; and (vi) P108S.

Isolated or recombinant Rubisco polynucleotides comprise a nucleic acid encoding a Rubisco large subunit polypeptide and a nucleic acid encoding a Rubisco small subunit polypeptide,

wherein the nucleic acid encoding the Rubisco large subunit polypeptide has a nucleotide sequence that encodes an amino acid sequence corresponding to SEQ ID NO: 2 and

wherein the nucleic acid encoding the Rubisco small subunit polypeptide encodes an amino acid sequence corresponding to SEQ ID NO: 3 that has one or more substitutions selected from the group consisting of: (a) D23N; (b) M33T; (c) K66N; (d) S67G; (e) S102G; and (f) P108S.

Specific Rubisco polynucleotides of the present invention include a polynucleotide sequence selected from the group consisting of SEQ ID NO: 4, SEQ ID NO: 7, SEQ ID NO: 10, SEQ ID NO: 13, SEQ ID NO: 16, SEQ ID NO: 19, SEQ ID NO: 22, SEQ ID NO: 25, SEQ ID NO: 28, SEQ ID NO: 31, SEQ ID NO: 34, SEQ ID NO: 37, SEQ ID NO: 40, SEQ ID NO: 43, SEQ ID NO: 46, SEQ ID NO: 49, and SEQ ID NO: 52.

Polynucleotides that encode both large and small subunits of the Rubisco polypeptides (rbcLS) of the present invention typically are separated by an intervening, non-coding polynucleotide sequence that operates as a linker. The linker separates the subunit polynucleotide coding sequences, and extends from the 3' end of the large subunit coding sequence to the 5' end of the small subunit coding sequence. The specific sequence of the linker is not critical. The linker is generally at least about 30 nucleotides in length, typically at least about 50 nucleotides in length, and usually at least about 80 nucleotides in length, up to about 100 nucleotides in length. The present invention provides isolated or recombinant Rubisco rbcLS polynucleotides having a linker sequence separating Rubisco rbcL and Rubisco rbcS polynucleotide sequences. Exemplary linkers include the polynucleotide sequence extending from position 1420 to position 1509, inclusive, of SEQ ID NOS: 1, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34, 37, 40, 43, 46, 49, and 52.

Polynucleotide Sequence Variations

Those having ordinary skill in the art will readily appreciate that due to the degeneracy of the genetic code, a multitude of nucleotide sequences encoding Rubisco polypeptides of the present invention exist. Table I is a Codon Table that provides the synonymous codons for each amino acid. For example, the codons AGA, AGG, CGA, CGC, CGG, and CGU all encode the amino acid arginine. Thus, at every position in the nucleic acids of the invention where an arginine is specified by a codon, the codon can be altered to any of the corresponding codons described above without altering the encoded polypeptide. It is understood that U in an RNA sequence corresponds to T in a DNA sequence.

TABLE 1

Codon Table

Amino acids			Codon			
Alanine	Ala	A	GCA	GCC	GCG	GCU
Cysteine	Cys	C	UGC	UGU		
Aspartic acid	Asp	D	GAC	GAU		

TABLE 1-continued

Amino acids		Codon Table					
		Codon					
Glutamic acid	Glu	E	GAA	GAG			
Phenylalanine	Phe	F	UUC	UUU			
Glycine	Gly	G	GGA	GGC	GGG	GGU	
Histidine	His	H	CAC	CAU			
Isoleucine	Ile	I	AUA	AUC	AUU		
Lysine	Lys	K	AAA	AAG			
Leucine	Leu	L	UUA	UUG	CUA	CUC	CUG
Methionine	Met	M	AUG				
Asparagine	Asn	N	AAC	AAU			
Proline	Pro	P	CCA	CCC	CCG	CCU	
Glutamine	Gln	Q	CAA	CAG			
Arginine	Arg	R	AGA	AGG	CGA	CGC	CGG
Serine	Ser	S	AGC	AGU	UCA	UCC	UCG
Threonine	Thr	T	ACA	ACC	ACG	ACU	
Valine	Val	V	GUA	GUC	GUG	GUU	
Tryptophan	Trp	W	UGG				
Tyrosine	Tyr	Y	UAC	UAU			

Such “silent variations” are one species of “conservative” variation. One of ordinary skill in the art will recognize that each codon in a nucleic acid (except AUG, which is ordinarily the only codon for methionine) can be modified by standard techniques to encode a functionally identical polypeptide. Accordingly, each silent variation of a nucleic acid which encodes a polypeptide is implicit in any described sequence. The invention provides each and every possible variation of nucleic acid sequence encoding a polypeptide of the invention that could be made by selecting combinations based on possible codon choices. These combinations are made in accordance with the standard triplet genetic code (set forth in Table 1), as applied to the polynucleotide sequences encoding the Rubisco large subunit, small subunit, and large and small subunit polypeptides of the present invention.

A group of two or more different codons that, when translated in the same context, all encode the same amino acid, are referred to herein as “synonymous codons.” Rubisco polynucleotides of the present invention may be codon optimized for expression in a particular host organism by modifying the polynucleotides to conform with the optimum codon usage of the desired host organism. Those having ordinary skill in the art will recognize that tables and other references providing preference information for a wide range of organisms are readily available. See e.g., the world wide web at kazusa.orgjp/codon/. For example, Rubisco polynucleotides may be codon optimized for expression from a blue green algae, such as a *Synechocystis* sp. An exemplary codon optimized Rubisco polynucleotide sequence of the present invention is provided as SEQ ID NO: 55, in which SEQ ID NO: 40 has been codon optimized for expression from *Synechocystis*.

The terms “conservatively modified variations” and “conservative variations” are used interchangeably herein to refer to those nucleic acids that encode identical or essentially identical amino acid sequences, or in the situation where the nucleic acids are not coding sequences, the term refers to nucleic acids that are identical. One of ordinary skill in the art will recognize that individual substitutions, deletions or additions which alter, add or delete a single amino acid or a small percentage of amino acids in an encoded sequence are considered conservatively modified variations where the alterations result in one or more of the following: the deletion of an amino acid, addition of an amino acid, or substitution of an amino acid with a chemically similar

amino acid. When more than one amino acid is affected, the percentage is typically less than 5% of amino acid residues over the length of the encoded sequence, and more typically less than 2%. Conservative substitution tables providing amino acids that are considered conservative substitutions for one another are well known in the art. Table 2 provides a list of six conservative substitution groupings of amino acids.

TABLE 2

Conservative Substitution Groups			
1	Alanine (A)	Serine (S)	Threonine (T)
2	Aspartic acid (D)	Glutamic acid (E)	
3	Asparagine (N)	Glutamine (Q)	
4	Arginine (R)	Lysine (K)	
5	Isoleucine (I)	Leucine (L)	Methionine (M) Valine (V)
6	Phenylalanine (F)	Tyrosine (Y)	Tryptophan (W)

Conservatively substituted variations of the Rubisco polypeptides of the present invention include substitutions of a small percentage, typically less than 5%, more typically less than 2%, and often less than 1% of the amino acids of the polypeptide sequence, with a conservatively selected amino acid of the same conservative substitution group. The addition of sequences which do not alter the encoded activity of a Rubisco polynucleotide, such as the addition of a non-functional or non-coding sequence, is considered a conservative variation of the Rubisco polynucleotide.

Vectors, Promoters, and Expression Systems

The present invention also includes recombinant constructs comprising one or more of the nucleic acid sequences as broadly described above. The term “construct” or “nucleic acid construct” refers herein to a nucleic acid, either single- or double-stranded, which is isolated from a naturally occurring gene or which has been modified to contain segments of nucleic acids in a manner that would not otherwise exist in nature. The term “nucleic acid construct” is synonymous with the term “expression cassette” when the nucleic acid construct contains the control sequences required for expression of a coding sequence of the present invention.

The term “control sequences” refers herein to all the components that are necessary or advantageous for the expression of a polypeptide of the present invention. Each control sequence may be native or foreign to the nucleotide sequence encoding the polypeptide. Such control sequences include, but are not limited to, a leader, polyadenylation sequence, propeptide sequence, promoter, signal peptide sequence, and transcription terminator. At a minimum, the control sequences include a promoter, and transcriptional and translational stop signals. The control sequences may be provided with linkers for the purpose of introducing specific restriction sites facilitating ligation of the control sequences with the coding region of the nucleotide sequence encoding a polypeptide.

The term “operably linked” refers herein to a configuration in which a control sequence is appropriately placed at a position relative to the coding sequence of the DNA sequence such that the control sequence directs the expression of a polypeptide.

When used herein, the term “coding sequence” is intended to cover a nucleotide sequence, which directly specifies the amino acid sequence of its protein product. The boundaries of the coding sequence are generally determined by an open reading frame, which usually begins with the

ATG start codon. The coding sequence typically includes a DNA, cDNA, and/or recombinant nucleotide sequence.

As used herein, the term "expression" includes any step involved in the production of the polypeptide including, but not limited to, transcription, post-transcriptional modification, translation, post-translational modification, and secretion.

The term "expression vector" refers herein to a DNA molecule, linear or circular, that comprises a segment encoding a polypeptide of the invention, and which is operably linked to additional segments that provide for its transcription.

As used herein, the term "host cell" refers to any cell type which is susceptible to transformation with a nucleic acid construct.

Nucleic acid constructs of the present invention comprise a vector, such as, a plasmid, a cosmid, a phage, a virus, a bacterial artificial chromosome (BAC), a yeast artificial chromosome (YAC), or the like, into which a nucleic acid sequence of the invention has been inserted, in a forward or reverse orientation. In a preferred aspect of this embodiment, the construct further comprises regulatory sequences, including, for example, a promoter, operably linked to the sequence. Large numbers of suitable vectors and promoters are known to those of skill in the art, and are commercially available.

General texts which describe molecular biological techniques useful herein, including the use of vectors, promoters and many other relevant topics, include Berger and Kimmel, *Guide to Molecular Cloning Techniques, Methods in Enzymology* volume 152 Academic Press, Inc., San Diego, Calif. (Berger); Sambrook et al., *Molecular Cloning—A Laboratory Manual* (2nd Ed.), Vol. 1-3, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., 1989 ("Sambrook") and *Current Protocols in Molecular Biology*, F. M. Ausubel et al., eds., Current Protocols, a joint venture between Greene Publishing Associates, Inc. and John Wiley & Sons, Inc., (supplemented through 1999) ("Ausubel"). Examples of protocols sufficient to direct persons of skill through in vitro amplification methods, including the polymerase chain reaction (PCR) the ligase chain reaction (LCR), Q β -replicase amplification and other RNA polymerase mediated techniques (e.g., NASBA), e.g., for the production of the homologous nucleic acids of the invention are found in Berger, Sambrook, and Ausubel, as well as Mullis et al., (1987) U.S. Pat. No. 4,683,202; *PCR Protocols A Guide to Methods and Applications* (Innis et al. eds) Academic Press Inc. San Diego, Calif. (1990) (Innis); Arnheim & Levinson (Oct. 1, 1990) *C&EN* 36-47; *The Journal Of NIH Research* (1991) 3, 81-94; (Kwoh et al. (1989) *Proc. Natl. Acad. Sci. USA* 86, 1173; Guatelli et al. (1990) *Proc. Natl. Acad. Sci. USA* 87, 1874; Lomell et al. (1989) *J. Clin. Chem* 35, 1826; Landegren et al., (1988) *Science* 241, 1077-1080; Van Brunt (1990) *Biotechnology* 8, 291-294; Wu and Wallace, (1989) *Gene* 4, 560; Barringer et al. (1990) *Gene* 89, 117, and Sooknunan and Malek (1995) *Biotechnology* 13: 563-564. Improved methods for cloning in vitro amplified nucleic acids are described in Wallace et al., U.S. Pat. No. 5,426,039. Improved methods for amplifying large nucleic acids by PCR are summarized in Cheng et al. (1994) *Nature* 369: 684-685 and the references cited therein, in which PCR amplicons of up to 40 kb are generated. One of ordinary skill in the art will readily appreciate that essentially any RNA can be converted into a double stranded DNA suitable for restriction digestion, PCR expansion and sequencing using reverse transcriptase and a polymerase. See, e.g., Ausubel, Sambrook and Berger, all supra.

The present invention also relates to engineered host cells that are transduced (transformed or transfected) with a vector of the invention (e.g., an invention cloning vector or an invention expression vector), as well as the production of polypeptides of the invention by recombinant techniques. The vector may be, for example, a plasmid, a viral particle, a phage, etc. The engineered host cells can be cultured in conventional nutrient media modified as appropriate for activating promoters, selecting transformants, or amplifying the Rubisco polynucleotide. Culture conditions, such as temperature, pH and the like, are those previously used with the host cell selected for expression, and will be apparent to those skilled in the art and in the references cited herein, including, e.g., Sambrook, Ausubel and Berger, as well as e.g., Freshney (1994) *Culture of Animal Cells, a Manual of Basic Technique*, third edition, Wiley-Liss, New York and the references cited therein.

Rubisco polypeptides of the invention can be produced in non-animal cells such as plants, yeast, fungi, bacteria (e.g., cyanobacteria) and the like. In addition to Sambrook, Berger and Ausubel, details regarding non-animal cell culture can be found in Payne et al. (1992) *Plant Cell and Tissue Culture in Liquid Systems* John Wiley & Sons, Inc. New York, N.Y.; Gamborg and Phillips (eds) (1995) *Plant Cell Tissue and Organ Culture; Fundamental Methods* Springer Lab Manual, Springer-Verlag (Berlin Heidelberg New York) and Atlas and Parks (eds) *The Handbook of Microbiological Media* (1993) CRC Press, Boca Raton, Fla.

Polynucleotides of the present invention can be incorporated into any one of a variety of expression vectors suitable for expressing a polypeptide. Suitable vectors include chromosomal, nonchromosomal and synthetic DNA sequences, e.g., derivatives of SV40; bacterial plasmids; phage DNA; baculovirus; yeast plasmids; vectors derived from combinations of plasmids and phage DNA, viral DNA such as vaccinia, adenovirus, fowl pox virus, pseudorabies, adenovirus, adeno-associated virus, retroviruses and many others. Any vector that transduces genetic material into a cell, and, if replication is desired, which is replicable and viable in the relevant host can be used.

When incorporated into an expression vector, a polynucleotide of the invention is operatively linked to an appropriate transcription control sequence (promoter) to direct mRNA synthesis. Examples of such transcription control sequences particularly suited for use in transgenic plants include the cauliflower mosaic virus (CaMV) and figwort mosaic virus (FMV). Other promoters known to control expression of genes in prokaryotic or eukaryotic cells or their viruses and which can be used in some embodiments of the invention include SV40 promoter, *E. coli* lac or trp promoter, phage lambda P_L promoter. An expression vector optionally contains a ribosome binding site for translation initiation, and a transcription terminator, such as PinII. The vector also optionally includes appropriate sequences for amplifying expression, e.g., an enhancer.

In addition, the expression vectors of the present invention optionally contain one or more selectable marker genes to provide a phenotypic trait for selection of transformed host cells. Suitable marker genes include those coding for resistance to the antibiotic spectinomycin or streptomycin (e.g., the aada gene), the streptomycin phosphotransferase (SPT) gene coding for streptomycin resistance, the neomycin phosphotransferase (NPTII) gene encoding kanamycin or geneticin resistance, the hygromycin phosphotransferase (HPT) gene coding for hygromycin resistance. Additional selectable marker genes include dihydrofolate reductase or

neomycin resistance for eukaryotic cell culture, and tetracycline or ampicillin resistance in *E. coli*.

Vectors of the present invention can be employed to transform an appropriate host to permit the host to express an invention protein or polypeptide. Examples of appropriate expression hosts include bacterial cells, such as *E. coli*, *B. subtilis*, and *Streptomyces*, cyanobacterial cells such as *Synechocystis*, *Synechococcus*, *Anabaena*, *Anacystis*, and the like, and plant cells.

In bacterial systems, a number of expression vectors may be selected, such as, for example, multifunctional *E. coli* cloning and expression vectors. In cyanobacterial systems, vectors such as those described in Example 5 may be used.

In plant cells, expression can be driven from a transgene integrated into a plant chromosome, or cytoplasmically from an episomal or viral nucleic acid. In the case of stably integrated transgenes, it is often desirable to provide sequences capable of driving constitutive or inducible expression of the Rubisco polynucleotides of the invention, for example, using viral, e.g., CaMV, or plant derived regulatory sequences. Numerous plant derived regulatory sequences have been described, including sequences which direct expression in a tissue specific manner, e.g., TobRB7, patatin B33, GRP gene promoters, the *rbcS-3A* promoter, and the like. Alternatively, high level expression can be achieved by transiently expressing exogenous sequences of a plant viral vector, e.g., TMV, BMV, etc. Typically, transgenic plants constitutively expressing a Rubisco polynucleotide of the invention will be preferred, and the regulatory sequences selected to insure constitutive stable expression of the Rubisco polypeptide.

Typical vectors useful for expression of nucleic acids in higher plants are well known in the art and include vectors derived from the tumor-inducing (Ti) plasmid of *Agrobacterium tumefaciens* described by Rogers et al., Meth. In Enzymol., 153:253-277 (1987). Exemplary *A. tumefaciens* vectors useful herein are plasmids pKYLX6 and pKYLX7 of Schardl et al., Gene, 61:1-11 (1987) and Berger et al., Proc. Natl. Acad. Sci. U.S.A., 86:8402-8406 (1989). Another useful vector herein is plasmid pBI101.2 that is available from Clontech Laboratories, Inc. (Palo Alto, Calif.). A variety of plant viruses that can be employed as vectors are known in the art and include cauliflower mosaic virus (CaMV), geminivirus, brome mosaic virus, and tobacco mosaic virus.

In some embodiments of the present invention, a Rubisco polynucleotide construct suitable for transformation of plant cells is prepared. For example, a desired Rubisco polynucleotide can be incorporated into a recombinant expression cassette to facilitate introduction of the gene into a plant and subsequent expression of the encoded polypeptide. An expression cassette will typically comprise a Rubisco polynucleotide, or functional fragment thereof, operably linked to a promoter sequence and other transcriptional and translational initiation regulatory sequences which will direct expression of the sequence in the intended tissues (e.g., entire plant, leaves, seeds) of the transformed plant.

For example, a strongly or weakly constitutive plant promoter can be employed which will direct expression of the Rubisco polypeptide all tissues of a plant. Such promoters are active under most environmental conditions and states of development or cell differentiation. Examples of constitutive promoters include the cauliflower mosaic virus (CaMV) 35S transcription initiation region, the 1'- or 2'-promoter derived from T-DNA of *Agrobacterium tumefaciens*, the ubiquitin 1 promoter, the Smas promoter, the cinnamyl alcohol dehydrogenase promoter (U.S. Pat. No.

5,683,439), the Nos promoter, the pEmu promoter, the rubisco promoter, the GRP1-8 promoter and other transcription initiation regions from various plant genes known to those of skill. In situations in which overexpression of a Rubisco polynucleotide is detrimental to the plant or otherwise undesirable, one of skill, upon review of this disclosure, will recognize that weak constitutive promoters can be used for low-levels of expression. In those cases where high levels of expression is not harmful to the plant, a strong promoter, e.g., a t-RNA or other pol III promoter, or a strong pol II promoter, such as the cauliflower mosaic virus promoter, can be used.

Alternatively, a plant promoter may be under environmental control. Such promoters are referred to here as "inducible" promoters. Examples of environmental conditions that may effect transcription by inducible promoters include pathogen attack, anaerobic conditions, or the presence of light. In particular, examples of inducible promoters are the Adh 1 promoter which is inducible by hypoxia or cold stress, the Hsp70 promoter which is inducible by heat stress, and the PPDK promoter which is inducible by light. Also useful are promoters which are chemically inducible.

The promoters used in the present invention can be "tissue-specific" and, as such, under developmental control in that the polynucleotide is expressed only in certain tissues, such as leaves, roots, fruit, flowers and seeds. An exemplary promoter is the anther specific promoter 5126 (U.S. Pat. Nos. 5,689,049 and 5,689,051). Examples of seed-preferred promoters include, but are not limited to, 27 kD gamma zein promoter and waxy promoter, Boronat, A., Martinez, M. C., Reina, M., Puigdomenech, P. and Palau, J.; Isolation and sequencing of a 28 kD glutelin-2 gene from maize: Common elements in the 5' flanking regions among zein and glutelin genes; *Plant Sci.* 47, 95-102 (1986) and Reina, M., Ponte, I., Guillen, P., Boronat, A. and Palau, J., Sequence analysis of a genomic clone encoding a Zc2 protein from *Zea mays* W64 A, *Nucleic Acids Res.* 18 (21), 6426 (1990). See the following site relating to the waxy promoter: Kloesgen, R. B., Gierl, A., Schwarz-Sommer, ZS. and Saedler, H., Molecular analysis of the waxy locus of *Zea mays*, *Mol. Gen. Genet.* 203, 237-244 (1986). In embodiments in which one or more nucleic acid sequences endogenous to the plant system are incorporated into the construct, the endogenous promoters (or variants thereof) from these genes can be employed for directing expression of the genes in the transfected plant. Tissue-specific promoters can also be used to direct expression of heterologous polynucleotides.

In general, the particular promoter used in the expression cassette in plants depends on the intended application. Either heterologous or non-heterologous (i.e., endogenous) promoters can be employed to direct expression of the nucleic acids of the present invention. These promoters can also be used, for example, in expression cassettes to drive expression of antisense nucleic acids to reduce, increase, or alter concentration and/or composition of the proteins of the present invention in a desired tissue. Any of a number of promoters which direct transcription in plant cells are suitable. The promoter can be either constitutive or inducible. In addition to the promoters noted above, promoters of bacterial origin which operate in plants include the octopine synthase promoter, the nopaline synthase promoter and other promoters derived from native Ti plasmids (see, Herrera-Estrella et al. (1983) *Nature* 303:209-213). Viral promoters include the 35S and 19S RNA promoters of cauliflower mosaic virus (Odell et al. (1985) *Nature* 313:810-812). Other plant promoters include the ribulose-1,3-bisphosphate

carboxylase small subunit promoter and the phaseolin promoter. The promoter sequence from the E8 gene and other genes may also be used. The isolation and sequence of the E8 promoter is described in detail in Deikman and Fischer (1988) *EMBO J.* 7:3315-3327.

To identify candidate promoters, the 5' portions of a genomic clone is analyzed for sequences characteristic of promoter sequences. For instance, promoter sequence elements include the TATA box consensus sequence (TATAAT), which is usually 20 to 30 base pairs upstream of the transcription start site. In plants, further upstream from the TATA box, at positions -80 to -100, there is typically a promoter element with a series of adenines surrounding the trinucleotide G (or T) as described by Messing, et al. (1983) *Genetic Engineering in Plants*, Kosage, et al. (Eds.), pp. 221-227.

In preparing polynucleotide constructs, vectors, of the invention, sequences other than the promoter and the cojoined polynucleotide can also be employed. The polyadenylation region can be derived, for example, from a variety of plant genes, or from T-DNA. The 3' end sequence to be added can be derived from, for example, the nopaline synthase or octopine synthase genes, or alternatively from another plant gene, or less preferably from any other eukaryotic gene.

An intron sequence can be added to the 5' untranslated region or the coding sequence of the partial coding sequence to increase the amount of the mature message that accumulates. See e.g., Buchman and Berg, *Mol. Cell Biol.* 8:4395-4405 (1988); Callis, et al., *Genes Dev.* 1:1183-1200 (1987). Use of maize introns Adh1-S intron 1, 2, and 6, the Bronze-1 intron are known in the art. See generally, "The Maize Handbook," Chapter 116, Freeling and Walbot, Eds., Springer, N.Y. (1994).

Specific initiation signals can aid in efficient translation of a Rubisco polynucleotide-encoding sequence of the present invention. These signals can include, e.g., the ATG initiation codon and adjacent sequences. In cases where a Rubisco polypeptide-encoding sequence, its initiation codon and upstream sequences are inserted into an appropriate expression vector, no additional translational control signals may be needed. However, in cases where only coding sequence (e.g., a mature protein coding sequence), or a portion thereof, is inserted, exogenous transcriptional control signals including the initiation codon must be provided. Furthermore, the initiation codon must be in the correct reading frame to ensure transcription of the entire insert. Exogenous transcriptional elements and initiation codons can be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers appropriate to the cell system in use (Scharf D et al. (1994) *Results Probl Cell Differ* 20:125-62; Bittner et al. (1987) *Methods in Enzymol* 153:516-544).

Secretion/Localization Sequences

Polynucleotides of the invention can also be fused, for example, in-frame to nucleic acids encoding a secretion/localization sequence, to target polypeptide expression to a desired cellular compartment, membrane, or organelle of a cell, or to direct polypeptide secretion to the periplasmic space or into the cell culture media. Such sequences are known to those of skill, and include secretion leader peptides, organelle targeting sequences (e.g., nuclear localization sequences, ER retention signals, mitochondrial transit sequences, chloroplast transit sequences), membrane localization/anchor sequences (e.g., stop transfer sequences, GPI anchor sequences), and the like.

Expression Hosts

In a further embodiment, the present invention relates to host cells containing the above-described constructs. The host cell can be a eukaryotic cell, such as a plant cell. Alternatively, the host cell can be a prokaryotic cell, such as a bacterial cell, and more typically, a cyanobacterial cell. Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-Dextran mediated transfection, electroporation, or other common techniques (Davis, L., Dibner, M., and Battey, I. (1986) *Basic Methods in Molecular Biology*). Preferred host cells are those having the cellular machinery to carry out photosynthesis.

Expression Conditions

Host cells transformed with a Rubisco polynucleotide are optionally cultured under conditions to optimize carbon fixation by the host cell. The present invention provides a method of fixing carbon in a host cell, the method comprising:

- (i) introducing the vector comprising a Rubisco rbcLS polynucleotide into one or more photosynthesizing host cell;
- (ii) incubating the host cell to allow expression of a Rubisco rbcLS polynucleotide. Photosynthesizing host cells employed in the practice of the present invention include plant cells and cyanobacterial cells.

Suitable conditions for inducing carbon fixation in a cell capable of photosynthesis include exposure to light in the visible range. Typically, light having a wavelength in the range of from about 380 nm to 780 nm is employed. Transformed host cells are optimally incubated at a pH in the range of from about 7 to 11, and at a temperature in the range of from about 24° C. to about 32° C. Carbon dioxide can be provided in the form of atmospheric air, or with added CO₂ in an air/CO₂ mixture. Typically up to about 5% CO₂ is provided in a CO₂/air mixture. For large scale carbon fixation processes, the cells are typically incubated in a vessel that is transparent to light, under low shear agitation.

Fusion Polypeptides for Purification

Rubisco polypeptides of the present invention may also be expressed as part of a fusion polypeptide to facilitate purification of the encoded Rubisco polypeptide. Polynucleotides encoding such fusion polypeptides comprise a nucleic acid sequence corresponding to a Rubisco polynucleotide of the present invention that is fused-in frame to a purification facilitating domain. As used herein, the term "purification facilitating domain" refers to a domain that mediates purification of the polypeptide to which it is fused. Suitable purification domains include metal chelating peptides, histidine-tryptophan modules that allow purification on immobilized metals, a sequence which binds glutathione (e.g., GST), a hemagglutinin (HA) tag (corresponding to an epitope derived from the influenza hemagglutinin protein; Wilson et al. (1984) *Cell* 37:767), maltose binding protein sequences, the FLAG epitope utilized in the FLAGS extension/affinity purification system (Immunex Corp, Seattle, Wash.), and the like. The inclusion of a protease-cleavable polypeptide linker sequence between the purification domain and the Rubisco polypeptide is useful to facilitate purification. One expression vector contemplated for use in the compositions and methods described herein provides for expression of a fusion protein comprising a polypeptide of the invention fused to a polyhistidine region separated by an enterokinase cleavage site. The histidine residues facilitate purification on IMIAC (immobilized metal ion affinity chromatography, as described in Porath et al. (1992) *Protein*

Expression and Purification 3:263-281) while the enterokinase cleavage site provides a means for separating the Rubisco polypeptide from the fusion protein. pGEX vectors (Promega; Madison, Wis.) may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption to ligand-agarose beads (e.g., glutathione-agarose in the case of GST-fusions) followed by elution in the presence of free ligand.

Production and Recovery of Rubisco Polypeptides

Following transduction of a suitable host strain and growth of the host strain to an appropriate cell density, the selected promoter is induced by appropriate means (e.g., temperature shift or chemical induction) and cells are cultured for an additional period. Cells are typically harvested by centrifugation, disrupted by physical or chemical means, and the resulting crude extract retained for further purification. Microbial cells employed in expression of proteins can be disrupted by any convenient method, including freeze-thaw cycling, sonication, mechanical disruption, or use of cell lysing agents, or other methods, which are well known to those skilled in the art.

As noted, many references are available for the culture and production of many cells, including cells of bacterial, plant, animal (especially mammalian) and archebacterial origin. See e.g., Sambrook, Ausubel, and Berger (all supra), as well as Freshney (1994) *Culture of Animal Cells, a Manual of Basic Technique*, third edition, Wiley-Liss, New York and the references cited therein; Doyle and Griffiths (1997) *Mammalian Cell Culture: Essential Techniques* John Wiley and Sons, NY; Humason (1979) *Animal Tissue Techniques*, fourth edition W. H. Freeman and Company; and Ricciardelli, et al., (1989) *In vitro Cell Dev. Biol.* 25:1016-1024. For plant cell culture and regeneration, Payne et al. (1992) *Plant Cell and Tissue Culture in Liquid Systems* John Wiley & Sons, Inc. New York, N.Y.; Gamborg and Phillips (eds) (1995) *Plant Cell, Tissue and Organ Culture; Fundamental Methods* Springer Lab Manual, Springer-Verlag (Berlin Heidelberg New York); Jones, ed. (1984) *Plant Gene Transfer and Expression Protocols*, Humana Press, Totowa, N.J. and *Plant Molecular Biology* (1993) R. R. D. Croy, Ed. Bios Scientific Publishers, Oxford, U.K. ISBN 0 12 198370 6. Cell culture media in general are set forth in Atlas and Parks (eds) *The Handbook of Microbiological Media* (1993) CRC Press, Boca Raton, Fla. Additional information for cell culture is found in available commercial literature such as the *Life Science Research Cell Culture Catalogue* (1998) from Sigma-Aldrich, Inc (St Louis, Mo.) ("Sigma-LSRCCC") and, e.g., *The Plant Culture Catalogue* and supplement (1997) also from Sigma-Aldrich, Inc (St Louis, Mo.) ("Sigma-PCCS"). Further details regarding plant cell transformation and transgenic plant production are found below.

Rubisco polypeptides of the present invention can be recovered and purified from recombinant cell cultures by any of a number of methods well known in the art, including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography (e.g., using any of the tagging systems noted herein), hydroxylapatite chromatography, and lectin chromatography. Protein refolding steps can be used, as desired, in completing the configuration of the mature protein. Finally, high performance liquid chromatography (HPLC) can be employed in the final purification steps. In

addition to the references noted supra, a variety of purification methods are well known in the art, including, e.g., those set forth in Sandana (1997) *Bioseparation of Proteins*, Academic Press, Inc.; and Bollag et al. (1996) *Protein Methods*, 2nd Edition Wiley-Liss, NY; Walker (1996) *The Protein Protocols Handbook* Humana Press, NJ, Harris and Angal (1990) *Protein Purification Applications: A Practical Approach* IRL Press at Oxford, Oxford, England; Harris and Angal *Protein Purification Methods: A Practical Approach* IRL Press at Oxford, Oxford, England; Scopes (1993) *Protein Purification: Principles and Practice 3rd Edition* Springer Verlag, NY; Janson and Ryden (1998) *Protein Purification: Principles, High Resolution Methods and Applications, Second Edition* Wiley-VCH, NY; and Walker (1998) *Protein Protocols on CD-ROM* Humana Press, NJ.

In some cases it may be desirable to produce the Rubisco polypeptides of the invention in a large scale suitable for industrial and/or commercial applications. In such cases bulk fermentation procedures are employed. Briefly, a Rubisco polynucleotide, is cloned into an expression vector, such as, for example, the vector described in U.S. Pat. No. 5,955,310 to Widner et al. "METHODS FOR PRODUCING A POLYPEPTIDE IN A BACILLUS CELL. After inserting the polynucleotide of interest into a vector, the vector is transformed into a bacterial, e.g., a *Bacillus subtilis* strain PL1801IIE (amyE, apr, npr, spoIIE::Tn917) host. The introduction of an expression vector into a *Bacillus* cell may, for instance, be effected by protoplast transformation (see, e.g., Chang and Cohen (1979) *Molecular General Genetics* 168: 111), by using competent cells (see, e.g., Young and Spizizin (1961) *Journal of Bacteriology* 81:823, or Dubnau and Davidoff-Abelson (1971) *Journal of Molecular Biology* 56:209), by electroporation (see, e.g., Shigekawa and Dower (1988) *Biotechniques* 6:742), or by conjugation (see, e.g., Koehler and Thome (1987) *Journal of Bacteriology* 169: 5271).

The transformed cells are cultivated in a nutrient medium suitable for production of the polypeptide using methods that are known in the art. For example, the cell may be cultivated by shake flask cultivation, small-scale or large-scale fermentation (including continuous, batch, fed-batch, or solid state fermentations) in laboratory or industrial fermentors performed in a suitable medium and under conditions allowing the polypeptide to be expressed and/or isolated. The cultivation takes place in a suitable nutrient medium comprising carbon and nitrogen sources and inorganic salts, using procedures known in the art. Suitable media are available from commercial suppliers or may be prepared according to published compositions (e.g., in catalogues of the American Type Culture Collection). The secreted polypeptide can be recovered directly from the medium.

The resulting polypeptide may be isolated by methods known in the art. For example, the polypeptide may be isolated from the nutrient medium by conventional procedures including, but not limited to, centrifugation, filtration, extraction, spray-drying, evaporation, or precipitation. The isolated polypeptide may then be further purified by a variety of procedures known in the art including, but not limited to, chromatography (e.g., ion exchange, affinity, hydrophobic, chromatofocusing, and size exclusion), electrophoretic procedures (e.g., preparative isoelectric focusing), differential solubility (e.g., ammonium sulfate precipitation), or extraction (see, e.g., Bollag et al. (1996) *Protein Methods*, 2nd Edition Wiley-Liss, NY; Walker (1996) *The Protein Protocols Handbook* Humana Press, NJ; Bollag et

al. (1996) *Protein Methods 2nd Edition* Wiley-Liss, NY; Walker (1996) *The Protein Protocols Handbook* Humana Press, NJ).

Cell-free transcription/translation systems can also be employed to produce polypeptides using DNAs or RNAs of the present invention. Several such systems are commercially available. A general guide to in vitro transcription and translation protocols is found in Tymms (1995) *In vitro Transcription and Translation Protocols: Methods in Molecular Biology* Volume 37, Garland Publishing, NY.

The foregoing and other aspects of the invention may be better understood in connection with the following non-limiting examples.

EXAMPLES

Example 1

Expression of Ribulose 1,5-Bisphosphate Carboxylase/Oxygenase from *E. coli*

Transformation:

Rubisco polynucleotides of the present invention that encode both Rubisco large and small subunits were cloned into vector pCK 110700-I-Bla depicted in FIG. 2, then transformed into *E. Coli* host strain NM522 (Stratagene, La Jolla, Calif.) using heat shock treatment at 42° C.

Cell Growth:

200 µl of cell growth media (32 g casein hydrosylate, 6 g KH₂HPO₄, 6 g Na₂HPO₄, and 0.68 g K₂SO₄) was aliquoted into a Nunc steril 96 well flat bottomed plate. Cultures were inoculated with 160 µl/well cell media containing 1% glucose and 30 µg/ml chloramphenicol. Plates were sealed with Qiagen Air Pore Tape and a sterile Nunc plate lid was placed over the plates. The plates were shaken at 37° C. in a Kuhner Shaker.

Induction:

The next day, 290 µl of cell growth media with 1% glucose and 30 µg/mL chloramphenicol ("inducing media") was added to each well of a 96 well MegaTitre plate. Cells from the overnight cultures were mixed, then inoculated into the wells (10 µl/well) of the Megatitre plates containing the inducing media. The plates were sealed with Air Pore Tape and shaken at 37° C. in a Kuhner Shaker for 1 to 2 hours until reaching an OD600 of 0.2 to 0.6, after which 30 µl of 1 mM isoprophylthio-β-galactoside (IPTG) was added to each well. The plates were resealed and allowed to incubate on the shaker for 6 hours. The plates were then centrifuged at 3300 rpm for 15 minutes at 4° C. The cell pellets were stored at -20° C. until assayed.

Cell Lysis:

Cells were lysed just prior to assaying. 300 µl of lysis buffer (50 mM HEPES buffer pH 7.5, 300 mM KCl, 20 mM MgCl₂, 1 mM DTT, 5% Glycerol, 1 µl ReadyLyse Lysozyme per ml lysis buffer, 20 µl 10 mg/ml PMBS per ml lysis buffer, 1 µl 200 mM PMSF in isopropanol per ml lysis buffer) was added to each well of the plates. The plates were then sealed and shaken until the cells were lysed (30 minutes to 2 hours).

Example 2

Assay for Presence of Rubisco Activity

The following assay was used to ascertain the presence of Rubisco activity. 100 µl cell lysate from Example 1 was

transferred into the wells of a 96 well flat bottomed plate. A solution of ¹⁴C sodium bicarbonate was prepared by mixing 1 ml of a ¹⁴C sodium bicarbonate solution, 1 mCi/1 ml, (Sigma-Aldrich, Inc., St. Louis, Mo.) with 63 ml of 16 mM ¹²C sodium bicarbonate. A 330 mM stock solution of ribulose 1,5-bisphosphate was prepared by dissolving 100 mg ribulose 1,5-bisphosphate (Sigma-Aldrich, Inc., St. Louis, Mo.) in 1 ml water. The 330 mM ribulose 1,5-bisphosphate stock solution was diluted to make a 6 mM stock solution. 50 µl of a 50:50 6 mM Ribulose 1,5-Bisphosphate: ¹⁴C sodium bicarbonate solution was added to each well of the plate. After 1.5 to 2 hours, 100 µl 1N HCl was added to each well. The plates were then placed in a 70° C. oven overnight to dry.

A Nunc nylon transfer membrane was placed into the bottom of a Nunc Omnitrax (Nalge Nunc International, Rochester, N.Y.) and 3 µl of cell lysate/Ribulose 1,5-Bisphosphate: ¹⁴C sodium bicarbonate mixture from each well of the flat bottomed plate was transferred onto the nylon membrane. The membrane was allowed to dry, after which it was placed in a Molecular Dynamics Phosphorimaging Cassette (Amersham Biosciences, Piscataway, N.J.). The cassette was exposed overnight and the phosphorscreen was removed from the cassette and scanned in a Molecular Dynamics Phosphorimager using standard methods.

¹⁴C incorporation at a level greater than a negative control, which was a vector without a Rubisco polynucleotide (rbcLS) insert, indicated the presence of Rubisco activity.

Example 3

Assay to determine Specific Activity of Ribulose 1,5-Bisphosphate Carboxylase/Oxygenase

The value that roughly describes the specific activity of Rubisco is CPM/nM Rubisco. The following assay utilizes an active site titration with 2-carboxyarabinitol 1,5-bisphosphate (CABP) along with a time course ¹⁴CO₂ incorporation assay to roughly determine Rubisco specific activity.

50 µl aliquots of cell lysate from Example 1 were dispensed into polypropylene 96 well plates. Various concentrations of CABP inhibitor were added to the wells. 50 µl of the 50:50 Ribulose 1,5-bisphosphate ("RuBP"): ¹⁴C sodium bicarbonate solution was added to each well of the plates. In half the wells the reaction was stopped after 10 minutes by adding 50 µl of 1 N HCl. After 20 minutes, the reaction was stopped in the remaining wells by adding 50 µl of 1 N HCl. The plates were dried overnight at 70° C. The following day, 150 µl of 10 mM HCl was added to each well to resuspend the mixtures. The plates were blotted onto a nylon membrane, then exposed to phosphorscreens prior to phosphorimaging as described in Example 2.

Initial rates were monitored at saturating RuBP concentrations (1 mM) for the carboxylation reaction run for 5 minutes, with samples take at the following timepoints: 5=0, 1 minute, 2 minutes, 3 minutes, 4 minutes, and 5 minutes. The rates were determined as counts incorporated per minute or as density per minute. Rubisco polypeptide sample concentrations were determined using CABP titration as described below, and/or by quantitative western blots.

To compute Rubisco polypeptide sample concentrations from CABP titrations, Intensity vs. time was plotted for each concentration of CABP. From the slope of each plot (i.e., each plot corresponds to a fixed concentration of CABP), the value for CPM (i.e., counts per minute) was determined. A

31

plot of CPM/min vs. concentration of CABP was then made. The x-intercept provided the concentration for Rubisco. The specific activity was computed for each Rubisco polypeptide as CPM/weight Rubisco.

The specific activity values for the enzymes corresponding to Rubisco polypeptides of the present invention are provided in Table 3.

TABLE 3

Rubisco Specific Activity (counts per minute ("cpm")/min/mg)	
Clone Name	Rubisco Specific Activity (cpm/min/mg Rubisco)
RT24 (Encoded by SEQ ID NO: 4)	180
RT25 (Encoded by SEQ ID NO: 7)	300
RT28 (Encoded by SEQ ID NO: 10)	600
RT30 (Encoded by SEQ ID NO: 13)	600
RT106 (Encoded by SEQ ID NO: 106)	270
RT108 (Encoded by SEQ ID NO: 19)	180
RT111 (Encoded by SEQ ID NO: 22)	300
RT113 (Encoded by SEQ ID NO: 25)	480
RT115 (Encoded by SEQ ID NO: 28)	300
RT116 (Encoded by SEQ ID NO: 31)	300
RT117 (Encoded by SEQ ID NO: 34)	300
RT118 (Encoded by SEQ ID NO: 37)	300
<i>Synechococcus</i> PCC 6301 (wildtype, encoded by SEQ ID NO: 1)	300
F2A-10 (encoded by SEQ ID NO: 40)	1710
F2A-16 (encoded by SEQ ID NO: 43)	1530
F2A-20 (encoded by SEQ ID NO: 46)	580
F2B-2 (encoded by SEQ ID NO: 49)	1280
F2B-3 (encoded by SEQ ID NO: 52)	1280

Example 4

Michaelis-Menten Kinetics Characterization of Rubisco Polypeptides

V_{max} and K_M were determined by Michaelis-Menten kinetics for the Rubisco polypeptides encoded by SEQ ID NO: 1, 10, and 40. $^{14}\text{CO}_2$ incorporation was measured as

32

described in Example 3 at various timepoints. Rates were measured over a range of RuBP concentrations to obtain rate (V) vs. [RuBP (substrate)] plots that provided a best fit to the Michaelis-Menten kinetic equation:

$$V = V_{max} \frac{[\text{substrate (RuBP)}]}{[\text{substrate (RuBP)}] + K_M}$$

Using GraphPad Prism software, the V. vs. [RuBP] plots were fit to the Michaelis-Menten kinetic equation and V_{max} and K_M were extracted. K_{cat} (i.e., $V_{max}/[\text{Rubisco Polypeptide}]$) was determined from the previously determined V_{max} . Rubisco polypeptide concentration was determined from a quantitative western in accordance with methods known to those having ordinary skill in the art. The kinetic characterization data is provided in Table 4.

TABLE 4

Kinetic Parameters for Rubisco Polypeptides				
Rubisco Polypeptide (RuBP)	K_{cat} (s^{-1})	K_M (μM RuBP)	K_{cat}/K_M	k_{cat}/K_M normalized to wildtype <i>Synechococcus</i> sp. PCC6301
<i>Synechococcus</i> sp. PCC6301 (wildtype encoded by SEQ ID NO: 1)	6.3	78.6	0.08	1
RT28 (encoded by SEQ ID NO: 10)	2.6	20.8	0.13	1.6
F2A-10 (encoded by SEQ ID NO: 40)	26.5	58.5	0.45	5.7

Example 5

Transformation of Rubisco Polynucleotides into *Synechocystis* sp.

Rubisco polypeptides of the present invention were transformed into *Synechocystis* sp. PCC 6803 using the Gene replacement vector pGR-1 depicted in FIG. 3. The vector contains 1.5 kb of upstream sequence of *Synechocystis* sp. PCC6803 wildtype Rubisco gene, *rbcLS*, which contains the wildtype promoter and ribosome binding site. The upstream sequence also provides for homologous recombination to replace the wildtype Rubisco gene in *Synechocystis* sp. PCC 6803. The vector was designed so that the wildtype rubisco coding sequence is replaced with SEQ ID NO: 10 (clone RT28) via a double crossover in both 5' and 3' flanking regions. The vector was a pBluescript II KS (2.96 kb) from Invitrogen, Inc. (Carlsbad, Calif.) with the internal AflIII site destroyed. The kanamycin resistance cassette, *nptII*, was cloned from pUC4K. The polynucleotide sequence corresponding to SEQ ID NO: 10 was cloned into this gene replacement vector and transformed into *Synechocystis* 6803 At kanamycin 150 $\mu\text{g}/\text{ml}$, by a PCR check, it was determined to have replaced the wildtype Rubisco gene in about 50% of the clones.

Other vectors were designed for transforming Rubisco polynucleotides into *Synechocystis* sp. pDNR-1 (BD Biosciences, Clontech, Palo Alto, Calif.) is modified to remove

the loxP sites, replace the pUC origin of replication with a p15A origin of replication, and remove the chloramphenicol resistance cassette (Cm^R). In addition, 5' and 3' sequences flanking *Synechocystis* sp. rbcLS are inserted to create gene replacement vectors, pGR-2a, pGR-2b, and pGR-3a. Vector pGR-2a contains the 5' and 3' sequences flanking *Synechocystis* sp. rbcLS depicted as SEQ ID NOS: 58 and 59, respectively. Vector pGR-2b contains the 5' sequence flanking *Synechocystis* sp. rbcLS depicted as SEQ ID NOS: 60, and the same 3' flanking sequence as in pGR-2a (i.e., SEQ ID NO: 59). Vector pGR-3a contains the same 3' rbcLS flanking sequence as pGR-2a, and the 3' rbcLS flanking sequence depicted as SEQ ID NO: 61.

Synechocystis sp. PCC 6803 is transformed with the Rubisco polynucleotides of the present invention. A 20-50 ml PCC 6803 culture are grown on BG11+16 mM NaHCO₃ for about 4 to 5 days and cultured until reaching an OD730 of about 1 to 1.5 (~10⁸ cells/ml). All steps are carried out under visible light. 100 µl of cells (clumps broken up by mixing) are transferred into the wells of a sterile 96-well plate. 1-7 µg DNA (plasmid) is added and mixed with the cells. The plate is left uncovered under light at room temperature for about 24 hours. On day 2, all cells are plated directly on selective medium (BG11 agar+10 µg/ml kanamycin+16 mM NaHCO₃) and incubated under light at room temperature prior to picking.

Example 6

Whole Cell CO₂ Fixation Assay

The whole cell CO₂ fixation assay measures the flux through the Calvin cycle in a live-photosynthesizing cell. The difference between this assay and the in vitro assays described above is that RuBP is not added to the cells. The cells have the capability to regenerate RuBP using their endogenous Calvin cycle machinery. A schematic of the assay is provided in FIG. 4.

Synechocystis sp. PCC 6803 was cultured at room temperature, under light, and in BG11, 16 mM bicarbonate.

After reaching an OD730 of about 0.45 to 0.7, 600 µl of culture was placed into a short glass vial with cap and placed on a light box for about 15 minutes. Add 50 µl of a ¹⁴C sodium bicarbonate solution, 1 mCi/1 ml, (Sigma-Aldrich, Inc., St. Louis, Mo.) to 450 µl of cell. Take 50 µl of the culture/¹⁴C-NaHCO₃ mixture was quenched in 100 µl of 1 N HCl at various timepoints (e.g., t=0 minutes, 5 minutes, 10 minutes, 15 minutes, and so on) on a NUNC Heat Resistant (96 well) plate. Dry the plate completely overnight in an oven at -70° C. 150 µl of scintillation cocktail was added, and the vials were maintained away from the light. The plates were read by a scintillation counter. Normalized rates (CPM/min) to Rubisco concentrations obtained by quantitative western.

While the above CO₂ fixation assay was performed, 150 µl of culture was removed and quickly spun down to remove all supernatant for use in a western blot quantitation assay. The cell pellet was resuspended in 32.5 µl of water, 12.5 µl of NP0007 NUPAGE LDS Sample Buffer (4×) (Invitrogen, Carlsbad, Calif.). The resuspended mixture was boiled for about 10 minutes, after which 10 µl of NP0004 NUPAGE Sample Reducing Agent (10×) reducing agent (Invitrogen, Carlsbad, Calif.) was added. The boiled samples were flash frozen in a mixture of ethanol and dry ice, then stored at -20° C.

A quantitative western blot was done using Spinach Rubisco (Sigma-Aldrich, St. Louis, Mo.) as a standard, to quantify the amount of Rubisco polypeptide in the CO₂ fixation assay.

All publications, patents, patent applications, and other documents cited in this application are incorporated by reference in their entirety for all purposes to the same extent as if each individual publication, patent, patent application, or other document were individually indicated to be incorporated by reference for all purposes.

While preferred embodiments of the invention have been illustrated and described, it will be readily appreciated that various changes can be made therein without departing from the spirit and scope of the invention.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 61

<210> SEQ ID NO 1

<211> LENGTH: 1845

<212> TYPE: DNA

<213> ORGANISM: *Synechococcus* PCC 6301 rbcLS

<220> FEATURE:

<221> NAME/KEY: CDS

<222> LOCATION: (1)...(1419)

<223> OTHER INFORMATION: rbcL

<220> FEATURE:

<221> NAME/KEY: CDS

<222> LOCATION: (1510)...(1845)

<223> OTHER INFORMATION: rbcS

<400> SEQUENCE: 1

atg ccc aag acg caa tct gcc gca ggc tat aag gcc ggg gtg aag gac 48
Met Pro Lys Thr Gln Ser Ala Ala Gly Tyr Lys Ala Gly Val Lys Asp
1 5 10 15

tac aaa ctc acc tat tac acc ccc gat tac acc ccc aaa gac act gac 96
Tyr Lys Leu Thr Tyr Tyr Thr Pro Asp Tyr Thr Pro Lys Asp Thr Asp
20 25 30

-continued

ctg ctg gcg gct ttc cgc ttc agc cct cag ccg ggt gtc cct gct gac	144
Leu Leu Ala Ala Phe Arg Phe Ser Pro Gln Pro Gly Val Pro Ala Asp	
35 40 45	
gaa gct ggt gcg gcg atc gcg gct gaa tct tcg acc ggt acc tgg acc	192
Glu Ala Gly Ala Ala Ile Ala Ala Glu Ser Ser Thr Gly Thr Trp Thr	
50 55 60	
acc gtg tgg acc gac ttg ctg acc gac atg gat cgg tac aaa ggc aag	240
Thr Val Trp Thr Asp Leu Leu Thr Asp Met Asp Arg Tyr Lys Gly Lys	
65 70 75 80	
tgc tac cac atc gag ccg gtg caa ggc gaa gag aac tcc tac ttt gcg	288
Cys Tyr His Ile Glu Pro Val Gln Gly Glu Glu Asn Ser Tyr Phe Ala	
85 90 95	
ttc atc gct tac ccg ctc gac ctg ttt gaa gaa ggg tcg gtc acc aac	336
Phe Ile Ala Tyr Pro Leu Asp Leu Phe Glu Glu Gly Ser Val Thr Asn	
100 105 110	
atc ctg acc tcg atc gtc ggt aac gtg ttt ggc ttc aaa gct atc cgt	384
Ile Leu Thr Ser Ile Val Gly Asn Val Phe Gly Phe Lys Ala Ile Arg	
115 120 125	
tcg ctg cgt ctg gaa gac atc cgc ttc ccc gtc gcc ttg gtc aaa acc	432
Ser Leu Arg Leu Glu Asp Ile Arg Phe Pro Val Ala Leu Val Lys Thr	
130 135 140	
ttc caa ggt cct ccc cac ggt atc caa gtc gag cgc gac ctg ctg aac	480
Phe Gln Gly Pro Pro His Gly Ile Gln Val Glu Arg Asp Leu Leu Asn	
145 150 155 160	
aag tac ggc cgt ccg atg ctg ggt tgc acg atc aaa cca aaa ctc ggt	528
Lys Tyr Gly Arg Pro Met Leu Gly Cys Thr Ile Lys Pro Lys Leu Gly	
165 170 175	
ctg tcg gcg aaa aac tac ggt cgt gcc gtc tac gaa tgt ctg cgc ggc	576
Leu Ser Ala Lys Asn Tyr Gly Arg Ala Val Tyr Glu Cys Leu Arg Gly	
180 185 190	
ggt ctg gac ttc acc aaa gac gac gaa aac atc aac tcg cag ccg ttc	624
Gly Leu Asp Phe Thr Lys Asp Asp Glu Asn Ile Asn Ser Gln Pro Phe	
195 200 205	
caa cgc tgg cgc gat cgc ttc ctg ttt gtg gct gat gca atc cac aaa	672
Gln Arg Trp Arg Asp Arg Phe Leu Phe Val Ala Asp Ala Ile His Lys	
210 215 220	
tcg caa gca gaa acc ggt gaa atc aaa ggt cac tac ctg aac gtg acc	720
Ser Gln Ala Glu Thr Gly Glu Ile Lys Gly His Tyr Leu Asn Val Thr	
225 230 235 240	
gcg ccg acc tgc gaa gaa atg atg aaa ccg gct gag ttc gct aaa gaa	768
Ala Pro Thr Cys Glu Glu Met Met Lys Arg Ala Glu Phe Ala Lys Glu	
245 250 255	
ctc ggc atg ccg atc atc atg cat gac ttc ttg acg gct ggt ttc acc	816
Leu Gly Met Pro Ile Ile Met His Asp Phe Leu Thr Ala Gly Phe Thr	
260 265 270	
gcc aac acc acc ttg gca aaa tgg tgc cgc gac aac ggc gtc ctg ctg	864
Ala Asn Thr Thr Leu Ala Lys Trp Cys Arg Asp Asn Gly Val Leu Leu	
275 280 285	
cac atc cac cgt gca atg cac gcg gtg atc gac cgt cag cgt aac cac	912
His Ile His Arg Ala Met His Ala Val Ile Asp Arg Gln Arg Asn His	
290 295 300	
ggg att cac ttc cgt gtc ttg gcc aag tgt ttg cgt ctg tcc ggt ggt	960
Gly Ile His Phe Arg Val Leu Ala Lys Cys Arg Leu Arg Leu Ser Gly Gly	
305 310 315 320	
gac cac ctc cac tcc ggc acc gtc gtc ggc aaa ctg gaa ggc gac aaa	1008
Asp His Leu His Ser Gly Thr Val Val Gly Lys Leu Glu Gly Asp Lys	
325 330 335	
gct tcg acc ttg ggc ttt gtt gac ttg atg cgc gaa gac cac atc gaa	1056
Ala Ser Thr Leu Gly Phe Val Asp Leu Met Arg Glu Asp His Ile Glu	
340 345 350	

-continued

```

gct gac cgc agc cgt ggg gtc ttc ttc acc caa gat tgg gcg tcg atg      1104
Ala Asp Arg Ser Arg Gly Val Phe Phe Thr Gln Asp Trp Ala Ser Met
          355                      360                      365

ccg ggc gtg ctg ccg gtt gct tcc ggt ggt atc cac gtg tgg cac atg      1152
Pro Gly Val Leu Pro Val Ala Ser Gly Gly Ile His Val Trp His Met
          370                      375                      380

ccc gca ctg gtg gaa atc ttc ggt gat gac tcc gtt ctc cag ttc ggt      1200
Pro Ala Leu Val Glu Ile Phe Gly Asp Asp Ser Val Leu Gln Phe Gly
385                      390                      395                      400

ggc ggc acc ttg ggt cac ccc tgg ggt aat gct cct ggt gca acc gcg      1248
Gly Gly Thr Leu Gly His Pro Trp Gly Asn Ala Pro Gly Ala Thr Ala
          405                      410                      415

aac cgt gtt gcc ttg gaa gct tgc gtc caa gct cgg aac gaa ggt cgc      1296
Asn Arg Val Ala Leu Glu Ala Cys Val Gln Ala Arg Asn Glu Gly Arg
          420                      425                      430

gac ctc tac cgt gaa ggc ggc gac atc ctt cgt gaa gct ggc aag tgg      1344
Asp Leu Tyr Arg Glu Gly Gly Asp Ile Leu Arg Glu Ala Gly Lys Trp
          435                      440                      445

tcg cct gaa ctg gct gct gcc ctc gac ctc tgg aaa gag atc aag ttc      1392
Ser Pro Glu Leu Ala Ala Ala Leu Asp Leu Trp Lys Glu Ile Lys Phe
          450                      455                      460

gaa ttc gaa acg atg gac aag ctc taa ggagcctctg actatcgctg          1439
Glu Phe Glu Thr Met Asp Lys Leu *
465                      470

ggggagtgag cggtgctgcg taaagctttc tccccagcct ttcgacttaa cctttcagga 1499

tttctgaatc atg agc atg aaa act ctg ccc aaa gag cgt cgt ttc gag      1548
          Met Ser Met Lys Thr Leu Pro Lys Glu Arg Arg Phe Glu
          475                      480                      485

act ttc tcg tac ctg cct ccc ctc agc gat cgc caa atc gct gca caa      1596
Thr Phe Ser Tyr Leu Pro Pro Leu Ser Asp Arg Gln Ile Ala Ala Gln
          490                      495                      500

atc gag tac atg atc gag caa ggc ttc cac ccc ttg atc gag ttc aac      1644
Ile Glu Tyr Met Ile Glu Gln Gly Phe His Pro Leu Ile Glu Phe Asn
          505                      510                      515

gag cac tcg aat ccg gaa gag ttc tac tgg acg atg tgg aag ctc ccc      1692
Glu His Ser Asn Pro Glu Glu Phe Tyr Trp Thr Met Trp Lys Leu Pro
          520                      525                      530

ctg ttt gac tgc aag agc cct cag caa gtc ctc gat gaa gtg cgt gag      1740
Leu Phe Asp Cys Lys Ser Pro Gln Gln Val Leu Asp Glu Val Arg Glu
          535                      540                      545

tgc cgc agc gaa tac ggt gat tgc tac atc cgt gtc gct ggc ttc gac      1788
Cys Arg Ser Glu Tyr Gly Asp Cys Tyr Ile Arg Val Ala Gly Phe Asp
550                      555                      560                      565

aac atc aag cag tgc caa acc gtg agc ttc atc gtt cat cgt ccc ggc      1836
Asn Ile Lys Gln Cys Gln Thr Val Ser Phe Ile Val His Arg Pro Gly
          570                      575                      580

cgc tac taa
Arg Tyr *
          1845

```

```

<210> SEQ ID NO 2
<211> LENGTH: 472
<212> TYPE: PRT
<213> ORGANISM: Synechococcus PCC 6301
<220> FEATURE:
<221> NAME/KEY: DOMAIN
<222> LOCATION: (1)...(472)
<223> OTHER INFORMATION: Synechococcus rbcL

```

```

<400> SEQUENCE: 2

```

```

Met Pro Lys Thr Gln Ser Ala Ala Gly Tyr Lys Ala Gly Val Lys Asp

```


-continued

1	5	10	15
Tyr	Lys	Leu	Thr
	20		
	Tyr	Tyr	Thr
		Pro	Asp
		25	
		Tyr	Thr
		Pro	Lys
		Asp	Thr
		30	
Leu	Leu	Ala	Ala
	35		
	Phe	Arg	Phe
		Ser	Pro
		40	
		Gln	Pro
		Gly	Val
		Pro	Ala
		Asp	Asp
		45	
Glu	Ala	Gly	Ala
	50		
	Ala	Ile	Ala
		Ala	Ala
		55	
		Glu	Ser
		Ser	Thr
		Thr	Gly
		Thr	Trp
		Thr	Thr
Thr	Val	Trp	Thr
		Asp	Leu
		Leu	Leu
		Thr	Asp
		70	
		Met	Asp
		Arg	Tyr
		Lys	Gly
		Lys	Lys
		Gly	Lys
		80	
Cys	Tyr	His	Ile
		Glu	Pro
		Val	Gln
		Gly	Glu
		Glu	Asn
		Ser	Tyr
		Phe	Ala
		95	
Phe	Ile	Ala	Tyr
		Pro	Leu
		Asp	Leu
		Phe	Glu
		Glu	Gly
		Ser	Val
		Thr	Asn
		110	
Ile	Leu	Thr	Ser
		Ile	Val
		Gly	Asn
		Val	Phe
		Gly	Phe
		Lys	Ala
		Ile	Arg
		125	
Ser	Leu	Arg	Leu
		Glu	Asp
		Ile	Arg
		Phe	Pro
		Val	Ala
		Leu	Val
		Lys	Thr
		140	
Phe	Gln	Gly	Pro
		Pro	His
		Gly	Ile
		Gln	Val
		Glu	Arg
		Asp	Leu
		Leu	Asn
		160	
Lys	Tyr	Gly	Arg
		Pro	Met
		Leu	Gly
		Cys	Thr
		Ile	Lys
		Pro	Lys
		Leu	Gly
		175	
Leu	Ser	Ala	Lys
		Asn	Tyr
		Gly	Arg
		Ala	Val
		Thr	Glu
		Cys	Leu
		Arg	Gly
		190	
Gly	Leu	Asp	Phe
		Thr	Lys
		Asp	Asp
		Glu	Asn
		Ile	Asn
		Ser	Gln
		Pro	Phe
		205	
Gln	Arg	Trp	Arg
		Asp	Arg
		Phe	Leu
		Val	Ala
		Asp	Ala
		Ile	His
		Lys	Lys
		220	
Ser	Gln	Ala	Glu
		Thr	Gly
		Glu	Ile
		Lys	Gly
		His	Tyr
		Leu	Asn
		Val	Thr
		240	
Ala	Pro	Thr	Cys
		Glu	Glu
		Met	Met
		Lys	Arg
		Ala	Glu
		Phe	Ala
		Lys	Glu
		255	
Leu	Gly	Met	Pro
		Ile	Ile
		Met	His
		Asp	Phe
		Leu	Thr
		Ala	Gly
		Phe	Thr
		270	
Ala	Asn	Thr	Thr
		Leu	Ala
		Lys	Trp
		Cys	Arg
		Asp	Asn
		Gly	Val
		Leu	Leu
		285	
His	Ile	His	Arg
		Ala	Met
		His	Ala
		Val	Ile
		Asp	Arg
		Gln	Arg
		Asn	His
		300	
Gly	Ile	His	Phe
		Arg	Val
		Leu	Ala
		Lys	Cys
		Leu	Arg
		Leu	Ser
		Gly	Gly
		320	
Asp	His	Leu	His
		Ser	Gly
		Thr	Val
		Val	Gly
		Lys	Leu
		Glu	Gly
		Asp	Lys
		335	
Ala	Ser	Thr	Leu
		Gly	Phe
		Val	Asp
		Leu	Met
		Arg	Glu
		Asp	His
		Ile	Glu
		350	
Ala	Asp	Arg	Ser
		Arg	Gly
		Val	Phe
		Phe	Thr
		Gln	Asp
		Trp	Ala
		Ser	Met
		365	
Pro	Gly	Val	Leu
		Pro	Val
		Ala	Ser
		Gly	Gly
		Ile	His
		Val	Trp
		His	Met
		380	
Pro	Ala	Leu	Val
		Glu	Ile
		Phe	Gly
		Asp	Asp
		Ser	Val
		Leu	Gln
		Phe	Gly
		400	
Gly	Gly	Thr	Leu
		Gly	His
		Pro	Trp
		Gly	Asn
		Ala	Pro
		Gly	Ala
		Thr	Ala
		415	
Asn	Arg	Val	Ala
		Leu	Glu
		Ala	Cys
		Val	Gln
		Ala	Arg
		Asn	Glu
		Gly	Arg
		430	

-continued

Asp Leu Tyr Arg Glu Gly Gly Asp Ile Leu Arg Glu Ala Gly Lys Trp
 435 440 445

Ser Pro Glu Leu Ala Ala Ala Leu Asp Leu Trp Lys Glu Ile Lys Phe
 450 455 460

Glu Phe Glu Thr Met Asp Lys Leu
 465 470

<210> SEQ ID NO 3
 <211> LENGTH: 111
 <212> TYPE: PRT
 <213> ORGANISM: Synechococcus PCC 6301
 <220> FEATURE:
 <221> NAME/KEY: DOMAIN
 <222> LOCATION: (1)...(111)
 <223> OTHER INFORMATION: Synechococcus rbcS

<400> SEQUENCE: 3

Met Ser Met Lys Thr Leu Pro Lys Glu Arg Arg Phe Glu Thr Phe Ser
 1 5 10 15

Tyr Leu Pro Pro Leu Ser Asp Arg Gln Ile Ala Ala Gln Ile Glu Tyr
 20 25 30

Met Ile Glu Gln Gly Phe His Pro Leu Ile Glu Phe Asn Glu His Ser
 35 40 45

Asn Pro Glu Glu Phe Tyr Trp Thr Met Trp Lys Leu Pro Leu Phe Asp
 50 55 60

Cys Lys Ser Pro Gln Gln Val Leu Asp Glu Val Arg Glu Cys Arg Ser
 65 70 75 80

Glu Tyr Gly Asp Cys Tyr Ile Arg Val Ala Gly Phe Asp Asn Ile Lys
 85 90 95

Gln Cys Gln Thr Val Ser Phe Ile Val His Arg Pro Gly Arg Tyr
 100 105 110

<210> SEQ ID NO 4
 <211> LENGTH: 1842
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: RT24 rbcLS
 <220> FEATURE:
 <221> NAME/KEY: CDS
 <222> LOCATION: (1)...(1419)
 <223> OTHER INFORMATION: RT 24 rbcL
 <220> FEATURE:
 <221> NAME/KEY: CDS
 <222> LOCATION: (1510)...(1842)
 <223> OTHER INFORMATION: RT24 rbcS

<400> SEQUENCE: 4

atg ccc aag acg caa tct gcc gca ggc tat aag gcc ggg gtg aag gac 48
 Met Pro Lys Thr Gln Ser Ala Ala Gly Tyr Lys Ala Gly Val Lys Asp
 1 5 10 15

tac aaa ctc acc tat tac acc ccc gat tac acc ccc aaa gac act gac 96
 Tyr Lys Leu Thr Tyr Tyr Thr Pro Asp Tyr Thr Pro Lys Asp Thr Asp
 20 25 30

ctg ctg gcg gct ttc cgc ttc agc cct cag ccg ggt gtc cct gct gac 144
 Leu Leu Ala Ala Phe Arg Phe Ser Pro Gln Pro Gly Val Pro Ala Asp
 35 40 45

gaa gct ggt gcg gcg atc gcg gct gaa tct tcg acc ggt acc tgg acc 192
 Glu Ala Gly Ala Ala Ile Ala Ala Glu Ser Ser Thr Gly Thr Trp Thr
 50 55 60

acc gtg tgg acc gac ttg ctg acc gac atg gat cgg tac aaa ggc aag 240
 Thr Val Trp Thr Asp Leu Leu Thr Asp Met Asp Arg Tyr Lys Gly Lys

-continued

65	70	75	80	
tgc tac cac atc gag ccg gtg caa ggc gaa gag aac tcc tac ttt gcg Cys Tyr His Ile Glu Pro Val Gln Gly Glu Glu Asn Ser Tyr Phe Ala 85 90 95				288
ttc atc gct tac ccg ctc gac ctg ttt gaa gaa ggg tcg gtc acc aac Phe Ile Ala Tyr Pro Leu Asp Leu Phe Glu Glu Gly Ser Val Thr Asn 100 105 110				336
atc ctg acc tcg atc gtc ggt aac gtg ttt ggc ttc aaa gct atc cgt Ile Leu Thr Ser Ile Val Gly Asn Val Phe Gly Phe Lys Ala Ile Arg 115 120 125				384
tcg ctg cgt ctg gaa gac atc cgc ttc ccc gtc gcc ttg gtc aaa acc Ser Leu Arg Leu Glu Asp Ile Arg Phe Pro Val Ala Leu Val Lys Thr 130 135 140				432
ttc caa ggt cct ccc cac ggt atc caa gtc gag cgc gac ctg ctg aac Phe Gln Gly Pro Pro His Gly Ile Gln Val Glu Arg Asp Leu Leu Asn 145 150 155 160				480
aag tac ggc cgt ccg atg ctg ggt tgc acg atc aaa cca aaa ctc ggt Lys Tyr Gly Arg Pro Met Leu Gly Cys Thr Ile Lys Pro Lys Leu Gly 165 170 175				528
ctg tcg gcg aaa aac tac ggt cgt gcc gtc tac gaa tgt ctg cgc ggc Leu Ser Ala Lys Asn Tyr Gly Arg Ala Val Tyr Glu Cys Leu Arg Gly 180 185 190				576
ggt ctg gac ttc acc aaa gac gac gaa aac atc aac tcg cag ccg ttc Gly Leu Asp Phe Thr Lys Asp Asp Glu Asn Ile Asn Ser Gln Pro Phe 195 200 205				624
caa cgc tgg cgc gat cgc ttc ctg ttt gtg gct gat gca atc cac aaa Gln Arg Trp Arg Asp Arg Phe Leu Phe Val Ala Asp Ala Ile His Lys 210 215 220				672
tcg caa gca gaa acc ggt gaa atc aaa ggt cac tac ctg aac gtg acc Ser Gln Ala Glu Thr Gly Glu Ile Lys Gly His Tyr Leu Asn Val Thr 225 230 235 240				720
gcg ccg acc tgc gaa gaa atg atg aaa cgg gct gag ttc gct aag gaa Ala Pro Thr Cys Glu Glu Met Met Lys Arg Ala Glu Phe Ala Lys Glu 245 250 255				768
atc ggc aca cca atc atc atg cat gac ttc ttg acg gct ggt ttc acc Ile Gly Thr Pro Ile Ile Met His Asp Phe Leu Thr Ala Gly Phe Thr 260 265 270				816
gcc aac acc acc ttg gca aaa tgg tgc cgc gac aac ggc gtc ctg ctg Ala Asn Thr Thr Leu Ala Lys Trp Cys Arg Asp Asn Gly Val Leu Leu 275 280 285				864
cac atc cac cgt gca atg cac gcg gtg atc gac cgt cag cgt aac cac His Ile His Arg Ala Met His Ala Val Ile Asp Arg Gln Arg Asn His 290 295 300				912
ggg att cac ttc cgt gtc ttg gcc aag tgt ttg cgt atg tct ggt ggt Gly Ile His Phe Arg Val Leu Ala Lys Cys Leu Arg Met Ser Gly Gly 305 310 315 320				960
gac cac ctc cac tcc ggc acc gtc gtc ggc aaa ctg gaa ggc gac aaa Asp His Leu His Ser Gly Thr Val Val Gly Lys Leu Glu Gly Asp Lys 325 330 335				1008
gct tcg acc ttg ggc ttt gtt gac ttg atg cgc gaa gac cac atc gaa Ala Ser Thr Leu Gly Phe Val Asp Leu Met Arg Glu Asp His Ile Glu 340 345 350				1056
gct gac cgc agc cgt ggg gtc ttc ttc acc caa gat tgg gcg tcg atg Ala Asp Arg Ser Arg Gly Val Phe Phe Thr Gln Asp Trp Ala Ser Met 355 360 365				1104
ccg ggc gtg ctg ccg gtt gct tcc ggc ggt atc cac gtg tgg cac atg Pro Gly Val Leu Pro Val Ala Ser Gly Gly Ile His Val Trp His Met 370 375 380				1152
ccc gcc ctg gtc gcc atc ttc ggt gac gac tcc gtg ctc cag ttc ggt				1200

-continued

Pro Ala Leu Val Ala Ile Phe Gly Asp Asp Ser Val Leu Gln Phe Gly	
385	390 395 400
ggc ggc acc ttg ggt cac ccc tgg ggt aat gct cct ggt gca acc gcg	1248
Gly Gly Thr Leu Gly His Pro Trp Gly Asn Ala Pro Gly Ala Thr Ala	
	405 410 415
aac cgt gtt gcc ttg gaa gct tgc gtc caa gca cgt aac gaa ggt cgc	1296
Asn Arg Val Ala Leu Glu Ala Cys Val Gln Ala Arg Asn Glu Gly Arg	
	420 425 430
gac ctc tac cgt gaa ggc ggc gac atc ctt cgt gaa gct ggc aag tgg	1344
Asp Leu Tyr Arg Glu Gly Gly Asp Ile Leu Arg Glu Ala Gly Lys Trp	
	435 440 445
tcg cct gag ctg gcc atc gcc ctc gac ctc tgg aaa gag atc aag ttc	1392
Ser Pro Glu Leu Ala Ile Ala Leu Asp Leu Trp Lys Glu Ile Lys Phe	
	450 455 460
gaa ttc gaa acg atg gac aag ctc taa ggagcctctg actatcgctg	1439
Glu Phe Glu Thr Met Asp Lys Leu *	
	465 470
ggggagtgag cggttgcgcg taaagctttc tccccagcct ttcgacttaa cctttcagga	1499
tttctgaatc atg agc atg aaa act ctg ccc aaa gag cgt cgt ttc gag	1548
Met Ser Met Lys Thr Leu Pro Lys Glu Arg Arg Phe Glu	
	475 480 485
act ttc tcg tac ctg cct ccc ctc agc gat cgc caa atc gct gca caa	1596
Thr Phe Ser Tyr Leu Pro Pro Leu Ser Asp Arg Gln Ile Ala Ala Gln	
	490 495 500
atc gag tac atg atc gag caa ggc ttc cac ccc ttg atc gag ttc aac	1644
Ile Glu Tyr Met Ile Glu Gln Gly Phe His Pro Leu Ile Glu Phe Asn	
	505 510 515
gag cac tcg aat ccg gaa gag ttc tac tgg acg atg tgg aag ctc ccc	1692
Glu His Ser Asn Pro Glu Glu Phe Tyr Trp Thr Met Trp Lys Leu Pro	
	520 525 530
ctg ttt gac tgc aag agc cct cag caa gtc ctc gat gaa gtg cgt gag	1740
Leu Phe Asp Cys Lys Ser Pro Gln Gln Val Leu Asp Glu Val Arg Glu	
	535 540 545
tgc cgc agc gaa tac ggt gat tgc tac atc cgt gtc gct ggc ttc gac	1788
Cys Arg Ser Glu Tyr Gly Asp Cys Tyr Ile Arg Val Ala Gly Phe Asp	
	550 555 560 565
aac atc aag cag tgc caa acc gtg agc ttc atc gtt cat cgt ccc ggc	1836
Asn Ile Lys Gln Cys Gln Thr Val Ser Phe Ile Val His Arg Pro Gly	
	570 575 580
cgc tac	1842
Arg Tyr	

<210> SEQ ID NO 5
 <211> LENGTH: 472
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: RT24 rbcL

<400> SEQUENCE: 5

Met Pro Lys Thr Gln Ser Ala Ala Gly Tyr Lys Ala Gly Val Lys Asp	
1	5 10 15
Tyr Lys Leu Thr Tyr Tyr Thr Pro Asp Tyr Thr Pro Lys Asp Thr Asp	
	20 25 30
Leu Leu Ala Ala Phe Arg Phe Ser Pro Gln Pro Gly Val Pro Ala Asp	
	35 40 45
Glu Ala Gly Ala Ala Ile Ala Ala Glu Ser Ser Thr Gly Thr Trp Thr	
	50 55 60
Thr Val Trp Thr Asp Leu Leu Thr Asp Met Asp Arg Tyr Lys Gly Lys	

-continued

65	70	75	80
Cys Tyr His Ile Glu Pro Val Gln Gly Glu Glu Asn Ser Tyr Phe Ala	85	90	95
Phe Ile Ala Tyr Pro Leu Asp Leu Phe Glu Glu Gly Ser Val Thr Asn	100	105	110
Ile Leu Thr Ser Ile Val Gly Asn Val Phe Gly Phe Lys Ala Ile Arg	115	120	125
Ser Leu Arg Leu Glu Asp Ile Arg Phe Pro Val Ala Leu Val Lys Thr	130	135	140
Phe Gln Gly Pro Pro His Gly Ile Gln Val Glu Arg Asp Leu Leu Asn	145	150	155
Lys Tyr Gly Arg Pro Met Leu Gly Cys Thr Ile Lys Pro Lys Leu Gly	165	170	175
Leu Ser Ala Lys Asn Tyr Gly Arg Ala Val Tyr Glu Cys Leu Arg Gly	180	185	190
Gly Leu Asp Phe Thr Lys Asp Asp Glu Asn Ile Asn Ser Gln Pro Phe	195	200	205
Gln Arg Trp Arg Asp Arg Phe Leu Phe Val Ala Asp Ala Ile His Lys	210	215	220
Ser Gln Ala Glu Thr Gly Glu Ile Lys Gly His Tyr Leu Asn Val Thr	225	230	235
Ala Pro Thr Cys Glu Glu Met Met Lys Arg Ala Glu Phe Ala Lys Glu	245	250	255
Ile Gly Thr Pro Ile Ile Met His Asp Phe Leu Thr Ala Gly Phe Thr	260	265	270
Ala Asn Thr Thr Leu Ala Lys Trp Cys Arg Asp Asn Gly Val Leu Leu	275	280	285
His Ile His Arg Ala Met His Ala Val Ile Asp Arg Gln Arg Asn His	290	295	300
Gly Ile His Phe Arg Val Leu Ala Lys Cys Leu Arg Met Ser Gly Gly	305	310	315
Asp His Leu His Ser Gly Thr Val Val Gly Lys Leu Glu Gly Asp Lys	325	330	335
Ala Ser Thr Leu Gly Phe Val Asp Leu Met Arg Glu Asp His Ile Glu	340	345	350
Ala Asp Arg Ser Arg Gly Val Phe Phe Thr Gln Asp Trp Ala Ser Met	355	360	365
Pro Gly Val Leu Pro Val Ala Ser Gly Gly Ile His Val Trp His Met	370	375	380
Pro Ala Leu Val Ala Ile Phe Gly Asp Asp Ser Val Leu Gln Phe Gly	385	390	395
Gly Gly Thr Leu Gly His Pro Trp Gly Asn Ala Pro Gly Ala Thr Ala	405	410	415
Asn Arg Val Ala Leu Glu Ala Cys Val Gln Ala Arg Asn Glu Gly Arg	420	425	430
Asp Leu Tyr Arg Glu Gly Gly Asp Ile Leu Arg Glu Ala Gly Lys Trp	435	440	445
Ser Pro Glu Leu Ala Ile Ala Leu Asp Leu Trp Lys Glu Ile Lys Phe	450	455	460
Glu Phe Glu Thr Met Asp Lys Leu	465	470	

-continued

```

<211> LENGTH: 111
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: RT24 rbcS

<400> SEQUENCE: 6

Met Ser Met Lys Thr Leu Pro Lys Glu Arg Arg Phe Glu Thr Phe Ser
 1                5                10                15
Tyr Leu Pro Pro Leu Ser Asp Arg Gln Ile Ala Ala Gln Ile Glu Tyr
                20                25                30
Met Ile Glu Gln Gly Phe His Pro Leu Ile Glu Phe Asn Glu His Ser
                35                40                45
Asn Pro Glu Glu Phe Tyr Trp Thr Met Trp Lys Leu Pro Leu Phe Asp
 50                55                60
Cys Lys Ser Pro Gln Gln Val Leu Asp Glu Val Arg Glu Cys Arg Ser
 65                70                75                80
Glu Tyr Gly Asp Cys Tyr Ile Arg Val Ala Gly Phe Asp Asn Ile Lys
                85                90                95
Gln Cys Gln Thr Val Ser Phe Ile Val His Arg Pro Gly Arg Tyr
                100                105                110

```

```

<210> SEQ ID NO 7
<211> LENGTH: 1842
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: RT 25 rbcLS
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1)...(1419)
<223> OTHER INFORMATION: RT 25 rbcL
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1510)...(1842)
<223> OTHER INFORMATION: RT25 rbcS

```

```

<400> SEQUENCE: 7

atg ccc aag acg caa tct gcc gca ggc tat aag gcc ggg gtg aag gac      48
Met Pro Lys Thr Gln Ser Ala Ala Gly Tyr Lys Ala Gly Val Lys Asp
 1                5                10                15

tac aaa ctc acc tat tac acc ccc gat tac acc ccc aaa gac act gac      96
Tyr Lys Leu Thr Tyr Tyr Thr Pro Asp Tyr Thr Pro Lys Asp Thr Asp
                20                25                30

ctg ctg gcg gct ttc cgc ttc agc cct cag ccg ggt gtc cct gct gac      144
Leu Leu Ala Ala Phe Arg Phe Ser Pro Gln Pro Gly Val Pro Ala Asp
                35                40                45

gaa gct ggt gcg gcg atc gcg gct gaa tct tcg acc ggt acc tgg acc      192
Glu Ala Gly Ala Ala Ile Ala Ala Glu Ser Ser Thr Gly Thr Trp Thr
 50                55                60

acc gtg tgg acc gac ttg ctg acc gac atg gat cgg tac aaa ggc aag      240
Thr Val Trp Thr Asp Leu Leu Thr Asp Met Asp Arg Tyr Lys Gly Lys
 65                70                75                80

tgc tac cac atc gag ccg gtg caa ggc gaa gag aac tcc tac ttt gcg      288
Cys Tyr His Ile Glu Pro Val Gln Gly Glu Glu Asn Ser Tyr Phe Ala
                85                90                95

ttc atc gct tac ccg ctc gac ctg ttt gaa gaa ggg tct gtc acc aac      336
Phe Ile Ala Tyr Pro Leu Asp Leu Phe Glu Glu Gly Ser Val Thr Asn
                100                105                110

ttg ctc acc tca ttg gtt ggt aac gta ttc ggt ttc aag gct ctt cgc      384
Leu Leu Thr Ser Leu Val Gly Asn Val Phe Gly Phe Lys Ala Leu Arg
                115                120                125

```


-continued

gca ctt cgt cta gaa gac atc cgc gta ccc atc gca tac ttg aag act	432
Ala Leu Arg Leu Glu Asp Ile Arg Val Pro Ile Ala Tyr Leu Lys Thr	
130 135 140	
ttc caa ggt cct ccc cac ggt att caa gtc gag cgc gac ctg ctg aac	480
Phe Gln Gly Pro Pro His Gly Ile Gln Val Glu Arg Asp Leu Leu Asn	
145 150 155 160	
aag tac ggc cgt ccg atg ctg ggt tgc acg atc aaa cca aaa ctc ggt	528
Lys Tyr Gly Arg Pro Met Leu Gly Cys Thr Ile Lys Pro Lys Leu Gly	
165 170 175	
ctg tcg gcg aaa aac tac ggt cgt gcc gtc tac gaa tgt ctg cgc ggc	576
Leu Ser Ala Lys Asn Tyr Gly Arg Ala Val Tyr Glu Cys Leu Arg Gly	
180 185 190	
ggt ctg gac ttc acc aaa gac gac gaa aac atc aac tcg cag ccg ttc	624
Gly Leu Asp Phe Thr Lys Asp Asp Glu Asn Ile Asn Ser Gln Pro Phe	
195 200 205	
caa cgc tgg cgc gat cgc ttc ctg ttt gtg gct gat gca atc cac aaa	672
Gln Arg Trp Arg Asp Arg Phe Leu Phe Val Ala Asp Ala Ile His Lys	
210 215 220	
tcg caa gca gaa acc ggt gaa atc aaa ggt cac tac ctg aac gtg acc	720
Ser Gln Ala Glu Thr Gly Glu Ile Lys Gly His Tyr Leu Asn Val Thr	
225 230 235 240	
gcg ccg acc tgc gaa gaa atg atg aaa cgg gct gag ttc gct aaa gaa	768
Ala Pro Thr Cys Glu Glu Met Met Lys Arg Ala Glu Phe Ala Lys Glu	
245 250 255	
ctc ggc atg ccg atc atc atg cat gac ttc ttg acg gct ggt ttc acc	816
Leu Gly Met Pro Ile Ile Met His Asp Phe Leu Thr Ala Gly Phe Thr	
260 265 270	
gcc aac acc acc ttg gca aaa tgg tgc cgc gac aac ggc gtc ctg ctg	864
Ala Asn Thr Thr Leu Ala Lys Trp Cys Arg Asp Asn Gly Val Leu Leu	
275 280 285	
cac att cac cgc gct atg cac gca gtt atc gac cgt cag cgt aac cac	912
His Ile His Arg Ala Met His Ala Val Ile Asp Arg Gln Arg Asn His	
290 295 300	
ggg att cac ttc cgt gtc ttg gcc aag tgc ctg cgc ctc tcc ggt ggc	960
Gly Ile His Phe Arg Val Leu Ala Lys Cys Leu Arg Leu Ser Gly Gly	
305 310 315 320	
gac cag ctc cac acc ggc acc gtg gtg ggc aag ctc gag ggt gac cgt	1008
Asp Gln Leu His Thr Gly Thr Val Val Gly Lys Leu Glu Gly Asp Arg	
325 330 335	
cag acc acc ctg ggc ttc atc gac cag ctg cgc gaa tcc ttc atc ccc	1056
Gln Thr Thr Leu Gly Phe Ile Asp Gln Leu Arg Glu Ser Phe Ile Pro	
340 345 350	
gaa gac cgc acc cgc ggc aac ttc ttc gat cag gac tgg ggt tcg atg	1104
Glu Asp Arg Thr Arg Gly Asn Phe Phe Asp Gln Asp Trp Gly Ser Met	
355 360 365	
ccc ggc gtc ttc gcc gtg gcc tcc ggc ggc atc cac gtg tgg cac atg	1152
Pro Gly Val Phe Ala Val Ala Ser Gly Gly Ile His Val Trp His Met	
370 375 380	
ccc gca ctg gtg gaa atc ttc ggt gat gac tcc gtg ctc cag ttc ggt	1200
Pro Ala Leu Val Glu Ile Phe Gly Asp Asp Ser Val Leu Gln Phe Gly	
385 390 395 400	
ggc ggc acc ttg ggt cac ccc tgg ggt aat gct cct ggt gca acc gcg	1248
Gly Gly Thr Leu Gly His Pro Trp Gly Asn Ala Pro Gly Ala Thr Ala	
405 410 415	
aac cgt gtt gcc ttg gaa gct tgc gtc caa gct cgg aac gaa ggt cgc	1296
Asn Arg Val Ala Leu Glu Ala Cys Val Gln Ala Arg Asn Glu Gly Arg	
420 425 430	
gac ctc tac cgt gaa ggc ggc gac atc ctt cgt gaa gct ggc aag tgg	1344
Asp Leu Tyr Arg Glu Gly Gly Asp Ile Leu Arg Glu Ala Gly Lys Trp	
435 440 445	

-continued

tcg cct gaa ctg gct gct gcc ctc gac ctc tgg aaa gag atc aag ttc	1392
Ser Pro Glu Leu Ala Ala Ala Leu Asp Leu Trp Lys Glu Ile Lys Phe	
450 455 460	
gaa ttc gaa acg atg gac aag ctc taa ggagcctctg actatcgctg	1439
Glu Phe Glu Thr Met Asp Lys Leu *	
465 470	
ggggagtgag cgttgctgcg taaagctttc tccccagcct ttcgacttaa cctttcagga	1499
tttctgaatc atg agc atg aaa act ctg ccc aaa gag cgt cgt ttc gag	1548
Met Ser Met Lys Thr Leu Pro Lys Glu Arg Arg Phe Glu	
475 480 485	
act ttc tcg tac ctg cct ccc ctc agc gat cgc caa atc gct gca cag	1596
Thr Phe Ser Tyr Leu Pro Pro Leu Ser Asp Arg Gln Ile Ala Ala Gln	
490 495 500	
atc gag tac atg atc gag caa ggc ttc cac ccc ttg atc gag ttc aac	1644
Ile Glu Tyr Met Ile Glu Gln Gly Phe His Pro Leu Ile Glu Phe Asn	
505 510 515	
gag cac tcg aat ccg gaa gag ttc tac tgg acg atg tgg aag ctc ccc	1692
Glu His Ser Asn Pro Glu Glu Phe Tyr Trp Thr Met Trp Lys Leu Pro	
520 525 530	
ctg ttt gac tgc aag agc cct cag caa gtc ctc gat gaa gtg cgt gag	1740
Leu Phe Asp Cys Lys Ser Pro Gln Gln Val Leu Asp Glu Val Arg Glu	
535 540 545	
tgc cgc agc gaa tac ggt gat tgc tac atc cgt gtc gct ggc ttc gac	1788
Cys Arg Ser Glu Tyr Gly Asp Cys Tyr Ile Arg Val Ala Gly Phe Asp	
550 555 560 565	
aac atc aag cag tgc caa acc gtg agc ttc atc gtt cat cgt ccc ggc	1836
Asn Ile Lys Gln Cys Gln Thr Val Ser Phe Ile Val His Arg Pro Gly	
570 575 580	
cgc tac	1842
Arg Tyr	

<210> SEQ ID NO 8
 <211> LENGTH: 472
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: RT25 rbcL

<400> SEQUENCE: 8

Met Pro Lys Thr Gln Ser Ala Ala Gly Tyr Lys Ala Gly Val Lys Asp	
1 5 10 15	
Tyr Lys Leu Thr Tyr Tyr Thr Pro Asp Tyr Thr Pro Lys Asp Thr Asp	
20 25 30	
Leu Leu Ala Ala Phe Arg Phe Ser Pro Gln Pro Gly Val Pro Ala Asp	
35 40 45	
Glu Ala Gly Ala Ala Ile Ala Ala Glu Ser Ser Thr Gly Thr Trp Thr	
50 55 60	
Thr Val Trp Thr Asp Leu Leu Thr Asp Met Asp Arg Tyr Lys Gly Lys	
65 70 75 80	
Cys Tyr His Ile Glu Pro Val Gln Gly Glu Glu Asn Ser Tyr Phe Ala	
85 90 95	
Phe Ile Ala Tyr Pro Leu Asp Leu Phe Glu Glu Gly Ser Val Thr Asn	
100 105 110	
Leu Leu Thr Ser Leu Val Gly Asn Val Phe Gly Phe Lys Ala Leu Arg	
115 120 125	
Ala Leu Arg Leu Glu Asp Ile Arg Val Pro Ile Ala Tyr Leu Lys Thr	
130 135 140	

-continued

Phe Gln Gly Pro Pro His Gly Ile Gln Val Glu Arg Asp Leu Leu Asn
 145 150 155 160

Lys Tyr Gly Arg Pro Met Leu Gly Cys Thr Ile Lys Pro Lys Leu Gly
 165 170 175

Leu Ser Ala Lys Asn Tyr Gly Arg Ala Val Tyr Glu Cys Leu Arg Gly
 180 185 190

Gly Leu Asp Phe Thr Lys Asp Asp Glu Asn Ile Asn Ser Gln Pro Phe
 195 200 205

Gln Arg Trp Arg Asp Arg Phe Leu Phe Val Ala Asp Ala Ile His Lys
 210 215 220

Ser Gln Ala Glu Thr Gly Glu Ile Lys Gly His Tyr Leu Asn Val Thr
 225 230 235 240

Ala Pro Thr Cys Glu Glu Met Met Lys Arg Ala Glu Phe Ala Lys Glu
 245 250 255

Leu Gly Met Pro Ile Ile Met His Asp Phe Leu Thr Ala Gly Phe Thr
 260 265 270

Ala Asn Thr Thr Leu Ala Lys Trp Cys Arg Asp Asn Gly Val Leu Leu
 275 280 285

His Ile His Arg Ala Met His Ala Val Ile Asp Arg Gln Arg Asn His
 290 295 300

Gly Ile His Phe Arg Val Leu Ala Lys Cys Leu Arg Leu Ser Gly Gly
 305 310 315 320

Asp Gln Leu His Thr Gly Thr Val Val Gly Lys Leu Glu Gly Asp Arg
 325 330 335

Gln Thr Thr Leu Gly Phe Ile Asp Gln Leu Arg Glu Ser Phe Ile Pro
 340 345 350

Glu Asp Arg Thr Arg Gly Asn Phe Phe Asp Gln Asp Trp Gly Ser Met
 355 360 365

Pro Gly Val Phe Ala Val Ala Ser Gly Gly Ile His Val Trp His Met
 370 375 380

Pro Ala Leu Val Glu Ile Phe Gly Asp Asp Ser Val Leu Gln Phe Gly
 385 390 395 400

Gly Gly Thr Leu Gly His Pro Trp Gly Asn Ala Pro Gly Ala Thr Ala
 405 410 415

Asn Arg Val Ala Leu Glu Ala Cys Val Gln Ala Arg Asn Glu Gly Arg
 420 425 430

Asp Leu Tyr Arg Glu Gly Gly Asp Ile Leu Arg Glu Ala Gly Lys Trp
 435 440 445

Ser Pro Glu Leu Ala Ala Ala Leu Asp Leu Trp Lys Glu Ile Lys Phe
 450 455 460

Glu Phe Glu Thr Met Asp Lys Leu
 465 470

<210> SEQ ID NO 9
 <211> LENGTH: 111
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: RT25 rbcS

<400> SEQUENCE: 9

Met Ser Met Lys Thr Leu Pro Lys Glu Arg Arg Phe Glu Thr Phe Ser
 1 5 10 15

Tyr Leu Pro Pro Leu Ser Asp Arg Gln Ile Ala Ala Gln Ile Glu Tyr
 20 25 30

-continued

```

Met Ile Glu Gln Gly Phe His Pro Leu Ile Glu Phe Asn Glu His Ser
      35                      40                      45

Asn Pro Glu Glu Phe Tyr Trp Thr Met Trp Lys Leu Pro Leu Phe Asp
      50                      55                      60

Cys Lys Ser Pro Gln Gln Val Leu Asp Glu Val Arg Glu Cys Arg Ser
      65                      70                      75                      80

Glu Tyr Gly Asp Cys Tyr Ile Arg Val Ala Gly Phe Asp Asn Ile Lys
      85                      90                      95

Gln Cys Gln Thr Val Ser Phe Ile Val His Arg Pro Gly Arg Tyr
      100                      105                      110

```

```

<210> SEQ ID NO 10
<211> LENGTH: 1865
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: RT28 rbcLS
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1)...(1419)
<223> OTHER INFORMATION: RT28 rbcL
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1510)...(1845)
<223> OTHER INFORMATION: RT28 rbcS

```

```

<400> SEQUENCE: 10

```

```

atg ccc aag acg caa tct gcc gca ggc tat aag gcc ggg gtg aag gac      48
Met Pro Lys Thr Gln Ser Ala Ala Gly Tyr Lys Ala Gly Val Lys Asp
 1                      5                      10                      15

tac aaa ctc acc tat tac acc ccc gat tac acc ccc aaa gac act gac      96
Tyr Lys Leu Thr Tyr Tyr Thr Pro Asp Tyr Thr Pro Lys Asp Thr Asp
      20                      25                      30

ctg ctg gcg gct ttc cgc ttc agc cct cag ccg ggt gtc cct gct gac      144
Leu Leu Ala Ala Phe Arg Phe Ser Pro Gln Pro Gly Val Pro Ala Asp
      35                      40                      45

gaa gct ggt gcg gcg atc gcg gct gaa tct tcg acc ggt acc tgg acc      192
Glu Ala Gly Ala Ala Ile Ala Ala Glu Ser Ser Thr Gly Thr Trp Thr
      50                      55                      60

acc gtg tgg acc gac ttg ctg acc gac atg gat cgg tac aaa ggc aag      240
Thr Val Trp Thr Asp Leu Leu Thr Asp Met Asp Arg Tyr Lys Gly Lys
      65                      70                      75                      80

tgc tac cac gtc gag ccg gtg caa ggc gaa gag aac tcc tac ttt gcg      288
Cys Tyr His Val Glu Pro Val Gln Gly Glu Glu Asn Ser Tyr Phe Ala
      85                      90                      95

ttc atc gct tac ccg ctc gac ctg ttt gaa gaa ggg tcg gtc acc aac      336
Phe Ile Ala Tyr Pro Leu Asp Leu Phe Glu Glu Gly Ser Val Thr Asn
      100                      105                      110

atc ctg acc tcg atc gtc ggt aac gtg ttt ggc ttc aaa gct atc cgt      384
Ile Leu Thr Ser Ile Val Gly Asn Val Phe Gly Phe Lys Ala Ile Arg
      115                      120                      125

tcg ctg cgt ctg gaa gac atc cgc ttc ccc gtc gcc ttg gtc aaa acc      432
Ser Leu Arg Leu Glu Asp Ile Arg Phe Pro Val Ala Leu Val Lys Thr
      130                      135                      140

ttc caa ggt cct cct cac ggt att caa gtt gaa cgc gac aag ttg aac      480
Phe Gln Gly Pro Pro His Gly Ile Gln Val Glu Arg Asp Lys Leu Asn
      145                      150                      155                      160

aag tac ggt cgt cct ctc ttg ggt tgt acc att aag ccc aaa cta ggc      528
Lys Tyr Gly Arg Pro Leu Leu Gly Cys Thr Ile Lys Pro Lys Leu Gly
      165                      170                      175

cta tct gct aag aac tac ggt cgt gca gta tac gaa tgt cta cgc ggt      576
Leu Ser Ala Lys Asn Tyr Gly Arg Ala Val Tyr Glu Cys Leu Arg Gly

```

-continued

180	185	190	
ggt ttg gac ttc acc aaa gac gac gaa aac atc aac tcg cag ccg ttc Gly Leu Asp Phe Thr Lys Asp Asp Glu Asn Ile Asn Ser Gln Pro Phe 195 200 205			624
caa cgc tgg cgc gat cgc ttc ctg ttt gtg gct gat gca atc cac aaa Gln Arg Trp Arg Asp Arg Phe Leu Phe Val Ala Asp Ala Ile His Lys 210 215 220			672
tcg caa gca gaa acc ggt gaa atc aaa ggt cac tac ctg aac gtg acc Ser Gln Ala Glu Thr Gly Glu Ile Lys Gly His Tyr Leu Asn Val Thr 225 230 235 240			720
gcg ccg acc tgc gaa gaa atg atg aaa cgg gct gag ttc gct aaa gaa Ala Pro Thr Cys Glu Glu Met Met Lys Arg Ala Glu Phe Ala Lys Glu 245 250 255			768
ctc ggc atg ccg atc atc atg cat gac ttc ttg acg gct ggt ttc acc Leu Gly Met Pro Ile Ile Met His Asp Phe Leu Thr Ala Gly Phe Thr 260 265 270			816
gcc aac acc acc ttg gca aaa tgg tgc cgc gac aac ggc gtc ctg ctg Ala Asn Thr Thr Leu Ala Lys Trp Cys Arg Asp Asn Gly Val Leu Leu 275 280 285			864
cac atc cac cgt gca atg cac gcg gtg atc gac cgt cag cgt aac cac His Ile His Arg Ala Met His Ala Val Ile Asp Arg Gln Arg Asn His 290 295 300			912
ggg att cac ttc cgc gtt ttg gct aag tgt ctg cgt atg tct ggt ggt Gly Ile His Phe Arg Val Leu Ala Lys Cys Leu Arg Met Ser Gly Gly 305 310 315 320			960
gat cac ctc cac tct ggc acc gtc gtc ggc aaa ctg gaa ggc gac aaa Asp His Leu His Ser Gly Thr Val Val Gly Lys Leu Glu Gly Asp Lys 325 330 335			1008
gct tcg acc ttg ggc ttt gtt gac ttg atg cgc gaa gac cac atc gaa Ala Ser Thr Leu Gly Phe Val Asp Leu Met Arg Glu Asp His Ile Glu 340 345 350			1056
gct gac cgc agc cgt ggg gtc ttc ttc acc caa gat tgg gcg tcg atg Ala Asp Arg Ser Arg Gly Val Phe Phe Thr Gln Asp Trp Ala Ser Met 355 360 365			1104
ccg ggc gtg ctg ccg gtt gct tcc ggt ggt atc cac gtg tgg cac atg Pro Gly Val Leu Pro Val Ala Ser Gly Gly Ile His Val Trp His Met 370 375 380			1152
ccc gca ctg gtg gaa atc ttc ggt gat gac tcc gtt ctc cag ttc ggt Pro Ala Leu Val Glu Ile Phe Gly Asp Asp Ser Val Leu Gln Phe Gly 385 390 395 400			1200
ggc ggc acc ttg ggt cac ccc tgg ggt aat gct cct ggt gca atc gcg Gly Gly Thr Leu Gly His Pro Trp Gly Asn Ala Pro Gly Ala Ile Ala 405 410 415			1248
aac cgt gtt gcc ttg gaa gct tgc gtc caa gct cgg aac gaa ggt cgc Asn Arg Val Ala Leu Glu Ala Cys Val Gln Ala Arg Asn Glu Gly Arg 420 425 430			1296
gac ctc tac cgt gaa ggc ggc gac atc ctt cgt gaa gct ggc aag tgg Asp Leu Tyr Arg Glu Gly Gly Asp Ile Leu Arg Glu Ala Gly Lys Trp 435 440 445			1344
tcg cct gaa ctg gct gct gcc ctc gac ctc tgg aaa gag atc aag ttc Ser Pro Glu Leu Ala Ala Ala Leu Asp Leu Trp Lys Glu Ile Lys Phe 450 455 460			1392
gaa ttc gaa acg atg gac aag ctc taa ggagcctctg actatcgcctg Glu Phe Glu Thr Met Asp Lys Leu * 465 470			1439
ggggagtgag cggttgctgcg taaagctttc tccccagcct ttcgacttaa cctttcagga			1499
tttctgaatc atg agc atg aaa act ctg ccc aaa gag cgt cgt ttc gag Met Ser Met Lys Thr Leu Pro Lys Glu Arg Arg Phe Glu 475 480 485			1548

-continued

```

act ttc tcg tac ctg cct ccc ctc agc aat cgc caa atc gct gca caa 1596
Thr Phe Ser Tyr Leu Pro Pro Leu Ser Asn Arg Gln Ile Ala Ala Gln
          490                      495                      500

atc gag tac atg atc gag caa ggc ttc cac ccc ttg atc gag ttc aac 1644
Ile Glu Tyr Met Ile Glu Gln Gly Phe His Pro Leu Ile Glu Phe Asn
          505                      510                      515

gag cac tcg aat ccg gaa gag ttc tac tgg acg atg tgg aag ctc ccc 1692
Glu His Ser Asn Pro Glu Glu Phe Tyr Trp Thr Met Trp Lys Leu Pro
          520                      525                      530

ctg ttt gac tgc aag agc cct cag caa gtc ctc gat gaa gtg cgt gag 1740
Leu Phe Asp Cys Lys Ser Pro Gln Gln Val Leu Asp Glu Val Arg Glu
          535                      540                      545

tgc cgc agc gaa tac ggt gat tgc tac atc cgt gtc gct ggc ttc gac 1788
Cys Arg Ser Glu Tyr Gly Asp Cys Tyr Ile Arg Val Ala Gly Phe Asp
550                      555                      560                      565

aac atc aag cag tgc caa acc gtg agc ttc atc gtt cat cgt ccc ggc 1836
Asn Ile Lys Gln Cys Gln Thr Val Ser Phe Ile Val His Arg Pro Gly
          570                      575                      580

cgc tac taa tgaggccaaa ctggccatgc 1865
Arg Tyr *
```

```

<210> SEQ ID NO 11
<211> LENGTH: 472
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: RT28 rbcL
```

```

<400> SEQUENCE: 11
```

```

Met Pro Lys Thr Gln Ser Ala Ala Gly Tyr Lys Ala Gly Val Lys Asp
 1          5          10          15

Tyr Lys Leu Thr Tyr Tyr Thr Pro Asp Tyr Thr Pro Lys Asp Thr Asp
          20          25          30

Leu Leu Ala Ala Phe Arg Phe Ser Pro Gln Pro Gly Val Pro Ala Asp
          35          40          45

Glu Ala Gly Ala Ala Ile Ala Ala Glu Ser Ser Thr Gly Thr Trp Thr
 50          55          60

Thr Val Trp Thr Asp Leu Leu Thr Asp Met Asp Arg Tyr Lys Gly Lys
65          70          75          80

Cys Tyr His Val Glu Pro Val Gln Gly Glu Glu Asn Ser Tyr Phe Ala
          85          90          95

Phe Ile Ala Tyr Pro Leu Asp Leu Phe Glu Glu Gly Ser Val Thr Asn
          100          105          110

Ile Leu Thr Ser Ile Val Gly Asn Val Phe Gly Phe Lys Ala Ile Arg
          115          120          125

Ser Leu Arg Leu Glu Asp Ile Arg Phe Pro Val Ala Leu Val Lys Thr
          130          135          140

Phe Gln Gly Pro Pro His Gly Ile Gln Val Glu Arg Asp Lys Leu Asn
          145          150          155          160

Lys Tyr Gly Arg Pro Leu Leu Gly Cys Thr Ile Lys Pro Lys Leu Gly
          165          170          175

Leu Ser Ala Lys Asn Tyr Gly Arg Ala Val Tyr Glu Cys Leu Arg Gly
          180          185          190

Gly Leu Asp Phe Thr Lys Asp Asp Glu Asn Ile Asn Ser Gln Pro Phe
          195          200          205

Gln Arg Trp Arg Asp Arg Phe Leu Phe Val Ala Asp Ala Ile His Lys
          210          215          220
```

-continued

Ser Gln Ala Glu Thr Gly Glu Ile Lys Gly His Tyr Leu Asn Val Thr
 225 230 235 240
 Ala Pro Thr Cys Glu Glu Met Met Lys Arg Ala Glu Phe Ala Lys Glu
 245 250 255
 Leu Gly Met Pro Ile Ile Met His Asp Phe Leu Thr Ala Gly Phe Thr
 260 265 270
 Ala Asn Thr Thr Leu Ala Lys Trp Cys Arg Asp Asn Gly Val Leu Leu
 275 280 285
 His Ile His Arg Ala Met His Ala Val Ile Asp Arg Gln Arg Asn His
 290 295 300
 Gly Ile His Phe Arg Val Leu Ala Lys Cys Leu Arg Met Ser Gly Gly
 305 310 315 320
 Asp His Leu His Ser Gly Thr Val Val Gly Lys Leu Glu Gly Asp Lys
 325 330 335
 Ala Ser Thr Leu Gly Phe Val Asp Leu Met Arg Glu Asp His Ile Glu
 340 345 350
 Ala Asp Arg Ser Arg Gly Val Phe Phe Thr Gln Asp Trp Ala Ser Met
 355 360 365
 Pro Gly Val Leu Pro Val Ala Ser Gly Gly Ile His Val Trp His Met
 370 375 380
 Pro Ala Leu Val Glu Ile Phe Gly Asp Asp Ser Val Leu Gln Phe Gly
 385 390 395 400
 Gly Gly Thr Leu Gly His Pro Trp Gly Asn Ala Pro Gly Ala Ile Ala
 405 410 415
 Asn Arg Val Ala Leu Glu Ala Cys Val Gln Ala Arg Asn Glu Gly Arg
 420 425 430
 Asp Leu Tyr Arg Glu Gly Gly Asp Ile Leu Arg Glu Ala Gly Lys Trp
 435 440 445
 Ser Pro Glu Leu Ala Ala Ala Leu Asp Leu Trp Lys Glu Ile Lys Phe
 450 455 460
 Glu Phe Glu Thr Met Asp Lys Leu
 465 470

<210> SEQ ID NO 12
 <211> LENGTH: 111
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: RT28 rbcS

<400> SEQUENCE: 12

Met Ser Met Lys Thr Leu Pro Lys Glu Arg Arg Phe Glu Thr Phe Ser
 1 5 10 15
 Tyr Leu Pro Pro Leu Ser Asn Arg Gln Ile Ala Ala Gln Ile Glu Tyr
 20 25 30
 Met Ile Glu Gln Gly Phe His Pro Leu Ile Glu Phe Asn Glu His Ser
 35 40 45
 Asn Pro Glu Glu Phe Tyr Trp Thr Met Trp Lys Leu Pro Leu Phe Asp
 50 55 60
 Cys Lys Ser Pro Gln Gln Val Leu Asp Glu Val Arg Glu Cys Arg Ser
 65 70 75 80
 Glu Tyr Gly Asp Cys Tyr Ile Arg Val Ala Gly Phe Asp Asn Ile Lys
 85 90 95
 Gln Cys Gln Thr Val Ser Phe Ile Val His Arg Pro Gly Arg Tyr
 100 105 110

-continued

```

<210> SEQ ID NO 13
<211> LENGTH: 1842
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: RT30 rbcLS
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1)...(1419)
<223> OTHER INFORMATION: RT30 rbcL
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1510)...(1842)
<223> OTHER INFORMATION: RT30 rbcS

<400> SEQUENCE: 13

atg ccc aag acg caa tct gcc gca ggc tat aag gcc ggg gtg aag gac      48
Met Pro Lys Thr Gln Ser Ala Ala Gly Tyr Lys Ala Gly Val Lys Asp
  1             5             10            15

tac aaa ctc acc tat tac acc ccc gat tac acc ccc aaa gac act gac      96
Tyr Lys Leu Thr Tyr Tyr Thr Pro Asp Tyr Thr Pro Lys Asp Thr Asp
             20            25            30

ctg ctg gcg gct ttc cgc ttc agc cct cag ccg ggt gtc cct gct gac     144
Leu Leu Ala Ala Phe Arg Phe Ser Pro Gln Pro Gly Val Pro Ala Asp
             35             40             45

gaa gct ggt gcg gcg atc gcg gct gaa tct tcg acc ggt acc tgg acc     192
Glu Ala Gly Ala Ala Ile Ala Ala Glu Ser Ser Thr Gly Thr Trp Thr
             50             55             60

acc gtg tgg acc gac ttg ctg acc gac atg gat cgg tac aaa ggc aag     240
Thr Val Trp Thr Asp Leu Leu Thr Asp Met Asp Arg Tyr Lys Gly Lys
             65             70             75             80

tgc tac cac atc gag ccg gtg caa ggc gaa gag gac tcc tac ttt gcg     288
Cys Tyr His Ile Glu Pro Val Gln Gly Glu Glu Asp Ser Tyr Phe Ala
             85             90             95

ttc atc gct tac ccg ctc gac ctg ttt gaa gaa ggg tcg gtc acc aac     336
Phe Ile Ala Tyr Pro Leu Asp Leu Phe Glu Glu Gly Ser Val Thr Asn
             100            105            110

atc ctg acc tcg atc gtc ggt aac gtg ttt ggc ttc aaa gct atc cgt     384
Ile Leu Thr Ser Ile Val Gly Asn Val Phe Gly Phe Lys Ala Ile Arg
             115            120            125

tcg ctg cgt ctg gaa gac atc cgc ttc ccc gtc gcc ttg gtc aaa acc     432
Ser Leu Arg Leu Glu Asp Ile Arg Phe Pro Val Ala Leu Val Lys Thr
             130            135            140

ttc caa ggt cct ccc cac ggt atc caa ggc gag cgc gac ctg ctg aac     480
Phe Gln Gly Pro Pro His Gly Ile Gln Gly Glu Arg Asp Leu Leu Asn
             145            150            155            160

aag tac ggc cgt ccg atg ctg ggt tgc acg atc aaa cca aaa ctc ggt     528
Lys Tyr Gly Arg Pro Met Leu Gly Cys Thr Ile Lys Pro Lys Leu Gly
             165            170            175

ctg tcg gcg aaa aac tac ggt cgt gcc gtc tac gaa tgt ctg cgc ggc     576
Leu Ser Ala Lys Asn Tyr Gly Arg Ala Val Tyr Glu Cys Leu Arg Gly
             180            185            190

ggt ctg gac ttc acc aaa gac gac gaa aac atc aac tcg cag ccg ttc     624
Gly Leu Asp Phe Thr Lys Asp Asp Glu Asn Ile Asn Ser Gln Pro Phe
             195            200            205

caa cgc tgg cgc gat cgc ttc ctg ttt gtg gct gat gca atc cac aaa     672
Gln Arg Trp Arg Asp Arg Phe Leu Phe Val Ala Asp Ala Ile His Lys
             210            215            220

tcg caa gca gaa acc ggt gaa atc aaa ggt cac tac ctg aac gtg acc     720
Ser Gln Ala Glu Thr Gly Glu Ile Lys Gly His Tyr Leu Asn Val Thr
             225            230            235            240

```

-continued

gcg ccg acc tgc gaa gaa atg atg aaa cgg gct gag ttc gct aaa gaa Ala Pro Thr Cys Glu Glu Met Met Lys Arg Ala Glu Phe Ala Lys Glu 245 250 255	768
ctc ggc atg ccg atc atc atg cat gac ttc ttg acg gct ggt ttc acc Leu Gly Met Pro Ile Ile Met His Asp Phe Leu Thr Ala Gly Phe Thr 260 265 270	816
gcc aac acc acc ttg gca aaa tgg tgc cgc gac aac ggc gtc ctg ctg Ala Asn Thr Thr Leu Ala Lys Trp Cys Arg Asp Asn Gly Val Leu Leu 275 280 285	864
cac atc cac cgt gca atg cac gcg gtg atc gac cgt cag cgt aac cac His Ile His Arg Ala Met His Ala Val Ile Asp Arg Gln Arg Asn His 290 295 300	912
ggg att cac ttc cgt gtc ttg gcc aag tgt ttg cgt ctg tcc ggt ggt Gly Ile His Phe Arg Val Leu Ala Lys Cys Leu Arg Leu Ser Gly Gly 305 310 315 320	960
gac cac ctc cac tcc ggc acc gtc gtc ggc aaa ctg gaa ggc gac aaa Asp His Leu His Ser Gly Thr Val Val Gly Lys Leu Glu Gly Asp Lys 325 330 335	1008
gct tcg acc ttg ggc ttt gtt gac ttg atg cgc gaa gac cac atc gaa Ala Ser Thr Leu Gly Phe Val Asp Leu Met Arg Glu Asp His Ile Glu 340 345 350	1056
gct gac cgc agc cgt ggg gtc ttc ttc acc caa gat tgg gcg tcg atg Ala Asp Arg Ser Arg Gly Val Phe Phe Thr Gln Asp Trp Ala Ser Met 355 360 365	1104
ccg ggc gtg ctg ccg gtt gct tcc ggt ggt atc cac gtg tgg cac atg Pro Gly Val Leu Pro Val Ala Ser Gly Gly Ile His Val Trp His Met 370 375 380	1152
ccc gca ctg gtg gaa atc ttc ggt gat gac tcc gtt ctc cag ttc ggt Pro Ala Leu Val Glu Ile Phe Gly Asp Asp Ser Val Leu Gln Phe Gly 385 390 395 400	1200
ggc ggc acc ttg ggt cac ccc tgg ggt aat gct cct ggt gca acc gcg Gly Gly Thr Leu Gly His Pro Trp Gly Asn Ala Pro Gly Ala Thr Ala 405 410 415	1248
aac cgt gtt gcc ttg gaa gct tgc gtc caa gct cgg aac gaa ggt cgc Asn Arg Val Ala Leu Glu Ala Cys Val Gln Ala Arg Asn Glu Gly Arg 420 425 430	1296
gac ctc tac cgt gaa ggc ggc gac atc ctt cgt gaa gct ggc aag tgg Asp Leu Tyr Arg Glu Gly Gly Asp Ile Leu Arg Glu Ala Gly Lys Trp 435 440 445	1344
tcg cct gaa ctg gct gct gcc ctc gac ctc tgg aaa gag atc aag ttc Ser Pro Glu Leu Ala Ala Leu Asp Leu Trp Lys Glu Ile Lys Phe 450 455 460	1392
gaa ttc gaa acg atg gac aag ctc taa ggagcctctg actatcgctg Glu Phe Glu Thr Met Asp Lys Leu * 465 470	1439
ggggagtgag cggttgctgcg taaagccttc tcccagcct ttcgacttaa cctttcagga	1499
tttctgaatc atg agc atg aaa act ctg ccc aaa gag cgt cgt ttc gag Met Ser Met Lys Thr Leu Pro Lys Glu Arg Arg Phe Glu 475 480 485	1548
act ttc tcg tac ctg cct ccc ctc agc gat cgc caa atc gct gca caa Thr Phe Ser Tyr Leu Pro Pro Leu Ser Asp Arg Gln Ile Ala Ala Gln 490 495 500	1596
atc gag tac atg atc gag caa ggc ttc cac ccc ttg atc gag ttc aac Ile Glu Tyr Met Ile Glu Gln Gly Phe His Pro Leu Ile Glu Phe Asn 505 510 515	1644
gag cac tcg aat ccg gaa gag ttc tac tgg acg atg tgg aag ctc ccc Glu His Ser Asn Pro Glu Glu Phe Tyr Trp Thr Met Trp Lys Leu Pro 520 525 530	1692
ctg ttt gac tgc aag agc cct cag caa gtc ctc gat gaa gtg cgt gag	1740

-continued

Leu	Phe	Asp	Cys	Lys	Ser	Pro	Gln	Gln	Val	Leu	Asp	Glu	Val	Arg	Glu		
	535					540					545						
tgc	cgc	agc	gaa	tac	ggt	gat	tgc	tac	atc	cgt	gtc	gct	ggc	ttc	gac		1788
Cys	Arg	Ser	Glu	Tyr	Gly	Asp	Cys	Tyr	Ile	Arg	Val	Ala	Gly	Phe	Asp		
550					555					560					565		
aac	atc	aag	cag	tgc	caa	acc	gtg	agc	ttc	atc	ggt	cat	cgt	ccc	ggc		1836
Asn	Ile	Lys	Gln	Cys	Gln	Thr	Val	Ser	Phe	Ile	Val	His	Arg	Pro	Gly		
				570					575						580		
cgc	tac																1842
Arg	Tyr																

<210> SEQ ID NO 14
 <211> LENGTH: 472
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: RT30 rbcL

<400> SEQUENCE: 14

Met	Pro	Lys	Thr	Gln	Ser	Ala	Ala	Gly	Tyr	Lys	Ala	Gly	Val	Lys	Asp		
1				5					10					15			
Tyr	Lys	Leu	Thr	Tyr	Tyr	Thr	Pro	Asp	Tyr	Thr	Pro	Lys	Asp	Thr	Asp		
			20					25					30				
Leu	Leu	Ala	Ala	Phe	Arg	Phe	Ser	Pro	Gln	Pro	Gly	Val	Pro	Ala	Asp		
		35					40					45					
Glu	Ala	Gly	Ala	Ala	Ile	Ala	Ala	Glu	Ser	Ser	Thr	Gly	Thr	Trp	Thr		
	50					55					60						
Thr	Val	Trp	Thr	Asp	Leu	Leu	Thr	Asp	Met	Asp	Arg	Tyr	Lys	Gly	Lys		
65					70					75					80		
Cys	Tyr	His	Ile	Glu	Pro	Val	Gln	Gly	Glu	Glu	Asp	Ser	Tyr	Phe	Ala		
				85					90					95			
Phe	Ile	Ala	Tyr	Pro	Leu	Asp	Leu	Phe	Glu	Glu	Gly	Ser	Val	Thr	Asn		
			100					105					110				
Ile	Leu	Thr	Ser	Ile	Val	Gly	Asn	Val	Phe	Gly	Phe	Lys	Ala	Ile	Arg		
		115					120						125				
Ser	Leu	Arg	Leu	Glu	Asp	Ile	Arg	Phe	Pro	Val	Ala	Leu	Val	Lys	Thr		
	130					135					140						
Phe	Gln	Gly	Pro	Pro	His	Gly	Ile	Gln	Gly	Glu	Arg	Asp	Leu	Leu	Asn		
145					150					155					160		
Lys	Tyr	Gly	Arg	Pro	Met	Leu	Gly	Cys	Thr	Ile	Lys	Pro	Lys	Leu	Gly		
				165					170					175			
Leu	Ser	Ala	Lys	Asn	Tyr	Gly	Arg	Ala	Val	Tyr	Glu	Cys	Leu	Arg	Gly		
			180					185					190				
Gly	Leu	Asp	Phe	Thr	Lys	Asp	Asp	Glu	Asn	Ile	Asn	Ser	Gln	Pro	Phe		
		195					200					205					
Gln	Arg	Trp	Arg	Asp	Arg	Phe	Leu	Phe	Val	Ala	Asp	Ala	Ile	His	Lys		
		210				215					220						
Ser	Gln	Ala	Glu	Thr	Gly	Glu	Ile	Lys	Gly	His	Tyr	Leu	Asn	Val	Thr		
225					230					235					240		
Ala	Pro	Thr	Cys	Glu	Glu	Met	Met	Lys	Arg	Ala	Glu	Phe	Ala	Lys	Glu		
				245					250					255			
Leu	Gly	Met	Pro	Ile	Ile	Met	His	Asp	Phe	Leu	Thr	Ala	Gly	Phe	Thr		
			260					265					270				
Ala	Asn	Thr	Thr	Leu	Ala	Lys	Trp	Cys	Arg	Asp	Asn	Gly	Val	Leu	Leu		
		275					280					285					
His	Ile	His	Arg	Ala	Met	His	Ala	Val	Ile	Asp	Arg	Gln	Arg	Asn	His		

-continued

290	295	300
Gly Ile His Phe Arg Val Leu Ala Lys Cys Leu Arg Leu Ser Gly Gly 305 310 315 320		
Asp His Leu His Ser Gly Thr Val Val Gly Lys Leu Glu Gly Asp Lys 325 330 335		
Ala Ser Thr Leu Gly Phe Val Asp Leu Met Arg Glu Asp His Ile Glu 340 345 350		
Ala Asp Arg Ser Arg Gly Val Phe Phe Thr Gln Asp Trp Ala Ser Met 355 360 365		
Pro Gly Val Leu Pro Val Ala Ser Gly Gly Ile His Val Trp His Met 370 375 380		
Pro Ala Leu Val Glu Ile Phe Gly Asp Asp Ser Val Leu Gln Phe Gly 385 390 395 400		
Gly Gly Thr Leu Gly His Pro Trp Gly Asn Ala Pro Gly Ala Thr Ala 405 410 415		
Asn Arg Val Ala Leu Glu Ala Cys Val Gln Ala Arg Asn Glu Gly Arg 420 425 430		
Asp Leu Tyr Arg Glu Gly Gly Asp Ile Leu Arg Glu Ala Gly Lys Trp 435 440 445		
Ser Pro Glu Leu Ala Ala Ala Leu Asp Leu Trp Lys Glu Ile Lys Phe 450 455 460		
Glu Phe Glu Thr Met Asp Lys Leu 465 470		

<210> SEQ ID NO 15
 <211> LENGTH: 111
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: RT30 rbcS

<400> SEQUENCE: 15

Met Ser Met Lys Thr Leu Pro Lys Glu Arg Arg Phe Glu Thr Phe Ser 1 5 10 15
Tyr Leu Pro Pro Leu Ser Asp Arg Gln Ile Ala Ala Gln Ile Glu Tyr 20 25 30
Met Ile Glu Gln Gly Phe His Pro Leu Ile Glu Phe Asn Glu His Ser 35 40 45
Asn Pro Glu Glu Phe Tyr Trp Thr Met Trp Lys Leu Pro Leu Phe Asp 50 55 60
Cys Lys Ser Pro Gln Gln Val Leu Asp Glu Val Arg Glu Cys Arg Ser 65 70 75 80
Glu Tyr Gly Asp Cys Tyr Ile Arg Val Ala Gly Phe Asp Asn Ile Lys 85 90 95
Gln Cys Gln Thr Val Ser Phe Ile Val His Arg Pro Gly Arg Tyr 100 105 110

<210> SEQ ID NO 16
 <211> LENGTH: 1845
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: RT106 rbcLS
 <220> FEATURE:
 <221> NAME/KEY: CDS
 <222> LOCATION: (1)...(1419)
 <223> OTHER INFORMATION: RT106 rbcL
 <220> FEATURE:
 <221> NAME/KEY: CDS

-continued

<222> LOCATION: (1510)...(1845)

<223> OTHER INFORMATION: RT106 rbcS

<400> SEQUENCE: 16

```

atg ccc aag acg caa tct gcc gca ggc tat aag gcc ggg gtg aag gac      48
Met Pro Lys Thr Gln Ser Ala Ala Gly Tyr Lys Ala Gly Val Lys Asp
  1             5             10            15

tac aaa ctc acc tat tac acc ccc gat tac acc ccc aaa gac act gac      96
Tyr Lys Leu Thr Tyr Tyr Thr Pro Asp Tyr Thr Pro Lys Asp Thr Asp
             20             25             30

ctg ctg gcg gct ttc cgc ttc agc cct cag ccg ggt gtc cct gct gac      144
Leu Leu Ala Ala Phe Arg Phe Ser Pro Gln Pro Gly Val Pro Ala Asp
             35             40             45

gaa gct ggt gcg gcg atc gcg gct gaa tct tcg acc ggt acc tgg acc      192
Glu Ala Gly Ala Ala Ile Ala Ala Glu Ser Ser Thr Gly Thr Trp Thr
             50             55             60

acc gtg tgg acc gac ttg ctg acc gac atg gat cgg tac aaa ggc aag      240
Thr Val Trp Thr Asp Leu Leu Thr Asp Met Asp Arg Tyr Lys Gly Lys
             65             70             75            80

tgc tac cac atc gag ccg gtg caa ggc gaa gag aac tcc tac ttt gcg      288
Cys Tyr His Ile Glu Pro Val Gln Gly Glu Glu Asn Ser Tyr Phe Ala
             85             90             95

ttc atc gct tac ccg ctc gac ctg ttt gaa gaa ggg tcg gtc acc aac      336
Phe Ile Ala Tyr Pro Leu Asp Leu Phe Glu Glu Gly Ser Val Thr Asn
             100            105            110

atc ctg acc tcg atc gtc ggt aac gtg ttt ggc ttc aaa gct atc cgt      384
Ile Leu Thr Ser Ile Val Gly Asn Val Phe Gly Phe Lys Ala Ile Arg
             115            120            125

tcg ctg cgt ctg gaa gac atc cgc ttc ccc gtc gcc ttg gtc aaa acc      432
Ser Leu Arg Leu Glu Asp Ile Arg Phe Pro Val Ala Leu Val Lys Thr
             130            135            140

ttc caa ggt cct ccc cac ggt atc caa gtc gag cgc gac ctg ctg aac      480
Phe Gln Gly Pro Pro His Gly Ile Gln Val Glu Arg Asp Leu Leu Asn
             145            150            155            160

aag tac ggc cgt ccg atg ctg ggt tgc acg atc aaa cca aaa ctc ggt      528
Lys Tyr Gly Arg Pro Met Leu Gly Cys Thr Ile Lys Pro Lys Leu Gly
             165            170            175

ctg tcg gcg aaa aac tac ggt cgt gcc gtc tac gaa tgt ctg cgc ggc      576
Leu Ser Ala Lys Asn Tyr Gly Arg Ala Val Tyr Glu Cys Leu Arg Gly
             180            185            190

ggt ctg gac ttc acc aaa gac gac gaa aac atc aac tcg cag ccg ttc      624
Gly Leu Asp Phe Thr Lys Asp Asp Glu Asn Ile Asn Ser Gln Pro Phe
             195            200            205

caa cgc tgg cgc gat cgc ttc ctg ttt gtg gct gat gca atc cac aaa      672
Gln Arg Trp Arg Asp Arg Phe Leu Phe Val Ala Asp Ala Ile His Lys
             210            215            220

tcg caa gca gaa acc ggt gaa atc aaa ggt cac tac ctg aac gtg acc      720
Ser Gln Ala Glu Thr Gly Glu Ile Lys Gly His Tyr Leu Asn Val Thr
             225            230            235            240

gcg ccg acc tgc gaa gaa atg atg aaa ccg gct gag ttc gct aaa gaa      768
Ala Pro Thr Cys Glu Glu Met Met Lys Arg Ala Glu Phe Ala Lys Glu
             245            250            255

ctc ggc atg ccg atc atc atg cat gac ttc ttg acg gct ggt ttc acc      816
Leu Gly Met Pro Ile Ile Met His Asp Phe Leu Thr Ala Gly Phe Thr
             260            265            270

gcc aac acc acc ttg gca aaa tgg tgc cgc gac aac ggc gtc ctg ctg      864
Ala Asn Thr Thr Leu Ala Lys Trp Cys Arg Asp Asn Gly Val Leu Leu
             275            280            285

cac atc cac cgt gca atg cac gcg gtg atc gac cgt cag cgt aac cac      912
His Ile His Arg Ala Met His Ala Val Ile Asp Arg Gln Arg Asn His

```

-continued

290	295	300	
ggg att cac ttc cgt gtc ttg gcc aag tgt ttg cgt ctg tcc ggt ggt Gly Ile His Phe Arg Val Leu Ala Lys Cys Leu Arg Leu Ser Gly Gly 305 310 315 320			960
gac cac ctc cac tcc ggc acc gtc gtc ggc aaa ctg gaa ggc gac aaa Asp His Leu His Ser Gly Thr Val Val Gly Lys Leu Glu Gly Asp Lys 325 330 335			1008
gct tcg acc ttg ggc ttt gtt gac ttg atg cgc gaa gac cac atc gaa Ala Ser Thr Leu Gly Phe Val Asp Leu Met Arg Glu Asp His Ile Glu 340 345 350			1056
gct gac cgc agc cgt ggg gtc ttc ttc acc caa gat tgg gcg tcg atg Ala Asp Arg Ser Arg Gly Val Phe Phe Thr Gln Asp Trp Ala Ser Met 355 360 365			1104
ccg ggc gtg ctg ccg gtt gct tcc ggt ggt atc cac gtg tgg cac atg Pro Gly Val Leu Pro Val Ala Ser Gly Gly Ile His Val Trp His Met 370 375 380			1152
ccc gca ctg gtg gaa atc ttc ggt gat gac tcc gtt ctc cag ttc ggt Pro Ala Leu Val Glu Ile Phe Gly Asp Asp Ser Val Leu Gln Phe Gly 385 390 395 400			1200
ggc ggc acc ttg ggt cac ccc tgg ggt aat gct cct ggt gca acc gcg Gly Gly Thr Leu Gly His Pro Trp Gly Asn Ala Pro Gly Ala Thr Ala 405 410 415			1248
aac cgt gtt gcc ttg gaa gct tgc gtc caa gct cgg aac gaa ggt cgc Asn Arg Val Ala Leu Glu Ala Cys Val Gln Ala Arg Asn Glu Gly Arg 420 425 430			1296
gac ctc tac cgt gaa ggc ggc gac atc ctt cgt gaa gct ggc aag tgg Asp Leu Tyr Arg Glu Gly Gly Asp Ile Leu Arg Glu Ala Gly Lys Trp 435 440 445			1344
tcg cct gaa ctg gct gct gcc ctc gac ctc tgg aaa gag atc aag ttc Ser Pro Glu Leu Ala Ala Ala Leu Asp Leu Trp Lys Glu Ile Lys Phe 450 455 460			1392
gaa ttc gaa acg atg gac aag ctc taa ggagcctctg actatcgctg Glu Phe Glu Thr Met Asp Lys Leu * 465 470			1439
ggggagtgag cgttgctgcg taaagctttc tccccagcct ttcgacttaa cctttcagga			1499
tttctgaatc atg agc atg aaa act ctg ccc aaa gag cgt cgt ttc gag Met Ser Met Lys Thr Leu Pro Lys Glu Arg Arg Phe Glu 475 480 485			1548
act ttc tcg tac ctg cct ccc ctc agc gat cgc caa atc gct gca caa Thr Phe Ser Tyr Leu Pro Pro Leu Ser Asp Arg Gln Ile Ala Ala Gln 490 495 500			1596
atc gag tac atg atc gag caa ggc ttc cac ccc ttg atc gag ttc aac Ile Glu Tyr Met Ile Glu Gln Gly Phe His Pro Leu Ile Glu Phe Asn 505 510 515			1644
gag cac tcg aat ccg gaa gag ttc tac tgg acg atg tgg aag ctc ccc Glu His Ser Asn Pro Glu Glu Phe Tyr Trp Thr Met Trp Lys Leu Pro 520 525 530			1692
ctg ttt gac tgc aag ggc cct cag caa gtc ctc gat gaa gtg cgt gag Leu Phe Asp Cys Lys Gly Pro Gln Gln Val Leu Asp Glu Val Arg Glu 535 540 545			1740
tgc cgc agc gaa tac ggt gat tgc tac atc cgt gtc gct ggc ttc gac Cys Arg Ser Glu Tyr 555 560 565			1788
aac atc aag cag tgc caa acc gtg agc ttc atc gtt cat cgt ccc ggc Asn Ile Lys Gln Cys Gln Thr Val Ser Phe Ile Val His Arg Pro Gly 570 575 580			1836
cgc tac taa Arg Tyr *			1845

-continued

```

<210> SEQ ID NO 17
<211> LENGTH: 472
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: RT106 rbcL

<400> SEQUENCE: 17

Met Pro Lys Thr Gln Ser Ala Ala Gly Tyr Lys Ala Gly Val Lys Asp
 1           5           10           15

Tyr Lys Leu Thr Tyr Tyr Thr Pro Asp Tyr Thr Pro Lys Asp Thr Asp
          20           25           30

Leu Leu Ala Ala Phe Arg Phe Ser Pro Gln Pro Gly Val Pro Ala Asp
          35           40           45

Glu Ala Gly Ala Ala Ile Ala Ala Glu Ser Ser Thr Gly Thr Trp Thr
          50           55           60

Thr Val Trp Thr Asp Leu Leu Thr Asp Met Asp Arg Tyr Lys Gly Lys
65           70           75           80

Cys Tyr His Ile Glu Pro Val Gln Gly Glu Glu Asn Ser Tyr Phe Ala
          85           90           95

Phe Ile Ala Tyr Pro Leu Asp Leu Phe Glu Glu Gly Ser Val Thr Asn
          100          105          110

Ile Leu Thr Ser Ile Val Gly Asn Val Phe Gly Phe Lys Ala Ile Arg
          115          120          125

Ser Leu Arg Leu Glu Asp Ile Arg Phe Pro Val Ala Leu Val Lys Thr
          130          135          140

Phe Gln Gly Pro Pro His Gly Ile Gln Val Glu Arg Asp Leu Leu Asn
          145          150          155          160

Lys Tyr Gly Arg Pro Met Leu Gly Cys Thr Ile Lys Pro Lys Leu Gly
          165          170          175

Leu Ser Ala Lys Asn Tyr Gly Arg Ala Val Tyr Glu Cys Leu Arg Gly
          180          185          190

Gly Leu Asp Phe Thr Lys Asp Asp Glu Asn Ile Asn Ser Gln Pro Phe
          195          200          205

Gln Arg Trp Arg Asp Arg Phe Leu Phe Val Ala Asp Ala Ile His Lys
          210          215          220

Ser Gln Ala Glu Thr Gly Glu Ile Lys Gly His Tyr Leu Asn Val Thr
          225          230          235          240

Ala Pro Thr Cys Glu Glu Met Met Lys Arg Ala Glu Phe Ala Lys Glu
          245          250          255

Leu Gly Met Pro Ile Ile Met His Asp Phe Leu Thr Ala Gly Phe Thr
          260          265          270

Ala Asn Thr Thr Leu Ala Lys Trp Cys Arg Asp Asn Gly Val Leu Leu
          275          280          285

His Ile His Arg Ala Met His Ala Val Ile Asp Arg Gln Arg Asn His
          290          295          300

Gly Ile His Phe Arg Val Leu Ala Lys Cys Leu Arg Leu Ser Gly Gly
          305          310          315          320

Asp His Leu His Ser Gly Thr Val Val Gly Lys Leu Glu Gly Asp Lys
          325          330          335

Ala Ser Thr Leu Gly Phe Val Asp Leu Met Arg Glu Asp His Ile Glu
          340          345          350

Ala Asp Arg Ser Arg Gly Val Phe Phe Thr Gln Asp Trp Ala Ser Met
          355          360          365

```

-continued

Pro Gly Val Leu Pro Val Ala Ser Gly Gly Ile His Val Trp His Met
 370 375 380

Pro Ala Leu Val Glu Ile Phe Gly Asp Asp Ser Val Leu Gln Phe Gly
 385 390 395 400

Gly Gly Thr Leu Gly His Pro Trp Gly Asn Ala Pro Gly Ala Thr Ala
 405 410 415

Asn Arg Val Ala Leu Glu Ala Cys Val Gln Ala Arg Asn Glu Gly Arg
 420 425 430

Asp Leu Tyr Arg Glu Gly Gly Asp Ile Leu Arg Glu Ala Gly Lys Trp
 435 440 445

Ser Pro Glu Leu Ala Ala Ala Leu Asp Leu Trp Lys Glu Ile Lys Phe
 450 455 460

Glu Phe Glu Thr Met Asp Lys Leu
 465 470

<210> SEQ ID NO 18
 <211> LENGTH: 111
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: RT106 rbcS

<400> SEQUENCE: 18

Met Ser Met Lys Thr Leu Pro Lys Glu Arg Arg Phe Glu Thr Phe Ser
 1 5 10 15

Tyr Leu Pro Pro Leu Ser Asp Arg Gln Ile Ala Ala Gln Ile Glu Tyr
 20 25 30

Met Ile Glu Gln Gly Phe His Pro Leu Ile Glu Phe Asn Glu His Ser
 35 40 45

Asn Pro Glu Glu Phe Tyr Trp Thr Met Trp Lys Leu Pro Leu Phe Asp
 50 55 60

Cys Lys Gly Pro Gln Gln Val Leu Asp Glu Val Arg Glu Cys Arg Ser
 65 70 75 80

Glu Tyr Gly Asp Cys Tyr Ile Arg Val Ala Gly Phe Asp Asn Ile Lys
 85 90 95

Gln Cys Gln Thr Val Ser Phe Ile Val His Arg Pro Gly Arg Tyr
 100 105 110

<210> SEQ ID NO 19
 <211> LENGTH: 1845
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: RT108 rbcLS
 <220> FEATURE:
 <221> NAME/KEY: CDS
 <222> LOCATION: (1)...(1419)
 <223> OTHER INFORMATION: RT108 rbcL
 <220> FEATURE:
 <221> NAME/KEY: CDS
 <222> LOCATION: (1510)...(1845)
 <223> OTHER INFORMATION: RT108 rbcS

<400> SEQUENCE: 19

atg ccc aag acg caa tct gcc gca ggc tat aag gcc ggg gtg aag gac 48
 Met Pro Lys Thr Gln Ser Ala Ala Gly Tyr Lys Ala Gly Val Lys Asp
 1 5 10 15

tac aaa ctc acc tat tac acc ccc gat tac acc ccc aaa gac act gac 96
 Tyr Lys Leu Thr Tyr Tyr Thr Pro Asp Tyr Thr Pro Lys Asp Thr Asp
 20 25 30

ctg ctg gcg gct ttc cgc ttc agc cct cag ccg ggt gtc cct gct gac 144

-continued

Leu	Leu	Ala	Ala	Phe	Arg	Phe	Ser	Pro	Gln	Pro	Gly	Val	Pro	Ala	Asp	
		35					40					45				
gaa	gct	ggt	gcg	gcg	atc	gcg	gct	gaa	tct	tcg	acc	ggt	acc	tgg	acc	192
Glu	Ala	Gly	Ala	Ala	Ile	Ala	Ala	Glu	Ser	Ser	Thr	Gly	Thr	Trp	Thr	
	50					55					60					
acc	gtg	tgg	acc	gac	ttg	ctg	acc	gac	atg	gat	cgg	tac	aaa	ggc	aag	240
Thr	Val	Trp	Thr	Asp	Leu	Leu	Thr	Asp	Met	Asp	Arg	Tyr	Lys	Gly	Lys	
	65				70					75					80	
tgc	tac	cac	atc	gag	ccg	gtg	caa	ggc	gaa	gag	aac	tcc	tac	ttt	gcg	288
Cys	Tyr	His	Ile	Glu	Pro	Val	Gln	Gly	Glu	Glu	Asn	Ser	Tyr	Phe	Ala	
			85					90						95		
ttc	atc	gct	tac	ccg	ctc	gac	ctg	ttt	gaa	gaa	ggg	tcg	gtc	acc	aac	336
Phe	Ile	Ala	Tyr	Pro	Leu	Asp	Leu	Phe	Glu	Glu	Gly	Ser	Val	Thr	Asn	
		100					105						110			
atc	ctg	acc	tcg	atc	gtc	ggg	aac	gtg	ttt	ggc	ttc	aaa	gct	atc	cgt	384
Ile	Leu	Thr	Ser	Ile	Val	Gly	Asn	Val	Phe	Gly	Phe	Lys	Ala	Ile	Arg	
		115					120					125				
tcg	ctg	cgt	ctg	gaa	gac	atc	cgc	ttc	ccc	gtc	gcc	ttg	gtc	aaa	acc	432
Ser	Leu	Arg	Leu	Glu	Asp	Ile	Arg	Phe	Pro	Val	Ala	Leu	Val	Lys	Thr	
	130					135					140					
ttc	caa	ggt	cct	ccc	cac	ggg	atc	caa	gtc	gag	cgc	gac	ctg	ctg	aac	480
Phe	Gln	Gly	Pro	Pro	His	Gly	Ile	Gln	Val	Glu	Arg	Asp	Leu	Leu	Asn	
	145				150					155					160	
aag	tac	ggc	cgt	ccg	atg	ctg	ggg	tgc	acg	atc	aaa	cca	aaa	ctc	ggg	528
Lys	Tyr	Gly	Arg	Pro	Met	Leu	Gly	Cys	Thr	Ile	Lys	Pro	Lys	Leu	Gly	
				165				170						175		
ctg	tcg	gcg	aaa	aac	tac	ggg	cgt	gcc	gtc	tac	gaa	tgt	ctg	cgc	ggc	576
Leu	Ser	Ala	Lys	Asn	Tyr	Gly	Arg	Ala	Val	Tyr	Glu	Cys	Leu	Arg	Gly	
			180					185					190			
ggg	ctg	gac	ttc	acc	aaa	gac	gac	gaa	aac	atc	aac	tcg	cag	ccg	ttc	624
Gly	Leu	Asp	Phe	Thr	Lys	Asp	Asp	Glu	Asn	Ile	Asn	Ser	Gln	Pro	Phe	
		195					200					205				
caa	cgc	tgg	cgc	gat	cgc	ttc	ctg	ttt	gtg	gct	gat	gca	atc	cac	aaa	672
Gln	Arg	Trp	Arg	Asp	Arg	Phe	Leu	Phe	Val	Ala	Asp	Ala	Ile	His	Lys	
	210					215						220				
tcg	caa	gca	gaa	acc	ggg	gaa	atc	aaa	ggg	cac	tac	ctg	aac	gtg	acc	720
Ser	Gln	Ala	Glu	Thr	Gly	Glu	Ile	Lys	Gly	His	Tyr	Leu	Asn	Val	Thr	
	225					230				235					240	
gcg	ccg	acc	tgc	gaa	gaa	atg	atg	aaa	cgg	gct	gag	ttc	gct	aaa	gaa	768
Ala	Pro	Thr	Cys	Glu	Glu	Met	Met	Lys	Arg	Ala	Glu	Phe	Ala	Lys	Glu	
				245					250					255		
ctc	ggc	acg	ccg	atc	atc	atg	cat	gac	ttc	ttg	acg	gct	ggg	ttc	acc	816
Leu	Gly	Thr	Pro	Ile	Ile	Met	His	Asp	Phe	Leu	Thr	Ala	Gly	Phe	Thr	
			260					265					270			
gcc	aac	acc	acc	ttg	gca	aaa	tgg	tgc	cgc	gac	aac	ggc	gtc	ctg	ctg	864
Ala	Asn	Thr	Thr	Leu	Ala	Lys	Trp	Cys	Arg	Asp	Asn	Gly	Val	Leu	Leu	
		275					280					285				
cac	atc	cac	cgt	gca	atg	cac	gcg	gtg	atc	gac	cgt	cag	cgt	aac	cac	912
His	Ile	His	Arg	Ala	Met	His	Ala	Val	Ile	Asp	Arg	Gln	Arg	Asn	His	
	290					295					300					
ggg	att	cac	ttc	cgt	gtc	ttg	gcc	aag	tgt	ttg	cgt	ctg	tcc	ggg	ggg	960
Gly	Ile	His	Phe	Arg	Val	Leu	Ala	Lys	Cys	Leu	Arg	Leu	Ser	Gly	Gly	
	305				310					315					320	
gac	cac	ctc	cac	tcc	ggc	acc	gtc	gtc	ggc	aaa	ctg	gaa	ggc	gac	aaa	1008
Asp	His	Leu	His	Ser	Gly	Thr	Val	Val	Gly	Lys	Leu	Glu	Gly	Asp	Lys	
				325					330					335		
gct	tcg	acc	ttg	ggc	ttt	ggt	gac	ttg	atg	cgc	gaa	gac	cac	atc	gaa	1056
Ala	Ser	Thr	Leu	Gly	Phe	Val	Asp	Leu	Met	Arg	Glu	Asp	His	Ile	Glu	
			340					345						350		

-continued

gct gac cgc agc cgt ggg gtc ttc ttc acc caa gat tgg gcg tcg atg	1104
Ala Asp Arg Ser Arg Gly Val Phe Phe Thr Gln Asp Trp Ala Ser Met	
355 360 365	
ccg ggc gtg ctg ccg gtt gct tcc ggt ggt atc cac gtg tgg cac atg	1152
Pro Gly Val Leu Pro Val Ala Ser Gly Gly Ile His Val Trp His Met	
370 375 380	
ccc gca ctg gtg gaa atc ttc ggt gat gac tcc gtt ctc cag ttc ggt	1200
Pro Ala Leu Val Glu Ile Phe Gly Asp Asp Ser Val Leu Gln Phe Gly	
385 390 395 400	
ggc ggc acc ttg ggt cac ccc tgg ggt aat gct cct ggt gca acc gcg	1248
Gly Gly Thr Leu Gly His Pro Trp Gly Asn Ala Pro Gly Ala Thr Ala	
405 410 415	
aac cgt gtt gcc ttg gaa gct tgc gtc caa gct cgg aac gaa ggt cgc	1296
Asn Arg Val Ala Leu Glu Ala Cys Val Gln Ala Arg Asn Glu Gly Arg	
420 425 430	
gac ctc tac cgt gaa ggc ggc gac atc ctt cgt gaa gct ggc aag tgg	1344
Asp Leu Tyr Arg Glu Gly Gly Asp Ile Leu Arg Glu Ala Gly Lys Trp	
435 440 445	
tcg cct gaa ctg gct gct gcc ctc gac ctc tgg aaa gag atc aag ttc	1392
Ser Pro Glu Leu Ala Ala Leu Asp Leu Trp Lys Glu Ile Lys Phe	
450 455 460	
gaa ttc gaa acg atg gac aag ctc taa ggagcctctg actatcgctg	1439
Glu Phe Glu Thr Met Asp Lys Leu *	
465 470	
ggggagtgag cgttgctgcg taaagctttc tccccagcct ttcgacttaa cctttcagga	1499
tttctgaatc atg agc atg aaa act ctg ccc aaa gag cgt cgt ttc gag	1548
Met Ser Met Lys Thr Leu Pro Lys Glu Arg Arg Phe Glu	
475 480 485	
act ttc tcg tac ctg cct ccc ctc agc gat cgc caa atc gct gca caa	1596
Thr Phe Ser Tyr Leu Pro Pro Leu Ser Asp Arg Gln Ile Ala Ala Gln	
490 495 500	
atc gag tac atg atc gag caa ggc ttc cac ccc ttg atc gag ttc aac	1644
Ile Glu Tyr Met Ile Glu Gln Gly Phe His Pro Leu Ile Glu Phe Asn	
505 510 515	
gag cac tcg aat ccg gaa gag ttc tac tgg acg atg tgg aag ctc ccc	1692
Glu His Ser Asn Pro Glu Glu Phe Tyr Trp Thr Met Trp Lys Leu Pro	
520 525 530	
ctg ttt gac tgc aag agc cct cag caa gtc ctc gat gaa gtg cgt gag	1740
Leu Phe Asp Cys Lys Ser Pro Gln Gln Val Leu Asp Glu Val Arg Glu	
535 540 545	
tgc cgc agc gaa tac ggt gat tgc tac atc cgt gtc gct ggc ttc gac	1788
Cys Arg Ser Glu Tyr Gly Asp Cys Tyr Ile Arg Val Ala Gly Phe Asp	
550 555 560 565	
aac atc aag cag tgc caa acc gtg agc ttc atc gtt cat cgt ccc ggc	1836
Asn Ile Lys Gln Cys Gln Thr Val Ser Phe Ile Val His Arg Pro Gly	
570 575 580	
cgc tac taa	1845
Arg Tyr *	

<210> SEQ ID NO 20
 <211> LENGTH: 472
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: RT108 rbcL

<400> SEQUENCE: 20

Met Pro Lys Thr Gln Ser Ala Ala Gly Tyr Lys Ala Gly Val Lys Asp
1 5 10 15
Tyr Lys Leu Thr Tyr Tyr Thr Pro Asp Tyr Thr Pro Lys Asp Thr Asp

-continued

20					25					30					
Leu	Leu	Ala	Ala	Phe	Arg	Phe	Ser	Pro	Gln	Pro	Gly	Val	Pro	Ala	Asp
		35					40					45			
Glu	Ala	Gly	Ala	Ala	Ile	Ala	Ala	Glu	Ser	Ser	Thr	Gly	Thr	Trp	Thr
		50					55					60			
Thr	Val	Trp	Thr	Asp	Leu	Leu	Thr	Asp	Met	Asp	Arg	Tyr	Lys	Gly	Lys
							70					75			80
Cys	Tyr	His	Ile	Glu	Pro	Val	Gln	Gly	Glu	Glu	Asn	Ser	Tyr	Phe	Ala
				85					90					95	
Phe	Ile	Ala	Tyr	Pro	Leu	Asp	Leu	Phe	Glu	Glu	Gly	Ser	Val	Thr	Asn
			100					105					110		
Ile	Leu	Thr	Ser	Ile	Val	Gly	Asn	Val	Phe	Gly	Phe	Lys	Ala	Ile	Arg
			115				120						125		
Ser	Leu	Arg	Leu	Glu	Asp	Ile	Arg	Phe	Pro	Val	Ala	Leu	Val	Lys	Thr
			130				135					140			
Phe	Gln	Gly	Pro	Pro	His	Gly	Ile	Gln	Val	Glu	Arg	Asp	Leu	Leu	Asn
						150					155				160
Lys	Tyr	Gly	Arg	Pro	Met	Leu	Gly	Cys	Thr	Ile	Lys	Pro	Lys	Leu	Gly
				165					170					175	
Leu	Ser	Ala	Lys	Asn	Tyr	Gly	Arg	Ala	Val	Tyr	Glu	Cys	Leu	Arg	Gly
			180					185					190		
Gly	Leu	Asp	Phe	Thr	Lys	Asp	Asp	Glu	Asn	Ile	Asn	Ser	Gln	Pro	Phe
		195					200					205			
Gln	Arg	Trp	Arg	Asp	Arg	Phe	Leu	Phe	Val	Ala	Asp	Ala	Ile	His	Lys
						215					220				
Ser	Gln	Ala	Glu	Thr	Gly	Glu	Ile	Lys	Gly	His	Tyr	Leu	Asn	Val	Thr
						230					235				240
Ala	Pro	Thr	Cys	Glu	Glu	Met	Met	Lys	Arg	Ala	Glu	Phe	Ala	Lys	Glu
				245					250					255	
Leu	Gly	Thr	Pro	Ile	Ile	Met	His	Asp	Phe	Leu	Thr	Ala	Gly	Phe	Thr
			260					265					270		
Ala	Asn	Thr	Thr	Leu	Ala	Lys	Trp	Cys	Arg	Asp	Asn	Gly	Val	Leu	Leu
			275				280					285			
His	Ile	His	Arg	Ala	Met	His	Ala	Val	Ile	Asp	Arg	Gln	Arg	Asn	His
	290					295					300				
Gly	Ile	His	Phe	Arg	Val	Leu	Ala	Lys	Cys	Leu	Arg	Leu	Ser	Gly	Gly
	305					310					315				320
Asp	His	Leu	His	Ser	Gly	Thr	Val	Val	Gly	Lys	Leu	Glu	Gly	Asp	Lys
				325					330					335	
Ala	Ser	Thr	Leu	Gly	Phe	Val	Asp	Leu	Met	Arg	Glu	Asp	His	Ile	Glu
			340					345					350		
Ala	Asp	Arg	Ser	Arg	Gly	Val	Phe	Phe	Thr	Gln	Asp	Trp	Ala	Ser	Met
		355					360					365			
Pro	Gly	Val	Leu	Pro	Val	Ala	Ser	Gly	Gly	Ile	His	Val	Trp	His	Met
						375					380				
Pro	Ala	Leu	Val	Glu	Ile	Phe	Gly	Asp	Asp	Ser	Val	Leu	Gln	Phe	Gly
						390			395						400
Gly	Gly	Thr	Leu	Gly	His	Pro	Trp	Gly	Asn	Ala	Pro	Gly	Ala	Thr	Ala
				405					410					415	
Asn	Arg	Val	Ala	Leu	Glu	Ala	Cys	Val	Gln	Ala	Arg	Asn	Glu	Gly	Arg
			420					425					430		
Asp	Leu	Tyr	Arg	Glu	Gly	Gly	Asp	Ile	Leu	Arg	Glu	Ala	Gly	Lys	Trp
			435				440					445			

-continued

Ser Pro Glu Leu Ala Ala Ala Leu Asp Leu Trp Lys Glu Ile Lys Phe
450 455 460

Glu Phe Glu Thr Met Asp Lys Leu
465 470

<210> SEQ ID NO 21
<211> LENGTH: 111
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: RT108 rbcS

<400> SEQUENCE: 21

Met Ser Met Lys Thr Leu Pro Lys Glu Arg Arg Phe Glu Thr Phe Ser
1 5 10 15

Tyr Leu Pro Pro Leu Ser Asp Arg Gln Ile Ala Ala Gln Ile Glu Tyr
20 25 30

Met Ile Glu Gln Gly Phe His Pro Leu Ile Glu Phe Asn Glu His Ser
35 40 45

Asn Pro Glu Glu Phe Tyr Trp Thr Met Trp Lys Leu Pro Leu Phe Asp
50 55 60

Cys Lys Ser Pro Gln Gln Val Leu Asp Glu Val Arg Glu Cys Arg Ser
65 70 75 80

Glu Tyr Gly Asp Cys Tyr Ile Arg Val Ala Gly Phe Asp Asn Ile Lys
85 90 95

Gln Cys Gln Thr Val Ser Phe Ile Val His Arg Pro Gly Arg Tyr
100 105 110

<210> SEQ ID NO 22
<211> LENGTH: 1845
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: RT111 rbcLS
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1)...(1419)
<223> OTHER INFORMATION: RT111 rbcL
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1510)...(1845)
<223> OTHER INFORMATION: RT111 rbcS

<400> SEQUENCE: 22

atg ccc aag acg caa tct gcc gca ggc tat aag gcc ggg gtg aag gac 48
Met Pro Lys Thr Gln Ser Ala Ala Gly Tyr Lys Ala Gly Val Lys Asp
1 5 10 15

tac aaa ctc acc tat tac acc ccc gat tac acc ccc aaa gac act gac 96
Tyr Lys Leu Thr Tyr Tyr Thr Pro Asp Tyr Thr Pro Lys Asp Thr Asp
20 25 30

ctg ctg gcg gct ttc cgc ttc agc cct cag ccg ggt gtc cct gct gac 144
Leu Leu Ala Ala Phe Arg Phe Ser Pro Gln Pro Gly Val Pro Ala Asp
35 40 45

gaa gct ggt gcg gcg atc gcg gct gaa tct tcg acc ggt acc tgg acc 192
Glu Ala Gly Ala Ala Ile Ala Ala Glu Ser Ser Thr Gly Thr Trp Thr
50 55 60

acc gtg tgg acc gac ttg ctg acc gac atg gat cgg tac aaa ggc aag 240
Thr Val Trp Thr Asp Leu Leu Thr Asp Met Asp Arg Tyr Lys Gly Lys
65 70 75 80

tgc tac cac atc gag ccg gtg caa ggc gaa gag aac tcc tac ttt gcg 288
Cys Tyr His Ile Glu Pro Val Gln Gly Glu Glu Asn Ser Tyr Phe Ala
85 90 95

-continued

ttc atc gct tac ccg ctc gac ctg ttt gaa gaa ggg tcg gtc acc aac	336
Phe Ile Ala Tyr Pro Leu Asp Leu Phe Glu Glu Gly Ser Val Thr Asn	
100 105 110	
atc ctg acc tcg atc gtc ggt aac gtg ttt ggc ttc aaa gct atc cgt	384
Ile Leu Thr Ser Ile Val Gly Asn Val Phe Gly Phe Lys Ala Ile Arg	
115 120 125	
tcg ctg cgt ctg gaa gac atc cgc ttc ccc gtc gcc ttg gtc aaa acc	432
Ser Leu Arg Leu Glu Asp Ile Arg Phe Pro Val Ala Leu Val Lys Thr	
130 135 140	
ttc caa ggt cct ccc cac ggt atc caa gtc gag cgc gac ctg ctg aac	480
Phe Gln Gly Pro Pro His Gly Ile Gln Val Glu Arg Asp Leu Leu Asn	
145 150 155 160	
aag tac ggc cgt ccg atg ctg ggt tgc acg atc aaa cca aaa ctc ggt	528
Lys Tyr Gly Arg Pro Met Leu Gly Cys Thr Ile Lys Pro Lys Leu Gly	
165 170 175	
ctg tcg gcg aaa aac tac ggt cgt gcc gtc tac gaa tgt ctg cgc ggc	576
Leu Ser Ala Lys Asn Tyr Gly Arg Ala Val Tyr Glu Cys Leu Arg Gly	
180 185 190	
ggt ctg gac ttc acc aaa gac gac gaa aac atc aac tcg cag ccg ttc	624
Gly Leu Asp Phe Thr Lys Asp Asp Glu Asn Ile Asn Ser Gln Pro Phe	
195 200 205	
caa cgc tgg cgc gat cgc ttc ctg ttt gtg gct gat gca atc cac aaa	672
Gln Arg Trp Arg Asp Arg Phe Leu Phe Val Ala Asp Ala Ile His Lys	
210 215 220	
tcg caa gca gaa acc ggt gaa atc aaa ggt cac tac ctg aac gtg acc	720
Ser Gln Ala Glu Thr Gly Glu Ile Lys Gly His Tyr Leu Asn Val Thr	
225 230 235 240	
gcg ccg acc tgc gaa gaa atg atg aaa cgg gct gag ttc gct aaa gaa	768
Ala Pro Thr Cys Glu Glu Met Met Lys Arg Ala Glu Phe Ala Lys Glu	
245 250 255	
ctc ggc atg ccg atc atc atg cat gac ttc ttg acg gct ggt ttc acc	816
Leu Gly Met Pro Ile Ile Met His Asp Phe Leu Thr Ala Gly Phe Thr	
260 265 270	
gcc aac acc acc ttg gca aaa tgg tgc cgc gac aac ggc gtc ctg ctg	864
Ala Asn Thr Thr Leu Ala Lys Trp Cys Arg Asp Asn Gly Val Leu Leu	
275 280 285	
cac atc cac cgt gca atg cac gcg gtg atc gac cgt cag cgt aac cac	912
His Ile His Arg Ala Met His Ala Val Ile Asp Arg Gln Arg Asn His	
290 295 300	
ggg att cac ttc cgt gtc ttg gcc aag tgt ttg cgt ctg tcc ggt ggt	960
Gly Ile His Phe Arg Val Leu Ala Lys Cys Leu Arg Leu Ser Gly Gly	
305 310 315 320	
gac cac ctc cac tcc ggc acc gtc gtc ggc aaa ctg gaa ggc gac aaa	1008
Asp His Leu His Ser Gly Thr Val Val Gly Lys Leu Glu Gly Asp Lys	
325 330 335	
gct tcg acc ttg ggc ttt gtt gac ttg atg cgc gaa gac cac atc gaa	1056
Ala Ser Thr Leu Gly Phe Val Asp Leu Met Arg Glu Asp His Ile Glu	
340 345 350	
gct gac cgc agc cgt ggg gtc ttc ttc acc caa gat tgg gcg tcg atg	1104
Ala Asp Arg Ser Arg Gly Val Phe Phe Thr Gln Asp Trp Ala Ser Met	
355 360 365	
ccg ggc gtg ctg ccg gtt gct tcc ggt ggt atc cac gtg tgg cac atg	1152
Pro Gly Val Leu Pro Val Ala Ser Gly Gly Ile His Val Trp His Met	
370 375 380	
ccc gca ctg gtg gaa atc ttc ggt gat gac tcc gtt ctc cag ttc ggt	1200
Pro Ala Leu Val Glu Ile Phe Gly Asp Asp Ser Val Leu Gln Phe Gly	
385 390 395 400	
ggc ggc acc ttg ggt cac ccc tgg ggt aat gct cct ggt gca acc gcg	1248
Gly Gly Thr Leu Gly His Pro Trp Gly Asn Ala Pro Gly Ala Thr Ala	

-continued

405	410	415	
aac cgt gtt gcc ttg gaa gct tgc gtc	caa gct cgg aac gaa ggt cgc		1296
Asn Arg Val Ala Leu Glu Ala Cys Val Gln Ala Arg Asn Glu Gly Arg			
420	425	430	
gac ctc tac cgt gaa ggc ggc gac atc ctt cgt gaa gct ggc aag tgg			1344
Asp Leu Tyr Arg Glu Gly Gly Asp Ile Leu Arg Glu Ala Gly Lys Trp			
435	440	445	
tcg cct gaa ctg gct gct gcc ctc gac ctc tgg aaa gag atc aag ttc			1392
Ser Pro Glu Leu Ala Ala Ala Leu Asp Leu Trp Lys Glu Ile Lys Phe			
450	455	460	
gaa ttc gaa acg atg gac aag ctc taa ggagcctctg actatcgctg			1439
Glu Phe Glu Thr Met Asp Lys Leu *			
465	470		
ggggagtgag cgttgctgcg taaagctttc tccccagcct ttcgacttaa cctttcagga			1499
tttctgaatc atg agc atg aaa act ctg ccc aaa gag cgt cgt ttc gag			1548
Met Ser Met Lys Thr Leu Pro Lys Glu Arg Arg Phe Glu			
475	480	485	
act ttc tcg tac ctg cct ccc ctc agc gat cgc caa atc gct gca caa			1596
Thr Phe Ser Tyr Leu Pro Pro Leu Ser Asp Arg Gln Ile Ala Ala Gln			
490	495	500	
atc gag tac atg atc gag caa ggc ttc cac ccc ttg atc gag ttc aac			1644
Ile Glu Tyr Met Ile Glu Gln Gly Phe His Pro Leu Ile Glu Phe Asn			
505	510	515	
gag cac tcg aat ccg gaa gag ttc tac tgg acg atg tgg aag ctc ccc			1692
Glu His Ser Asn Pro Glu Glu Phe Tyr Trp Thr Met Trp Lys Leu Pro			
520	525	530	
ctg ttt gac tgc aag agc cct cag caa gtc ctc gat gaa gtg cgt gag			1740
Leu Phe Asp Cys Lys Ser Pro Gln Gln Val Leu Asp Glu Val Arg Glu			
535	540	545	
tgc cgc agc gaa tac ggt gat tgc tac atc cgt gtc gct ggc ttc gac			1788
Cys Arg Ser Glu Tyr Gly Asp Cys Tyr Ile Arg Val Ala Gly Phe Asp			
550	555	560	565
aac atc aag cag tgc caa acc gtg agc ttc atc gtt cat cgt tcc ggc			1836
Asn Ile Lys Gln Cys Gln Thr Val Ser Phe Ile Val His Arg Ser Gly			
570	575	580	
cgc tac taa			1845
Arg Tyr *			
<p><210> SEQ ID NO 23 <211> LENGTH: 472 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: RT111 rbcL</p>			
<p><400> SEQUENCE: 23</p>			
Met Pro Lys Thr Gln Ser Ala Ala Gly Tyr Lys Ala Gly Val Lys Asp			
1	5	10	15
Tyr Lys Leu Thr Tyr Tyr Thr Pro Asp Tyr Thr Pro Lys Asp Thr Asp			
20	25	30	
Leu Leu Ala Ala Phe Arg Phe Ser Pro Gln Pro Gly Val Pro Ala Asp			
35	40	45	
Glu Ala Gly Ala Ala Ile Ala Ala Glu Ser Ser Thr Gly Thr Trp Thr			
50	55	60	
Thr Val Trp Thr Asp Leu Leu Thr Asp Met Asp Arg Tyr Lys Gly Lys			
65	70	75	80
Cys Tyr His Ile Glu Pro Val Gln Gly Glu Glu Asn Ser Tyr Phe Ala			
85	90	95	

-continued

```

Phe Ile Ala Tyr Pro Leu Asp Leu Phe Glu Glu Gly Ser Val Thr Asn
      100                               105                               110

Ile Leu Thr Ser Ile Val Gly Asn Val Phe Gly Phe Lys Ala Ile Arg
      115                               120                               125

Ser Leu Arg Leu Glu Asp Ile Arg Phe Pro Val Ala Leu Val Lys Thr
      130                               135                               140

Phe Gln Gly Pro Pro His Gly Ile Gln Val Glu Arg Asp Leu Leu Asn
145                               150                               155                               160

Lys Tyr Gly Arg Pro Met Leu Gly Cys Thr Ile Lys Pro Lys Leu Gly
      165                               170                               175

Leu Ser Ala Lys Asn Tyr Gly Arg Ala Val Tyr Glu Cys Leu Arg Gly
      180                               185                               190

Gly Leu Asp Phe Thr Lys Asp Asp Glu Asn Ile Asn Ser Gln Pro Phe
      195                               200                               205

Gln Arg Trp Arg Asp Arg Phe Leu Phe Val Ala Asp Ala Ile His Lys
      210                               215                               220

Ser Gln Ala Glu Thr Gly Glu Ile Lys Gly His Tyr Leu Asn Val Thr
225                               230                               235                               240

Ala Pro Thr Cys Glu Glu Met Met Lys Arg Ala Glu Phe Ala Lys Glu
      245                               250                               255

Leu Gly Met Pro Ile Ile Met His Asp Phe Leu Thr Ala Gly Phe Thr
      260                               265                               270

Ala Asn Thr Thr Leu Ala Lys Trp Cys Arg Asp Asn Gly Val Leu Leu
      275                               280                               285

His Ile His Arg Ala Met His Ala Val Ile Asp Arg Gln Arg Asn His
      290                               295                               300

Gly Ile His Phe Arg Val Leu Ala Lys Cys Leu Arg Leu Ser Gly Gly
305                               310                               315                               320

Asp His Leu His Ser Gly Thr Val Val Gly Lys Leu Glu Gly Asp Lys
      325                               330                               335

Ala Ser Thr Leu Gly Phe Val Asp Leu Met Arg Glu Asp His Ile Glu
      340                               345                               350

Ala Asp Arg Ser Arg Gly Val Phe Phe Thr Gln Asp Trp Ala Ser Met
      355                               360                               365

Pro Gly Val Leu Pro Val Ala Ser Gly Gly Ile His Val Trp His Met
      370                               375                               380

Pro Ala Leu Val Glu Ile Phe Gly Asp Asp Ser Val Leu Gln Phe Gly
385                               390                               395                               400

Gly Gly Thr Leu Gly His Pro Trp Gly Asn Ala Pro Gly Ala Thr Ala
      405                               410                               415

Asn Arg Val Ala Leu Glu Ala Cys Val Gln Ala Arg Asn Glu Gly Arg
      420                               425                               430

Asp Leu Tyr Arg Glu Gly Gly Asp Ile Leu Arg Glu Ala Gly Lys Trp
      435                               440                               445

Ser Pro Glu Leu Ala Ala Ala Leu Asp Leu Trp Lys Glu Ile Lys Phe
      450                               455                               460

Glu Phe Glu Thr Met Asp Lys Leu
465                               470

```

```

<210> SEQ ID NO 24
<211> LENGTH: 111
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: RT111 rbcS

```

-continued

<400> SEQUENCE: 24

```

Met Ser Met Lys Thr Leu Pro Lys Glu Arg Arg Phe Glu Thr Phe Ser
1           5           10           15
Tyr Leu Pro Pro Leu Ser Asp Arg Gln Ile Ala Ala Gln Ile Glu Tyr
           20           25           30
Met Ile Glu Gln Gly Phe His Pro Leu Ile Glu Phe Asn Glu His Ser
           35           40           45
Asn Pro Glu Glu Phe Tyr Trp Thr Met Trp Lys Leu Pro Leu Phe Asp
           50           55           60
Cys Lys Ser Pro Gln Gln Val Leu Asp Glu Val Arg Glu Cys Arg Ser
65           70           75           80
Glu Tyr Gly Asp Cys Tyr Ile Arg Val Ala Gly Phe Asp Asn Ile Lys
           85           90           95
Gln Cys Gln Thr Val Ser Phe Ile Val His Arg Ser Gly Arg Tyr
           100          105          110

```

<210> SEQ ID NO 25

<211> LENGTH: 1845

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: RT113 rbcLS

<220> FEATURE:

<221> NAME/KEY: CDS

<222> LOCATION: (1)...(1419)

<223> OTHER INFORMATION: RT113 rbcL

<220> FEATURE:

<221> NAME/KEY: CDS

<222> LOCATION: (1510)...(1845)

<223> OTHER INFORMATION: RT113 rbcS

<400> SEQUENCE: 25

```

atg ccc aag acg caa tct gcc gca ggc tat aag gcc ggg gtg aag gac      48
Met Pro Lys Thr Gln Ser Ala Ala Gly Tyr Lys Ala Gly Val Lys Asp
1           5           10           15
tac aaa ctc acc tat tac acc ccc gat tac acc ccc aaa gac act gac      96
Tyr Lys Leu Thr Tyr Tyr Thr Pro Asp Tyr Thr Pro Lys Asp Thr Asp
           20           25           30
ctg ctg gcg gct ttc cgc ttc agc cct cag ccg ggt gtc cct gct gac      144
Leu Leu Ala Ala Phe Arg Phe Ser Pro Gln Pro Gly Val Pro Ala Asp
           35           40           45
gaa gct ggt gcg gcg atc gcg gct gaa tct tcg acc ggt acc tgg acc      192
Glu Ala Gly Ala Ala Ile Ala Ala Glu Ser Ser Thr Gly Thr Trp Thr
           50           55           60
acc gtg tgg acc gac ttg ctg acc gac atg gat cgg tac aaa ggc aag      240
Thr Val Trp Thr Asp Leu Leu Thr Asp Met Asp Arg Tyr Lys Gly Lys
           65           70           75           80
tgc tac cac atc gag ccg gtg caa ggc gaa gag aac tcc tac ttt gcg      288
Cys Tyr His Ile Glu Pro Val Gln Gly Glu Glu Asn Ser Tyr Phe Ala
           85           90           95
ttc atc gct tac ccg ctc gac ctg ttt gaa gaa ggg tcg gtc acc aac      336
Phe Ile Ala Tyr Pro Leu Asp Leu Phe Glu Glu Gly Ser Val Thr Asn
           100          105          110
atc ctg acc tcg atc gtc ggt aac gtg ttt ggc ttc aaa gct atc cgt      384
Ile Leu Thr Ser Ile Val Gly Asn Val Phe Gly Phe Lys Ala Ile Arg
           115          120          125
tcg ctg cgt ctg gaa gac atc cgc ttc ccc gtc gcc ttg gtc aaa acc      432
Ser Leu Arg Leu Glu Asp Ile Arg Phe Pro Val Ala Leu Val Lys Thr
           130          135          140
ttc caa ggt cct ccc cac ggt atc caa gtc gag cgc gac ctg ctg aac      480

```


-continued

```

gaa ttc gaa acg atg gac aag ctc taa ggagcctctg actatcgctg      1439
Glu Phe Glu Thr Met Asp Lys Leu *
465                      470

ggggagtgcg cggtgctgcg taaagctttc tccccagcct ttcgacttaa cctttcagga 1499

tttctgaatc atg agc atg aaa act ctg ccc aaa gag cgt cgt ttc gag      1548
          Met Ser Met Lys Thr Leu Pro Lys Glu Arg Arg Phe Glu
          475                      480                      485

act ttc tcg tac ctg cct ccc ctc agc gat cgc caa atc gct gca caa      1596
Thr Phe Ser Tyr Leu Pro Pro Leu Ser Asp Arg Gln Ile Ala Ala Gln
          490                      495                      500

atc gag tac atg atc gag caa ggc ttc cac ccc ttg atc gag ttc aac      1644
Ile Glu Tyr Met Ile Glu Gln Gly Phe His Pro Leu Ile Glu Phe Asn
          505                      510                      515

gag cac tcg aat ccg gaa gag ttc tac tgg acg atg tgg aag ctc ccc      1692
Glu His Ser Asn Pro Glu Glu Phe Tyr Trp Thr Met Trp Lys Leu Pro
          520                      525                      530

ctg ttt gac tgc aat agc cct cag caa gtc ctc gat gaa gtg cgt gag      1740
Leu Phe Asp Cys Asn Ser Pro Gln Gln Val Leu Asp Glu Val Arg Glu
          535                      540                      545

tgc cgc agc gaa tac ggt gat tgc tac atc cgt gtc gct ggc ttc gac      1788
Cys Arg Ser Glu Tyr Gly Asp Cys Tyr Ile Arg Val Ala Gly Phe Asp
550                      555                      560                      565

aac atc aag cag tgc caa acc gtg agc ttc atc gtt cat cgt ccc ggc      1836
Asn Ile Lys Gln Cys Gln Thr Val Ser Phe Ile Val His Arg Pro Gly
          570                      575                      580

cgc tac taa
Arg Tyr *
1845

```

```

<210> SEQ ID NO 26
<211> LENGTH: 472
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: RT113 rbcL

```

```

<400> SEQUENCE: 26

```

```

Met Pro Lys Thr Gln Ser Ala Ala Gly Tyr Lys Ala Gly Val Lys Asp
 1                      5                      10                      15

Tyr Lys Leu Thr Tyr Tyr Thr Pro Asp Tyr Thr Pro Lys Asp Thr Asp
          20                      25                      30

Leu Leu Ala Ala Phe Arg Phe Ser Pro Gln Pro Gly Val Pro Ala Asp
          35                      40                      45

Glu Ala Gly Ala Ala Ile Ala Ala Glu Ser Ser Thr Gly Thr Trp Thr
          50                      55                      60

Thr Val Trp Thr Asp Leu Leu Thr Asp Met Asp Arg Tyr Lys Gly Lys
65                      70                      75                      80

Cys Tyr His Ile Glu Pro Val Gln Gly Glu Glu Asn Ser Tyr Phe Ala
          85                      90                      95

Phe Ile Ala Tyr Pro Leu Asp Leu Phe Glu Glu Gly Ser Val Thr Asn
          100                      105                      110

Ile Leu Thr Ser Ile Val Gly Asn Val Phe Gly Phe Lys Ala Ile Arg
          115                      120                      125

Ser Leu Arg Leu Glu Asp Ile Arg Phe Pro Val Ala Leu Val Lys Thr
          130                      135                      140

Phe Gln Gly Pro Pro His Gly Ile Gln Val Glu Arg Asp Leu Leu Asn
145                      150                      155                      160

Lys Tyr Gly Arg Pro Met Leu Gly Cys Thr Ile Lys Pro Lys Leu Gly
          165                      170                      175

```


-continued

Leu Ser Ala Lys Asn Tyr Gly Arg Ala Val Tyr Glu Cys Leu Arg Gly
 180 185 190
 Gly Leu Asp Phe Thr Lys Asp Asp Glu Asn Ile Asn Ser Gln Pro Phe
 195 200 205
 Gln Arg Trp Arg Asp Arg Phe Leu Phe Val Ala Asp Ala Ile His Lys
 210 215 220
 Ser Gln Ala Glu Thr Gly Glu Ile Lys Gly His Tyr Leu Asn Val Thr
 225 230 235 240
 Ala Pro Thr Cys Glu Glu Met Met Lys Arg Ala Glu Phe Ala Lys Glu
 245 250 255
 Leu Gly Met Pro Ile Ile Met His Asp Phe Leu Thr Ala Gly Phe Thr
 260 265 270
 Ala Asn Thr Thr Leu Ala Lys Trp Cys Arg Asp Asn Gly Val Leu Leu
 275 280 285
 His Ile His Arg Ala Met His Ala Val Ile Asp Arg Gln Arg Asn His
 290 295 300
 Gly Ile His Phe Arg Val Leu Ala Lys Cys Leu Arg Leu Ser Gly Gly
 305 310 315 320
 Asp His Leu His Ser Gly Thr Val Val Gly Lys Leu Glu Gly Asp Lys
 325 330 335
 Ala Ser Thr Leu Gly Phe Val Asp Leu Met Arg Glu Asp His Ile Glu
 340 345 350
 Ala Asp Arg Ser Arg Gly Val Phe Phe Thr Gln Asp Trp Ala Ser Met
 355 360 365
 Pro Gly Val Leu Pro Val Ala Ser Gly Gly Ile His Val Trp His Met
 370 375 380
 Pro Ala Leu Val Glu Ile Phe Gly Asp Asp Ser Val Leu Gln Phe Gly
 385 390 395 400
 Gly Gly Thr Leu Gly His Pro Trp Gly Asn Ala Pro Gly Ala Thr Ala
 405 410 415
 Asn Arg Val Ala Leu Glu Ala Cys Val Gln Ala Arg Asn Glu Gly Arg
 420 425 430
 Asp Leu Tyr Arg Glu Gly Gly Asp Ile Leu Arg Glu Ala Gly Lys Trp
 435 440 445
 Ser Pro Glu Leu Ala Ala Ala Leu Asp Leu Trp Lys Glu Ile Lys Phe
 450 455 460
 Glu Phe Glu Thr Met Asp Lys Leu
 465 470

<210> SEQ ID NO 27
 <211> LENGTH: 111
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: RT113 rbcS

<400> SEQUENCE: 27

Met Ser Met Lys Thr Leu Pro Lys Glu Arg Arg Phe Glu Thr Phe Ser
 1 5 10 15
 Tyr Leu Pro Pro Leu Ser Asp Arg Gln Ile Ala Ala Gln Ile Glu Tyr
 20 25 30
 Met Ile Glu Gln Gly Phe His Pro Leu Ile Glu Phe Asn Glu His Ser
 35 40 45
 Asn Pro Glu Glu Phe Tyr Trp Thr Met Trp Lys Leu Pro Leu Phe Asp
 50 55 60

-continued

Cys Asn Ser Pro Gln Gln Val Leu Asp Glu Val Arg Glu Cys Arg Ser
 65 70 75 80
 Glu Tyr Gly Asp Cys Tyr Ile Arg Val Ala Gly Phe Asp Asn Ile Lys
 85 90 95
 Gln Cys Gln Thr Val Ser Phe Ile Val His Arg Pro Gly Arg Tyr
 100 105 110

<210> SEQ ID NO 28
 <211> LENGTH: 1845
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: RT115 rbcLS
 <220> FEATURE:
 <221> NAME/KEY: CDS
 <222> LOCATION: (1)...(1419)
 <223> OTHER INFORMATION: RT115 rbcL
 <220> FEATURE:
 <221> NAME/KEY: CDS
 <222> LOCATION: (1510)...(1845)
 <223> OTHER INFORMATION: RT115 rbcS

<400> SEQUENCE: 28

atg ccc aag acg caa tct gcc gca ggc tat aag gcc ggg gtg aag gac 48
 Met Pro Lys Thr Gln Ser Ala Ala Gly Tyr Lys Ala Gly Val Lys Asp
 1 5 10 15
 tac aaa ctc acc tat tac acc ccc gat tac acc ccc aaa gac act gac 96
 Tyr Lys Leu Thr Tyr Tyr Thr Pro Asp Tyr Thr Pro Lys Asp Thr Asp
 20 25 30
 ctg ctg gcg gct ttc cgc ttc agc cct cag ccg ggt gtc cct gct gac 144
 Leu Leu Ala Ala Phe Arg Phe Ser Pro Gln Pro Gly Val Pro Ala Asp
 35 40 45
 gaa gct ggt gcg gcg atc gcg gct gaa tct tcg acc ggt acc tgg acc 192
 Glu Ala Gly Ala Ala Ile Ala Ala Glu Ser Ser Thr Gly Thr Trp Thr
 50 55 60
 acc gtg tgg acc gac ttg ctg acc gac atg gat cgg tac aaa ggc aag 240
 Thr Val Trp Thr Asp Leu Leu Thr Asp Met Asp Arg Tyr Lys Gly Lys
 65 70 75 80
 tgc tac cac atc gag ccg gtg caa ggc gaa gag aac tcc tac ttt gcg 288
 Cys Tyr His Ile Glu Pro Val Gln Gly Glu Glu Asn Ser Tyr Phe Ala
 85 90 95
 ttc atc gct tac ccg ctc gac ctg ttt gaa gaa ggg tcg gtc acc aac 336
 Phe Ile Ala Tyr Pro Leu Asp Leu Phe Glu Glu Gly Ser Val Thr Asn
 100 105 110
 atc ctg acc tcg atc gtc ggt aac gtg ttt ggc ttc aaa gct atc cgt 384
 Ile Leu Thr Ser Ile Val Gly Asn Val Phe Gly Phe Lys Ala Ile Arg
 115 120 125
 tcg ctg cgt ctg gaa gac atc cgc ttc ccc gtc gcc ttg gtc aaa acc 432
 Ser Leu Arg Leu Glu Asp Ile Arg Phe Pro Val Ala Leu Val Lys Thr
 130 135 140
 ttc caa ggt cct ccc cac ggt atc caa gtc gag cgc gac ctg ctg aac 480
 Phe Gln Gly Pro Pro His Gly Ile Gln Val Glu Arg Asp Leu Leu Asn
 145 150 155 160
 aag tac ggc cgt ccg atg ctg ggt tgc acg atc aaa cca aaa ctc ggt 528
 Lys Tyr Gly Arg Pro Met Leu Gly Cys Thr Ile Lys Pro Lys Leu Gly
 165 170 175
 ctg tcg gcg aaa aac tac ggt cgt gcc gtc tac gaa tgt ctg cgc ggc 576
 Leu Ser Ala Lys Asn Tyr Gly Arg Ala Val Tyr Glu Cys Leu Arg Gly
 180 185 190
 ggt ctg gac ttc acc aaa gac gac gaa aac atc aac tcg cag cct ttc 624
 Gly Leu Asp Phe Thr Lys Asp Asp Glu Asn Ile Asn Ser Gln Pro Phe
 195 200 205

-continued

atg cgt tgg cgc gat cgc ttc ctg ttt gtg gct gat gca atc cac aaa	672
Met Arg Trp Arg Asp Arg Phe Leu Phe Val Ala Asp Ala Ile His Lys	
210 215 220	
tcg caa gca gaa acc ggt gaa acc aag ggt cac tac ctg aac gtg acc	720
Ser Gln Ala Glu Thr Gly Glu Thr Lys Gly His Tyr Leu Asn Val Thr	
225 230 235 240	
gcg ccg acc tgc gaa gaa atg atg aaa cgg gct gag ttc gct aaa gaa	768
Ala Pro Thr Cys Glu Glu Met Met Lys Arg Ala Glu Phe Ala Lys Glu	
245 250 255	
ctc ggc atg ccg atc atc atg cat gac ttc ttg acg gct ggt ttc acc	816
Leu Gly Met Pro Ile Ile Met His Asp Phe Leu Thr Ala Gly Phe Thr	
260 265 270	
gcc aac acc acc ttg gca aaa tgg tgc cgc gac aac ggc gtc ctg ctg	864
Ala Asn Thr Thr Leu Ala Lys Trp Cys Arg Asp Asn Gly Val Leu Leu	
275 280 285	
cac atc cac cgt gca atg cac gcg gtg atc gac cgt cag cgt aac cac	912
His Ile His Arg Ala Met His Ala Val Ile Asp Arg Gln Arg Asn His	
290 295 300	
ggg att cac ttc cgt gtc ttg gcc aag tgc ctg cgc ctc tcc ggt ggc	960
Gly Ile His Phe Arg Val Leu Ala Lys Cys Leu Arg Leu Ser Gly Gly	
305 310 315 320	
gac cag ctc cac acc ggc acc gtg gtg ggc aag ctc gag ggt gac cgt	1008
Asp Gln Leu His Thr Gly Thr Val Val Gly Lys Leu Glu Gly Asp Arg	
325 330 335	
cag acc acc ctg ggc ttc atc gac cag ctg cgc gaa tcc ttc atc ccc	1056
Gln Thr Thr Leu Gly Phe Ile Asp Gln Leu Arg Glu Ser Phe Ile Pro	
340 345 350	
gaa gac cgc acc cgc ggc aac ttc ttc gat cag gac tgg ggt tcg atg	1104
Glu Asp Arg Thr Arg Gly Asn Phe Phe Asp Gln Asp Trp Gly Ser Met	
355 360 365	
ccc ggc gtc ttc gcc gtg gcc tcc ggc ggc atc cac gtg tgg cac atg	1152
Pro Gly Val Phe Ala Val Ala Ser Gly Gly Ile His Val Trp His Met	
370 375 380	
ccc gcc ctg gtg gaa atc ttc ggt gat gac tcc gtt ctc cag ttc ggt	1200
Pro Ala Leu Val Glu Ile Phe Gly Asp Asp Ser Val Leu Gln Phe Gly	
385 390 395 400	
ggc ggc acc ttg ggt cac ccc tgg ggt aat gct cct ggt gca acc gcg	1248
Gly Gly Thr Leu Gly His Pro Trp Gly Asn Ala Pro Gly Ala Thr Ala	
405 410 415	
aac cgt gtt gcc ttg gaa gct tgc gtc caa gct cgg aac gaa ggt cgc	1296
Asn Arg Val Ala Leu Glu Ala Cys Val Gln Ala Arg Asn Glu Gly Arg	
420 425 430	
gac ctc tac cgt gaa ggc ggc gac atc ctt cgt gag gct ggc aag tgg	1344
Asp Leu Tyr Arg Glu Gly Gly Asp Ile Leu Arg Glu Ala Gly Lys Trp	
435 440 445	
tcg cct gaa ctg gct gca gct ctc gac ctc tgg aaa gag atc aag ttc	1392
Ser Pro Glu Leu Ala Ala Ala Leu Asp Leu Trp Lys Glu Ile Lys Phe	
450 455 460	
gaa ttc gaa acg atg gac aag ctc taa ggagcctctg actatcgctg	1439
Glu Phe Glu Thr Met Asp Lys Leu *	
465 470	
ggggagtgag cggttgctgcg taaagctttc tccccagcct ttcgacttaa cctttcagga	1499
tttctgaatc atg agc atg aaa act ctg ccc aaa gag cgt cgt ttc gag	1548
Met Ser Met Lys Thr Leu Pro Lys Glu Arg Arg Phe Glu	
475 480 485	
act ttc tcg tac ctg cct ccc ctc agc gat cgc caa atc gct gca caa	1596
Thr Phe Ser Tyr Leu Pro Pro Leu Ser Asp Arg Gln Ile Ala Ala Gln	
490 495 500	

-continued

atc gag tac atg atc gag caa ggc ttc cac ccc ttg atc gag ttc aac	1644
Ile Glu Tyr Met Ile Glu Gln Gly Phe His Pro Leu Ile Glu Phe Asn	
505 510 515	
gag cac tcg aat ccg gaa gag ttc tac tgg acg atg tgg aag ctc ccc	1692
Glu His Ser Asn Pro Glu Glu Phe Tyr Trp Thr Met Trp Lys Leu Pro	
520 525 530	
ctg ttt gac tgc aag agc cct cag caa gtc ctc gat gaa gtg cgt gag	1740
Leu Phe Asp Cys Lys Ser Pro Gln Gln Val Leu Asp Glu Val Arg Glu	
535 540 545	
tgc cgc agc gaa tac ggt gat tgc tac atc cgt gtc gct ggc ttc gac	1788
Cys Arg Ser Glu Tyr Gly Asp Cys Tyr Ile Arg Val Ala Gly Phe Asp	
550 555 560 565	
aac atc aag cag tgc caa acc gtg ggc ttc atc gtt cat cgt ccc ggc	1836
Asn Ile Lys Gln Cys Gln Thr Val Gly Phe Ile Val His Arg Pro Gly	
570 575 580	
cgc tac taa	1845
Arg Tyr *	

<210> SEQ ID NO 29

<211> LENGTH: 472

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: RT115 rbcL

<400> SEQUENCE: 29

Met Pro Lys Thr Gln Ser Ala Ala Gly Tyr Lys Ala Gly Val Lys Asp	
1 5 10 15	
Tyr Lys Leu Thr Tyr Tyr Thr Pro Asp Tyr Thr Pro Lys Asp Thr Asp	
20 25 30	
Leu Leu Ala Ala Phe Arg Phe Ser Pro Gln Pro Gly Val Pro Ala Asp	
35 40 45	
Glu Ala Gly Ala Ala Ile Ala Ala Glu Ser Ser Thr Gly Thr Trp Thr	
50 55 60	
Thr Val Trp Thr Asp Leu Leu Thr Asp Met Asp Arg Tyr Lys Gly Lys	
65 70 75 80	
Cys Tyr His Ile Glu Pro Val Gln Gly Glu Glu Asn Ser Tyr Phe Ala	
85 90 95	
Phe Ile Ala Tyr Pro Leu Asp Leu Phe Glu Glu Gly Ser Val Thr Asn	
100 105 110	
Ile Leu Thr Ser Ile Val Gly Asn Val Phe Gly Phe Lys Ala Ile Arg	
115 120 125	
Ser Leu Arg Leu Glu Asp Ile Arg Phe Pro Val Ala Leu Val Lys Thr	
130 135 140	
Phe Gln Gly Pro Pro His Gly Ile Gln Val Glu Arg Asp Leu Leu Asn	
145 150 155 160	
Lys Tyr Gly Arg Pro Met Leu Gly Cys Thr Ile Lys Pro Lys Leu Gly	
165 170 175	
Leu Ser Ala Lys Asn Tyr Gly Arg Ala Val Tyr Glu Cys Leu Arg Gly	
180 185 190	
Gly Leu Asp Phe Thr Lys Asp Asp Glu Asn Ile Asn Ser Gln Pro Phe	
195 200 205	
Met Arg Trp Arg Asp Arg Phe Leu Phe Val Ala Asp Ala Ile His Lys	
210 215 220	
Ser Gln Ala Glu Thr Gly Glu Thr Lys Gly His Tyr Leu Asn Val Thr	
225 230 235 240	
Ala Pro Thr Cys Glu Glu Met Met Lys Arg Ala Glu Phe Ala Lys Glu	

-continued

```

<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: RT116 rbcLS
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1)...(1419)
<223> OTHER INFORMATION: RT116 rbcL
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1510)...(1845)
<223> OTHER INFORMATION: RT116 rbcS

<400> SEQUENCE: 31

atg ccc aag acg caa tct gcc gca ggc tat aag gcc ggg gtg aag gac      48
Met Pro Lys Thr Gln Ser Ala Ala Gly Tyr Lys Ala Gly Val Lys Asp
  1             5             10             15

tac aaa ctc acc tat tac acc ccc gat tac acc ccc aaa gac act gac      96
Tyr Lys Leu Thr Tyr Tyr Thr Pro Asp Tyr Thr Pro Lys Asp Thr Asp
             20             25             30

ctg ctg gcg gct ttc cgc ttc agc cct cag ccg ggt gtc cct gct gac      144
Leu Leu Ala Ala Phe Arg Phe Ser Pro Gln Pro Gly Val Pro Ala Asp
             35             40             45

gaa gct ggt gcg gcg atc gcg gct gaa tct tcg acc ggt acc tgg acc      192
Glu Ala Gly Ala Ala Ile Ala Ala Glu Ser Ser Thr Gly Thr Trp Thr
             50             55             60

acc gtg tgg acc gac ttg ctg acc gac atg gat cgg tac aaa ggc aag      240
Thr Val Trp Thr Asp Leu Leu Thr Asp Met Asp Arg Tyr Lys Gly Lys
             65             70             75             80

tgc tac cac atc gag ccg gtg caa ggc gaa gag aac tcc tac ttt gcg      288
Cys Tyr His Ile Glu Pro Val Gln Gly Glu Glu Asn Ser Tyr Phe Ala
             85             90             95

ttc atc gct tac ccg ctc gac ctg ttt gaa gaa ggg tcg gtc acc aac      336
Phe Ile Ala Tyr Pro Leu Asp Leu Phe Glu Glu Gly Ser Val Thr Asn
             100            105            110

atc ctg acc tcg atc gtc ggt aac gtg ttt ggc ttc aaa gct atc cgt      384
Ile Leu Thr Ser Ile Val Gly Asn Val Phe Gly Phe Lys Ala Ile Arg
             115            120            125

tcg ctg cgt ctg gaa gac atc cgc ttc ccc gtc gcc ttg gtc aaa acc      432
Ser Leu Arg Leu Glu Asp Ile Arg Phe Pro Val Ala Leu Val Lys Thr
             130            135            140

ttc caa ggt cct ccc cac ggt atc caa gtc gag cgc gac ctg ctg aac      480
Phe Gln Gly Pro Pro His Gly Ile Gln Val Glu Arg Asp Leu Leu Asn
             145            150            155            160

aag tac ggc cgt ccg atg ctg ggt tgc acg atc aaa cca aaa ctc ggt      528
Lys Tyr Gly Arg Pro Met Leu Gly Cys Thr Ile Lys Pro Lys Leu Gly
             165            170            175

ctg tcg gcg aaa aac tac ggt cgt gcc gtc tac gaa tgt ctg cgc ggc      576
Leu Ser Ala Lys Asn Tyr Gly Arg Ala Val Tyr Glu Cys Leu Arg Gly
             180            185            190

ggt ctg gac ttc acc aaa gac gac gaa aac atc aac tcg cag ccg ttc      624
Gly Leu Asp Phe Thr Lys Asp Asp Glu Asn Ile Asn Ser Gln Pro Phe
             195            200            205

caa cgc tgg cgc gat cgc ttc ctg ttt gtg gct gat gca atc cac aaa      672
Gln Arg Trp Arg Asp Arg Phe Leu Phe Val Ala Asp Ala Ile His Lys
             210            215            220

tcg caa gca gaa acc ggt gaa atc aaa ggt cac tac ctg aac gtg acc      720
Ser Gln Ala Glu Thr Gly Glu Ile Lys Gly His Tyr Leu Asn Val Thr
             225            230            235            240

gcg ccg acc tgc gaa gaa atg atg aaa cgg gct gag ttc gct aaa gaa      768
Ala Pro Thr Cys Glu Glu Met Met Lys Arg Ala Glu Phe Ala Lys Glu
             245            250            255

ctc ggc atg ccg atc atc atg cat gac ttc ttg acg gct ggt ttc acc      816

```


-continued

Leu	Gly	Met	Pro	Ile	Ile	Met	His	Asp	Phe	Leu	Thr	Ala	Gly	Phe	Thr		
			260					265					270				
gcc	aac	acc	acc	ttg	gca	aaa	tgg	tgc	cgc	gac	aac	ggc	gtc	ctg	ctg	864	
Ala	Asn	Thr	Thr	Leu	Ala	Lys	Trp	Cys	Arg	Asp	Asn	Gly	Val	Leu	Leu		
		275					280					285					
cac	atc	cac	cgt	gca	atg	cac	gcg	gcg	atc	gac	cgt	cag	cgt	aac	cac	912	
His	Ile	His	Arg	Ala	Met	His	Ala	Ala	Ile	Asp	Arg	Gln	Arg	Asn	His		
		290				295					300						
ggg	att	cac	ttc	cgc	ggt	ttg	gct	aag	tgt	ttg	cgt	ctg	tcc	ggt	ggt	960	
Gly	Ile	His	Phe	Arg	Val	Leu	Ala	Lys	Cys	Leu	Arg	Leu	Ser	Gly	Gly		
305					310					315					320		
gac	cac	ctc	cac	tcc	ggc	acc	gtc	gtc	ggc	aaa	ctg	gaa	ggc	gac	aaa	1008	
Asp	His	Leu	His	Ser	Gly	Thr	Val	Val	Gly	Lys	Leu	Glu	Gly	Asp	Lys		
				325					330					335			
gct	tcg	acc	ttg	ggc	ttt	ggt	gac	ttg	atg	cgc	gaa	gac	cac	atc	gaa	1056	
Ala	Ser	Thr	Leu	Gly	Phe	Val	Asp	Leu	Met	Arg	Glu	Asp	His	Ile	Glu		
			340					345					350				
gct	gac	cgc	agc	cgt	ggg	gtc	ttc	ttc	acc	caa	gat	tgg	gcg	tcg	atg	1104	
Ala	Asp	Arg	Ser	Arg	Gly	Val	Phe	Phe	Thr	Gln	Asp	Trp	Ala	Ser	Met		
			355				360						365				
ccg	ggc	gtg	ctg	ccg	ggt	gct	tcc	ggt	ggt	atc	cac	gtg	tgg	cac	atg	1152	
Pro	Gly	Val	Leu	Pro	Val	Ala	Ser	Gly	Gly	Ile	His	Val	Trp	His	Met		
	370					375					380						
ccc	gca	ctg	gtg	gaa	atc	ttc	ggt	gat	gac	tcc	ggt	ctc	cag	ttc	ggt	1200	
Pro	Ala	Leu	Val	Glu	Ile	Phe	Gly	Asp	Asp	Ser	Val	Leu	Gln	Phe	Gly		
385					390					395					400		
ggc	ggc	acc	ttg	ggt	cac	ccc	tgg	ggt	aat	gct	cct	ggt	gca	acc	gcg	1248	
Gly	Gly	Thr	Leu	Gly	His	Pro	Trp	Gly	Asn	Ala	Pro	Gly	Ala	Thr	Ala		
				405					410					415			
aac	cgt	ggt	gcc	ttg	gaa	gct	tgc	gtc	caa	gct	cgg	aac	gaa	ggt	cgc	1296	
Asn	Arg	Val	Ala	Leu	Glu	Ala	Cys	Val	Gln	Ala	Arg	Asn	Glu	Gly	Arg		
			420					425					430				
gac	ctc	tac	cgt	gaa	ggc	ggc	gac	atc	ctt	cgt	gaa	gct	ggc	aag	tgg	1344	
Asp	Leu	Tyr	Arg	Glu	Gly	Gly	Asp	Ile	Leu	Arg	Glu	Ala	Gly	Lys	Trp		
		435					440					445					
tcg	cct	gaa	ctg	gct	gct	gcc	ctc	gac	ctc	tgg	aaa	gag	atc	aag	ttc	1392	
Ser	Pro	Glu	Leu	Ala	Ala	Ala	Leu	Asp	Leu	Trp	Lys	Glu	Ile	Lys	Phe		
		450				455					460						
gaa	ttc	gaa	acg	atg	gac	aag	ctc	taa	ggagcctctg	actatcgctg						1439	
Glu	Phe	Glu	Thr	Met	Asp	Lys	Leu	*									
465						470											
ggggagtgag	cggtgctgcg	taaagctttc	tccccagcct	ttcgacttaa	cctttcagga											1499	
tttctgaatc	atg	agc	atg	aaa	act	ctg	ccc	aaa	gag	cgt	cgt	ttc	gag			1548	
			Met	Ser	Met	Lys	Thr	Leu	Pro	Lys	Glu	Arg	Arg	Phe	Glu		
					475					480					485		
act	ttc	tcg	tac	ctg	cct	ccc	ctc	agc	gat	cgc	caa	atc	gct	gca	caa	1596	
Thr	Phe	Ser	Tyr	Leu	Pro	Pro	Leu	Ser	Asp	Arg	Gln	Ile	Ala	Ala	Gln		
				490					495					500			
atc	gag	tac	atg	atc	gag	caa	ggc	ttc	cac	ccc	ttg	atc	gag	ttc	aac	1644	
Ile	Glu	Tyr	Met	Ile	Glu	Gln	Gly	Phe	His	Pro	Leu	Ile	Glu	Phe	Asn		
			505					510						515			
gag	cac	tcg	aat	ccg	gaa	gag	ttc	tac	tgg	acg	atg	tgg	aag	ctc	ccc	1692	
Glu	His	Ser	Asn	Pro	Glu	Glu	Phe	Tyr	Trp	Thr	Met	Trp	Lys	Leu	Pro		
			520				525						530				
ctg	ttt	gac	tgc	aag	agc	cct	cag	caa	gtc	ctc	gat	gaa	gtg	cgt	gag	1740	
Leu	Phe	Asp	Cys	Lys	Ser	Pro	Gln	Gln	Val	Leu	Asp	Glu	Val	Arg	Glu		
		535				540					545						
tgc	cgc	agc	gaa	tac	ggt	gat	tgc	tac	atc	cgt	gtc	gct	ggc	ttc	gac	1788	
Cys	Arg	Ser	Glu	Tyr	Gly	Asp	Cys	Tyr	Ile	Arg	Val	Ala	Gly	Phe	Asp		

-continued

```

550          555          560          565
aac atc aag cag tgc caa acc gtg agc ttc atc gtt cat cgt ccc ggc      1836
Asn Ile Lys Gln Cys Gln Thr Val Ser Phe Ile Val His Arg Pro Gly
          570          575          580

cgc tac taa      1845
Arg Tyr *

<210> SEQ ID NO 32
<211> LENGTH: 472
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: RT116 rbcL

<400> SEQUENCE: 32
Met Pro Lys Thr Gln Ser Ala Ala Gly Tyr Lys Ala Gly Val Lys Asp
 1          5          10          15
Tyr Lys Leu Thr Tyr Tyr Thr Pro Asp Tyr Thr Pro Lys Asp Thr Asp
          20          25          30
Leu Leu Ala Ala Phe Arg Phe Ser Pro Gln Pro Gly Val Pro Ala Asp
          35          40          45
Glu Ala Gly Ala Ala Ile Ala Ala Glu Ser Ser Thr Gly Thr Trp Thr
          50          55          60
Thr Val Trp Thr Asp Leu Leu Thr Asp Met Asp Arg Tyr Lys Gly Lys
          65          70          75          80
Cys Tyr His Ile Glu Pro Val Gln Gly Glu Glu Asn Ser Tyr Phe Ala
          85          90          95
Phe Ile Ala Tyr Pro Leu Asp Leu Phe Glu Glu Gly Ser Val Thr Asn
          100          105          110
Ile Leu Thr Ser Ile Val Gly Asn Val Phe Gly Phe Lys Ala Ile Arg
          115          120          125
Ser Leu Arg Leu Glu Asp Ile Arg Phe Pro Val Ala Leu Val Lys Thr
          130          135          140
Phe Gln Gly Pro Pro His Gly Ile Gln Val Glu Arg Asp Leu Leu Asn
          145          150          155          160
Lys Tyr Gly Arg Pro Met Leu Gly Cys Thr Ile Lys Pro Lys Leu Gly
          165          170          175
Leu Ser Ala Lys Asn Tyr Gly Arg Ala Val Tyr Glu Cys Leu Arg Gly
          180          185          190
Gly Leu Asp Phe Thr Lys Asp Asp Glu Asn Ile Asn Ser Gln Pro Phe
          195          200          205
Gln Arg Trp Arg Asp Arg Phe Leu Phe Val Ala Asp Ala Ile His Lys
          210          215          220
Ser Gln Ala Glu Thr Gly Glu Ile Lys Gly His Tyr Leu Asn Val Thr
          225          230          235          240
Ala Pro Thr Cys Glu Glu Met Met Lys Arg Ala Glu Phe Ala Lys Glu
          245          250          255
Leu Gly Met Pro Ile Ile Met His Asp Phe Leu Thr Ala Gly Phe Thr
          260          265          270
Ala Asn Thr Thr Leu Ala Lys Trp Cys Arg Asp Asn Gly Val Leu Leu
          275          280          285
His Ile His Arg Ala Met His Ala Ala Ile Asp Arg Gln Arg Asn His
          290          295          300
Gly Ile His Phe Arg Val Leu Ala Lys Cys Leu Arg Leu Ser Gly Gly
          305          310          315          320

```


-continued

Asp His Leu His Ser Gly Thr Val Val Gly Lys Leu Glu Gly Asp Lys
 325 330 335
 Ala Ser Thr Leu Gly Phe Val Asp Leu Met Arg Glu Asp His Ile Glu
 340 345 350
 Ala Asp Arg Ser Arg Gly Val Phe Phe Thr Gln Asp Trp Ala Ser Met
 355 360 365
 Pro Gly Val Leu Pro Val Ala Ser Gly Gly Ile His Val Trp His Met
 370 375 380
 Pro Ala Leu Val Glu Ile Phe Gly Asp Asp Ser Val Leu Gln Phe Gly
 385 390 395 400
 Gly Gly Thr Leu Gly His Pro Trp Gly Asn Ala Pro Gly Ala Thr Ala
 405 410 415
 Asn Arg Val Ala Leu Glu Ala Cys Val Gln Ala Arg Asn Glu Gly Arg
 420 425 430
 Asp Leu Tyr Arg Glu Gly Gly Asp Ile Leu Arg Glu Ala Gly Lys Trp
 435 440 445
 Ser Pro Glu Leu Ala Ala Ala Leu Asp Leu Trp Lys Glu Ile Lys Phe
 450 455 460
 Glu Phe Glu Thr Met Asp Lys Leu
 465 470

<210> SEQ ID NO 33
 <211> LENGTH: 111
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: RT116 rbcS

<400> SEQUENCE: 33

Met Ser Met Lys Thr Leu Pro Lys Glu Arg Arg Phe Glu Thr Phe Ser
 1 5 10 15
 Tyr Leu Pro Pro Leu Ser Asp Arg Gln Ile Ala Ala Gln Ile Glu Tyr
 20 25 30
 Met Ile Glu Gln Gly Phe His Pro Leu Ile Glu Phe Asn Glu His Ser
 35 40 45
 Asn Pro Glu Glu Phe Tyr Trp Thr Met Trp Lys Leu Pro Leu Phe Asp
 50 55 60
 Cys Lys Ser Pro Gln Gln Val Leu Asp Glu Val Arg Glu Cys Arg Ser
 65 70 75 80
 Glu Tyr Gly Asp Cys Tyr Ile Arg Val Ala Gly Phe Asp Asn Ile Lys
 85 90 95
 Gln Cys Gln Thr Val Ser Phe Ile Val His Arg Pro Gly Arg Tyr
 100 105 110

<210> SEQ ID NO 34
 <211> LENGTH: 1845
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: RT117 rbcLS
 <220> FEATURE:
 <221> NAME/KEY: CDS
 <222> LOCATION: (1)...(1419)
 <223> OTHER INFORMATION: RT117 rbcL
 <220> FEATURE:
 <221> NAME/KEY: CDS
 <222> LOCATION: (1510)...(1845)
 <223> OTHER INFORMATION: RT117 rbcS

<400> SEQUENCE: 34

-continued

atg ccc aag acg caa tct gcc gca ggc tat aag gcc ggg gtg aag gac	48
Met Pro Lys Thr Gln Ser Ala Ala Gly Tyr Lys Ala Gly Val Lys Asp	
1 5 10 15	
tac aaa ctc acc tat tac acc ccc gat tac acc ccc aaa gac act gac	96
Tyr Lys Leu Thr Tyr Tyr Thr Pro Asp Tyr Thr Pro Lys Asp Thr Asp	
20 25 30	
ctg ctg gcg gct ttc cgc ttc agc cct cag ccg ggt gtc cct gct gac	144
Leu Leu Ala Ala Phe Arg Phe Ser Pro Gln Pro Gly Val Pro Ala Asp	
35 40 45	
gaa gct ggt gcg gcg atc gcg gct gaa tct tcg acc ggt acc tgg acc	192
Glu Ala Gly Ala Ala Ile Ala Ala Glu Ser Ser Thr Gly Thr Trp Thr	
50 55 60	
acc gtg tgg acc gac ttg ctg acc gac atg gat cgg tac aaa ggc aag	240
Thr Val Trp Thr Asp Leu Leu Thr Asp Met Asp Arg Tyr Lys Gly Lys	
65 70 75 80	
tgc tac cac atc gag ccg gtg caa ggc gaa gag aac tcc tac ttt gcg	288
Cys Tyr His Ile Glu Pro Val Gln Gly Glu Glu Asn Ser Tyr Phe Ala	
85 90 95	
ttc atc gct tac ccg ctc gac ctg ttt gaa gaa ggg tcg gtc acc aac	336
Phe Ile Ala Tyr Pro Leu Asp Leu Phe Glu Glu Gly Ser Val Thr Asn	
100 105 110	
atc ctg acc tcg atc gtc ggt aac gtg ttt ggc ttc aaa gct atc cgt	384
Ile Leu Thr Ser Ile Val Gly Asn Val Phe Gly Phe Lys Ala Ile Arg	
115 120 125	
tcg ctg cgt ctg gaa gac atc cgc ttc ccc gtc gcc ttg gtc aaa acc	432
Ser Leu Arg Leu Glu Asp Ile Arg Phe Pro Val Ala Leu Val Lys Thr	
130 135 140	
ttc caa ggt cct tcc cac ggt atc caa gtc gag cgc gac ctg ctg aac	480
Phe Gln Gly Pro Ser His Gly Ile Gln Val Glu Arg Asp Leu Leu Asn	
145 150 155 160	
aag tac ggc cgt ccg atg ctg ggt tgc acg atc aaa cca aaa ctc ggt	528
Lys Tyr Gly Arg Pro Met Leu Gly Cys Thr Ile Lys Pro Lys Leu Gly	
165 170 175	
ctg tcg gcg aaa aac tac ggt cgt gca gta tac gaa tgt ctg cgc ggt	576
Leu Ser Ala Lys Asn Tyr Gly Arg Ala Val Tyr Glu Cys Leu Arg Gly	
180 185 190	
ggt ttg gac ttc acc aaa gac gac gaa aac atc aac tct cag cct ttc	624
Gly Leu Asp Phe Thr Lys Asp Asp Glu Asn Ile Asn Ser Gln Pro Phe	
195 200 205	
atg cgt tgg cgc gat cgc ttc ctg ttt gta caa gaa gca att gaa aaa	672
Met Arg Trp Arg Asp Arg Phe Leu Phe Val Gln Glu Ala Ile Glu Lys	
210 215 220	
gct caa gct gaa act ggc gaa atc aag ggt cac tac ttg aac gta act	720
Ala Gln Ala Glu Thr Gly Glu Ile Lys Gly His Tyr Leu Asn Val Thr	
225 230 235 240	
gct cct acc tgt gag caa atg atg gaa cgt gca gct ttc gct aag gaa	768
Ala Pro Thr Cys Glu Gln Met Met Glu Arg Ala Ala Phe Ala Lys Glu	
245 250 255	
atc ggc aca cca atc atc atg cat gac ttc ttg act ggt ggt ttc aca	816
Ile Gly Thr Pro Ile Ile Met His Asp Phe Leu Thr Gly Gly Phe Thr	
260 265 270	
gca aac acc tct ctt gct aag tat tgc cgt gac aat ggc ttg ctc ttg	864
Ala Asn Thr Ser Leu Ala Lys Tyr Cys Arg Asp Asn Gly Leu Leu Leu	
275 280 285	
cac att cac cgc gct atg cac gca gtt atc gac cgt caa aaa acc cac	912
His Ile His Arg Ala Met His Ala Val Ile Asp Arg Gln Lys Thr His	
290 295 300	
ggg att cac ttc cgc gtt ttg gcc aag tgt ttg cgt ctg tcc ggt ggt	960
Gly Ile His Phe Arg Val Leu Ala Lys Cys Leu Arg Leu Ser Gly Gly	
305 310 315 320	

-continued

gac cac ctc cac tcc ggc acc gtc gtc ggc aaa ctg gaa ggc gac aaa Asp His Leu His Ser Gly Thr Val Val Gly Lys Leu Glu Gly Asp Lys 325 330 335	1008
gct tcg acc ttg ggc ttt gtt gac ttg atg cgc gaa gac cac atc gaa Ala Ser Thr Leu Gly Phe Val Asp Leu Met Arg Glu Asp His Ile Glu 340 345 350	1056
gct gac cgc agc cgt ggg gtc ttc ttc acc caa gat tgg gcg tcg atg Ala Asp Arg Ser Arg Gly Val Phe Phe Thr Gln Asp Trp Ala Ser Met 355 360 365	1104
ccg ggc gtg ctg ccg gtt gct tcc ggt ggt atc cac gtg tgg cac atg Pro Gly Val Leu Pro Val Ala Ser Gly Gly Ile His Val Trp His Met 370 375 380	1152
ccc gcc ctg gtc gcc atc ttc ggt gac gac tcc gtg ctc cag ttc ggt Pro Ala Leu Val Ala Ile Phe Gly Asp Asp Ser Val Leu Gln Phe Gly 385 390 395 400	1200
ggt ggc acc ttg ggt cac ccc tgg ggt aat gct cct ggt gca acc gcg Gly Gly Thr Leu Gly His Pro Trp Gly Asn Ala Pro Gly Ala Thr Ala 405 410 415	1248
aac cgt gtt gcc ttg gaa gct tgc gtc caa gct cgg aac gaa ggt cgc Asn Arg Val Ala Leu Glu Ala Cys Val Gln Ala Arg Asn Glu Gly Arg 420 425 430	1296
gac ctc tac cgt gaa ggc ggc gac atc ctt cgt gaa gct ggc aag tgg Asp Leu Tyr Arg Glu Gly Gly Asp Ile Leu Arg Glu Ala Gly Lys Trp 435 440 445	1344
tcg cct gaa ctg gct gct gcc ctc gac ctc tgg aaa gag atc aag ttc Ser Pro Glu Leu Ala Ala Leu Asp Leu Trp Lys Glu Ile Lys Phe 450 455 460	1392
gaa ttc gaa acg atg gac aag ctc taa ggagcctctg actatcgctg Glu Phe Glu Thr Met Asp Lys Leu * 465 470	1439
ggggagtgag cggtgctgcg taaagctttc tccccagcct ttcgacttaa cctttcagga	1499
tttctgaatc atg agc atg aaa act ctg ccc aaa gag cgt cgt ttc gag Met Ser Met Lys Thr Leu Pro Lys Glu Arg Arg Phe Glu 475 480 485	1548
act ttc tcg tac ctg cct ccc ctc agc gat cgc caa atc gct gca caa Thr Phe Ser Tyr Leu Pro Pro Leu Ser Asp Arg Gln Ile Ala Ala Gln 490 495 500	1596
atc gag tac atg atc gag caa ggc ttc cac ccc ttg atc gag ttc aac Ile Glu Tyr Met Ile Glu Gln Gly Phe His Pro Leu Ile Glu Phe Asn 505 510 515	1644
gag cac tcg aat ccg gaa gag ttc tac tgg acg atg tgg aag ctc ccc Glu His Ser Asn Pro Glu Glu Phe Tyr Trp Thr Met Trp Lys Leu Pro 520 525 530	1692
ctg ttt gac tgc aag agc cct cag caa gtc ctc gat gaa gtg cgt gag Leu Phe Asp Cys Lys Ser Pro Gln Gln Val Leu Asp Glu Val Arg Glu 535 540 545	1740
tgc cgc agc gaa tac ggt gat tgc tac atc cgt gtc gct ggc ttc gac Cys Arg Ser Glu Tyr Gly Asp Cys Tyr Ile Arg Val Ala Gly Phe Asp 550 555 560 565	1788
aac atc aag cag tgc caa acc gtg agc ttc atc gtt cat cgt ccc ggc Asn Ile Lys Gln Cys Gln Thr Val Ser Phe Ile Val His Arg Pro Gly 570 575 580	1836
cgc tac taa Arg Tyr *	1845

<210> SEQ ID NO 35

<211> LENGTH: 472

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

-continued

<220> FEATURE:

<223> OTHER INFORMATION: RT117 rbcL

<400> SEQUENCE: 35

Met Pro Lys Thr Gln Ser Ala Ala Gly Tyr Lys Ala Gly Val Lys Asp
1 5 10 15
Tyr Lys Leu Thr Tyr Tyr Thr Pro Asp Tyr Thr Pro Lys Asp Thr Asp
20 25 30
Leu Leu Ala Ala Phe Arg Phe Ser Pro Gln Pro Gly Val Pro Ala Asp
35 40 45
Glu Ala Gly Ala Ala Ile Ala Ala Glu Ser Ser Thr Gly Thr Trp Thr
50 55 60
Thr Val Trp Thr Asp Leu Leu Thr Asp Met Asp Arg Tyr Lys Gly Lys
65 70 75 80
Cys Tyr His Ile Glu Pro Val Gln Gly Glu Glu Asn Ser Tyr Phe Ala
85 90 95
Phe Ile Ala Tyr Pro Leu Asp Leu Phe Glu Glu Gly Ser Val Thr Asn
100 105 110
Ile Leu Thr Ser Ile Val Gly Asn Val Phe Gly Phe Lys Ala Ile Arg
115 120 125
Ser Leu Arg Leu Glu Asp Ile Arg Phe Pro Val Ala Leu Val Lys Thr
130 135 140
Phe Gln Gly Pro Ser His Gly Ile Gln Val Glu Arg Asp Leu Leu Asn
145 150 155 160
Lys Tyr Gly Arg Pro Met Leu Gly Cys Thr Ile Lys Pro Lys Leu Gly
165 170 175
Leu Ser Ala Lys Asn Tyr Gly Arg Ala Val Tyr Glu Cys Leu Arg Gly
180 185 190
Gly Leu Asp Phe Thr Lys Asp Asp Glu Asn Ile Asn Ser Gln Pro Phe
195 200 205
Met Arg Trp Arg Asp Arg Phe Leu Phe Val Gln Glu Ala Ile Glu Lys
210 215 220
Ala Gln Ala Glu Thr Gly Glu Ile Lys Gly His Tyr Leu Asn Val Thr
225 230 235 240
Ala Pro Thr Cys Glu Gln Met Met Glu Arg Ala Ala Phe Ala Lys Glu
245 250 255
Ile Gly Thr Pro Ile Ile Met His Asp Phe Leu Thr Gly Gly Phe Thr
260 265 270
Ala Asn Thr Ser Leu Ala Lys Tyr Cys Arg Asp Asn Gly Leu Leu Leu
275 280 285
His Ile His Arg Ala Met His Ala Val Ile Asp Arg Gln Lys Thr His
290 295 300
Gly Ile His Phe Arg Val Leu Ala Lys Cys Leu Arg Leu Ser Gly Gly
305 310 315 320
Asp His Leu His Ser Gly Thr Val Val Gly Lys Leu Glu Gly Asp Lys
325 330 335
Ala Ser Thr Leu Gly Phe Val Asp Leu Met Arg Glu Asp His Ile Glu
340 345 350
Ala Asp Arg Ser Arg Gly Val Phe Phe Thr Gln Asp Trp Ala Ser Met
355 360 365
Pro Gly Val Leu Pro Val Ala Ser Gly Gly Ile His Val Trp His Met
370 375 380
Pro Ala Leu Val Ala Ile Phe Gly Asp Asp Ser Val Leu Gln Phe Gly
385 390 395 400

-continued

Gly Gly Thr Leu Gly His Pro Trp Gly Asn Ala Pro Gly Ala Thr Ala
 405 410 415

Asn Arg Val Ala Leu Glu Ala Cys Val Gln Ala Arg Asn Glu Gly Arg
 420 425 430

Asp Leu Tyr Arg Glu Gly Gly Asp Ile Leu Arg Glu Ala Gly Lys Trp
 435 440 445

Ser Pro Glu Leu Ala Ala Ala Leu Asp Leu Trp Lys Glu Ile Lys Phe
 450 455 460

Glu Phe Glu Thr Met Asp Lys Leu
 465 470

<210> SEQ ID NO 36
 <211> LENGTH: 111
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: RT117 rbcS

<400> SEQUENCE: 36

Met Ser Met Lys Thr Leu Pro Lys Glu Arg Arg Phe Glu Thr Phe Ser
 1 5 10 15

Tyr Leu Pro Pro Leu Ser Asp Arg Gln Ile Ala Ala Gln Ile Glu Tyr
 20 25 30

Met Ile Glu Gln Gly Phe His Pro Leu Ile Glu Phe Asn Glu His Ser
 35 40 45

Asn Pro Glu Glu Phe Tyr Trp Thr Met Trp Lys Leu Pro Leu Phe Asp
 50 55 60

Cys Lys Ser Pro Gln Gln Val Leu Asp Glu Val Arg Glu Cys Arg Ser
 65 70 75 80

Glu Tyr Gly Asp Cys Tyr Ile Arg Val Ala Gly Phe Asp Asn Ile Lys
 85 90 95

Gln Cys Gln Thr Val Ser Phe Ile Val His Arg Pro Gly Arg Tyr
 100 105 110

<210> SEQ ID NO 37
 <211> LENGTH: 1845
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: RT118 rbcLS
 <220> FEATURE:
 <221> NAME/KEY: CDS
 <222> LOCATION: (1)...(1419)
 <223> OTHER INFORMATION: RT118 rbcL
 <220> FEATURE:
 <221> NAME/KEY: CDS
 <222> LOCATION: (1510)...(1845)
 <223> OTHER INFORMATION: RT118 rbcS

<400> SEQUENCE: 37

atg ccc aag acg caa tct gcc gca ggc tat aag gcc ggg gtg aag gac 48
 Met Pro Lys Thr Gln Ser Ala Ala Gly Tyr Lys Ala Gly Val Lys Asp
 1 5 10 15

tac aaa ctc acc tat tac acc ccc gat tac acc ccc aaa gac act gac 96
 Tyr Lys Leu Thr Tyr Tyr Thr Pro Asp Tyr Thr Pro Lys Asp Thr Asp
 20 25 30

ctg ctg gcg gct ttc cgc ttc agc cct cag ccg ggt gtc cct gct gac 144
 Leu Leu Ala Ala Phe Arg Phe Ser Pro Gln Pro Gly Val Pro Ala Asp
 35 40 45

gaa gct ggt gcg gcg atc gcg gct gaa tct tcg acc ggt acc tgg acc 192
 Glu Ala Gly Ala Ala Ile Ala Ala Glu Ser Ser Thr Gly Thr Trp Thr

-continued

50	55	60	
acc gtg tgg acc gac ttg ctg acc gac atg gat cgg tac aaa ggc aag			240
Thr Val Trp Thr Asp Leu Leu Thr Asp Met Asp Arg Tyr Lys Gly Lys			
65	70	75	80
tgc tac cac atc gag ccg gtg caa ggc gaa gag aac ttc tac ttt gcg			288
Cys Tyr His Ile Glu Pro Val Gln Gly Glu Glu Asn Phe Tyr Phe Ala			
	85	90	95
ttc atc gct tac ccg ctc gac ctg ttt gaa gaa ggt tcg gtc acc aac			336
Phe Ile Ala Tyr Pro Leu Asp Leu Phe Glu Glu Gly Ser Val Thr Asn			
	100	105	110
atc ctg acc ttg atc gtc ggt aac gtg ttt ggc ttc aaa gct atc cgt			384
Ile Leu Thr Leu Ile Val Gly Asn Val Phe Gly Phe Lys Ala Ile Arg			
	115	120	125
tcg ctg cgt ctg gaa gac att cgc ttc ccc gtc gcc ttg gtc aaa acc			432
Ser Leu Arg Leu Glu Asp Ile Arg Phe Pro Val Ala Leu Val Lys Thr			
	130	135	140
ttc caa ggt cct ccc cac ggt atc caa gtc gag cgc gac ctg ctg aac			480
Phe Gln Gly Pro Pro His Gly Ile Gln Val Glu Arg Asp Leu Leu Asn			
	145	150	155
aag tac ggc cgt ccg atg ctg ggt tgc acg atc aaa cca aaa ctc ggt			528
Lys Tyr Gly Arg Pro Met Leu Gly Cys Thr Ile Lys Pro Lys Leu Gly			
	165	170	175
ctg tcg gcg aaa aac tac ggt cgt gcc gtc tac gaa tgt ctg cgc ggc			576
Leu Ser Ala Lys Asn Tyr Gly Arg Ala Val Tyr Glu Cys Leu Arg Gly			
	180	185	190
ggt ctg gac ttc acc aaa gac gac gaa aac atc aac tct cag cct ttc			624
Gly Leu Asp Phe Thr Lys Asp Asp Glu Asn Ile Asn Ser Gln Pro Phe			
	195	200	205
atg cgt tgg cgc gat cgc ttc ctg ttt gta caa gaa gca att gaa aaa			672
Met Arg Trp Arg Asp Arg Phe Leu Phe Val Gln Glu Ala Ile Glu Lys			
	210	215	220
gct caa gct gaa act ggc gaa acc aag ggt cac tac ttg aac gta act			720
Ala Gln Ala Glu Thr Gly Glu Thr Lys Gly His Tyr Leu Asn Val Thr			
	225	230	235
gct cct acc tgt gag caa atg atg gaa cgt gca gct ttc gct aag gaa			768
Ala Pro Thr Cys Glu Gln Met Met Glu Arg Ala Ala Phe Ala Lys Glu			
	245	250	255
atc ggc aca cca atc atc atg cat gac ttc ttg act ggt ggt ttc aca			816
Ile Gly Thr Pro Ile Ile Met His Asp Phe Leu Thr Gly Gly Phe Thr			
	260	265	270
gca aac acc tct ctt gct aag tat tgc cgt gac aat ggc ttg ctc ttg			864
Ala Asn Thr Ser Leu Ala Lys Tyr Cys Arg Asp Asn Gly Leu Leu Leu			
	275	280	285
cac atc cac cgt gca atg cac gcg gtg atc gac cgt cag cgt aac cac			912
His Ile His Arg Ala Met His Ala Val Ile Asp Arg Gln Arg Asn His			
	290	295	300
ggg att cac ttc cgt gtc ttg gcc aag tgt ttg cgt ctg tcc ggt ggt			960
Gly Ile His Phe Arg Val Leu Ala Lys Cys Leu Arg Leu Ser Gly Gly			
	305	310	315
gac cac ctc cac tcc ggc acc gtc gtc ggc aaa ctg gaa ggc gac aaa			1008
Asp His Leu His Ser Gly Thr Val Val Gly Lys Leu Glu Gly Asp Lys			
	325	330	335
gct tcg acc ttg ggc ttt gtt gac ttg atg cgc gaa gac cac atc gaa			1056
Ala Ser Thr Leu Gly Phe Val Asp Leu Met Arg Glu Asp His Ile Glu			
	340	345	350
gct gac cgc agc cgt ggg gtc ttc ttc acc caa gat tgg gcg tcg atg			1104
Ala Asp Arg Ser Arg Gly Val Phe Phe Thr Gln Asp Trp Ala Ser Met			
	355	360	365
ccg ggc gtg ctg ccg gtt gct tcc ggt ggt atc cac gtg tgg cac atg			1152

-continued

Pro Gly Val Leu Pro Val Ala Ser Gly Gly Ile His Val Trp His Met 370 375 380	
ccc gca ctg gtg gaa atc ttc ggt gat gac tcc gtt ctc cag ttc ggt Pro Ala Leu Val Glu Ile Phe Gly Asp Asp Ser Val Leu Gln Phe Gly 385 390 395 400	1200
ggc ggc acc ttg ggt cac ccc tgg ggt aat gct cct ggt gca acc gcg Gly Gly Thr Leu Gly His Pro Trp Gly Asn Ala Pro Gly Ala Thr Ala 405 410 415	1248
aac cgt gtt gcc ttg gaa gct tgc gtc caa gct cgg aac gaa ggt cgc Asn Arg Val Ala Leu Glu Ala Cys Val Gln Ala Arg Asn Glu Gly Arg 420 425 430	1296
gac ctc tac cgt gaa ggc ggc gac atc ctt cgt gaa gct ggc aag tgg Asp Leu Tyr Arg Glu Gly Gly Asp Ile Leu Arg Glu Ala Gly Lys Trp 435 440 445	1344
tcg cct gaa ctg gct gct gcc ctc gac ctc tgg aaa gag atc aag ttc Ser Pro Glu Leu Ala Ala Ala Leu Asp Leu Trp Lys Glu Ile Lys Phe 450 455 460	1392
gaa ttc gaa acg atg gac aag ctc taa ggagcctctg actatcgctg Glu Phe Glu Thr Met Asp Lys Leu * 465 470	1439
ggggagtgag cggttgctgcg taaagctttc tccccagcct ttcgacttaa cctttcagga	1499
tttctgaatc atg agc atg aaa act ctg ccc aaa gag cgt cgt ttc gag Met Ser Met Lys Thr Leu Pro Lys Glu Arg Arg Phe Glu 475 480 485	1548
act ttc tcg tac ctg cct ccc ctc agc gat cgc caa atc gct gca caa Thr Phe Ser Tyr Leu Pro Pro Leu Ser Asp Arg Gln Ile Ala Ala Gln 490 495 500	1596
atc gag tac acg atc gag caa ggc ttc cac ccc ttg atc gag ttc aac Ile Glu Tyr Thr Ile Glu Gln Gly Phe His Pro Leu Ile Glu Phe Asn 505 510 515	1644
gag cac tcg aat ccg gaa gag ttc tac tgg acg atg tgg aag ctc ccc Glu His Ser Asn Pro Glu Glu Phe Tyr Trp Thr Met Trp Lys Leu Pro 520 525 530	1692
ctg ttt gac tgc aag agc cct cag caa gtc ctc gat gaa gtg cgt gag Leu Phe Asp Cys Lys Ser Pro Gln Gln Val Leu Asp Glu Val Arg Glu 535 540 545	1740
tgc cgc agc gaa tac ggt gat tgc tac atc cgt gtc gct ggc ttc gac Cys Arg Ser Glu Tyr Gly Asp Cys Tyr Ile Arg Val Ala Gly Phe Asp 550 555 560 565	1788
aac atc aag cag tgc caa acc gtg agc ttc atc gtt cat cgt ccc ggc Asn Ile Lys Gln Cys Gln Thr Val Ser Phe Ile Val His Arg Pro Gly 570 575 580	1836
cgc tac taa Arg Tyr *	1845

<210> SEQ ID NO 38
 <211> LENGTH: 472
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: RT118 rbcL

<400> SEQUENCE: 38

Met Pro Lys Thr Gln Ser Ala Ala Gly Tyr Lys Ala Gly Val Lys Asp 1 5 10 15
Tyr Lys Leu Thr Tyr Tyr Thr Pro Asp Tyr Thr Pro Lys Asp Thr Asp 20 25 30
Leu Leu Ala Ala Phe Arg Phe Ser Pro Gln Pro Gly Val Pro Ala Asp 35 40 45

-continued

465

470

<210> SEQ ID NO 39
 <211> LENGTH: 111
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: RT118 rbcS

<400> SEQUENCE: 39

Met Ser Met Lys Thr Leu Pro Lys Glu Arg Arg Phe Glu Thr Phe Ser
 1 5 10 15
 Tyr Leu Pro Pro Leu Ser Asp Arg Gln Ile Ala Ala Gln Ile Glu Tyr
 20 25 30
 Thr Ile Glu Gln Gly Phe His Pro Leu Ile Glu Phe Asn Glu His Ser
 35 40 45
 Asn Pro Glu Glu Phe Tyr Trp Thr Met Trp Lys Leu Pro Leu Phe Asp
 50 55 60
 Cys Lys Ser Pro Gln Gln Val Leu Asp Glu Val Arg Glu Cys Arg Ser
 65 70 75 80
 Glu Tyr Gly Asp Cys Tyr Ile Arg Val Ala Gly Phe Asp Asn Ile Lys
 85 90 95
 Gln Cys Gln Thr Val Ser Phe Ile Val His Arg Pro Gly Arg Tyr
 100 105 110

<210> SEQ ID NO 40
 <211> LENGTH: 1845
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: F2A-10 rbcLS
 <220> FEATURE:
 <221> NAME/KEY: CDS
 <222> LOCATION: (1)...(1419)
 <223> OTHER INFORMATION: F2A-10 rbcL
 <220> FEATURE:
 <221> NAME/KEY: CDS
 <222> LOCATION: (1510)...(1845)
 <223> OTHER INFORMATION: F2A-10 rbcS

<400> SEQUENCE: 40

atg ccc aag acg caa tct gcc gca ggc tat aag gcc ggg gtg aag gac 48
 Met Pro Lys Thr Gln Ser Ala Ala Gly Tyr Lys Ala Gly Val Lys Asp
 1 5 10 15
 tac aaa ctc acc tat tac acc ccc gat tac acc ccc aaa gac act gac 96
 Tyr Lys Leu Thr Tyr Tyr Thr Pro Asp Tyr Thr Pro Lys Asp Thr Asp
 20 25 30
 ctg ctg gcg gct ttc cgc ttc agc cct cag ccg ggt gtc cct gct gac 144
 Leu Leu Ala Ala Phe Arg Phe Ser Pro Gln Pro Gly Val Pro Ala Asp
 35 40 45
 gaa gct ggt gcg gcg atc gcg gct gaa tct tcg acc ggt acc tgg acc 192
 Glu Ala Gly Ala Ala Ile Ala Ala Glu Ser Ser Thr Gly Thr Trp Thr
 50 55 60
 acc gtg tgg acc gac ttg ctg acc gac atg gat cgg tac aaa ggc aag 240
 Thr Val Trp Thr Asp Leu Leu Thr Asp Met Asp Arg Tyr Lys Gly Lys
 65 70 75 80
 tgc tac cac atc gag ccg gtg caa ggc gaa gag aac tcc tac ttt gcg 288
 Cys Tyr His Ile Glu Pro Val Gln Gly Glu Glu Asn Ser Tyr Phe Ala
 85 90 95
 ttc atc gct tac ccg ctc gac ctg ttt gaa gaa ggg tcg gtc acc aac 336
 Phe Ile Ala Tyr Pro Leu Asp Leu Phe Glu Glu Gly Ser Val Thr Asn
 100 105 110

-continued

atc ctg acc tcg atc gtc ggt aac gtg ttt ggc ttc aaa gct atc cgt Ile Leu Thr Ser Ile Val Gly Asn Val Phe Gly Phe Lys Ala Ile Arg 115 120 125	384
tcg ctg cgt ctg gaa gac atc cgc ttc ccc gtc gcc ttg gtc aaa acc Ser Leu Arg Leu Glu Asp Ile Arg Phe Pro Val Ala Leu Val Lys Thr 130 135 140	432
ttc caa ggt cct ccc cac ggt atc caa gtc gag cgc gac ctg ctg aac Phe Gln Gly Pro Pro His Gly Ile Gln Val Glu Arg Asp Leu Leu Asn 145 150 155 160	480
aag tac ggc cgt ccg atg ctg ggt tgc acg atc aaa cca aaa ctc ggt Lys Tyr Gly Arg Pro Met Leu Gly Cys Thr Ile Lys Pro Lys Leu Gly 165 170 175	528
ctg tcg gcg aaa aac tac ggt cgt gcc gtc tac gaa tgt ctg cgc ggc Leu Ser Ala Lys Asn Tyr Gly Arg Ala Val Tyr Glu Cys Leu Arg Gly 180 185 190	576
ggt ctg gac ttc acc aaa gac gac gaa aac atc aac tcg cag ccg ttc Gly Leu Asp Phe Thr Lys Asp Asp Glu Asn Ile Asn Ser Gln Pro Phe 195 200 205	624
caa cgc tgg cgc gat cgc ttc ctg ttt gtg gct gat gca atc cac aaa Gln Arg Trp Arg Asp Arg Phe Leu Phe Val Ala Asp Ala Ile His Lys 210 215 220	672
tcg caa gca gaa acc ggt gaa atc aaa ggt cac tac ctg aac gtg acc Ser Gln Ala Glu Thr Gly Glu Ile Lys Gly His Tyr Leu Asn Val Thr 225 230 235 240	720
gcg ccg acc tgc gaa gaa atg atg aaa cgg gct gag ttc gct aaa gaa Ala Pro Thr Cys Glu Glu Met Met Lys Arg Ala Glu Phe Ala Lys Glu 245 250 255	768
ctc ggc atg ccg atc atc atg cat gac ttc ttg acg gct ggt ttc acc Leu Gly Met Pro Ile Ile Met His Asp Phe Leu Thr Ala Gly Phe Thr 260 265 270	816
gcc aac acc acc ttg gca aaa tgg tgc cgc gac aac ggc gtc ctg ctg Ala Asn Thr Thr Leu Ala Lys Trp Cys Arg Asp Asn Gly Val Leu Leu 275 280 285	864
cac atc cac cgt gca atg cac gcg gtg atc gac cgt cag cgt aac cac His Ile His Arg Ala Met His Ala Val Ile Asp Arg Gln Arg Asn His 290 295 300	912
ggg att cac ttc cgt gtc ttg gcc aag tgt ttg cgt ctg tcc ggt ggt Gly Ile His Phe Arg Val Leu Ala Lys Cys Leu Arg Leu Ser Gly Gly 305 310 315 320	960
gac cac ctc cac tcc ggc acc gtc gtc ggc aaa ctg gaa ggc gac aaa Asp His Leu His Ser Gly Thr Val Val Gly Lys Leu Glu Gly Asp Lys 325 330 335	1008
gct tcg acc ttg ggc ttt gtt gac ttg atg cgc gaa gac cac atc gaa Ala Ser Thr Leu Gly Phe Val Asp Leu Met Arg Glu Asp His Ile Glu 340 345 350	1056
gct gac cgc agc cgt ggg gtc ttc ttc acc caa gat tgg gcg tcg atg Ala Asp Arg Ser Arg Gly Val Phe Phe Thr Gln Asp Trp Ala Ser Met 355 360 365	1104
ccg ggc gtg ctg ccg gtt gct tcc ggt ggt atc cac gtg tgg cac atg Pro Gly Val Leu Pro Val Ala Ser Gly Gly Ile His Val Trp His Met 370 375 380	1152
ccc gca ctg gtg gaa atc ttc ggt gat gac tcc gtt ctc cag ttc ggt Pro Ala Leu Val Glu Ile Phe Gly Asp Asp Ser Val Leu Gln Phe Gly 385 390 395 400	1200
ggc ggc acc ttg ggt cac ccc tgg ggt aat gct cct ggt gca acc gcg Gly Gly Thr Leu Gly His Pro Trp Gly Asn Ala Pro Gly Ala Thr Ala 405 410 415	1248
aac cgt gtt gcc ttg gaa gct tgc gtc caa gca cgt aac gaa ggt cgc Asn Arg Val Ala Leu Glu Ala Cys Val Gln Ala Arg Asn Glu Gly Arg 420 425 430	1296

-continued

gac ctc tac cgt gaa ggc ggc gac atc ctt cgt gaa gct ggc aag tgg 1344
 Asp Leu Tyr Arg Glu Gly Gly Asp Ile Leu Arg Glu Ala Gly Lys Trp
 435 440 445

tcg cct gag ctg gcc atc gcc ctc gac ctc tgg aaa gag atc aag ttc 1392
 Ser Pro Glu Leu Ala Ile Ala Leu Asp Leu Trp Lys Glu Ile Lys Phe
 450 455 460

gaa ttc gaa acg atg gac aag ctc taa ggagcctctg actatcgctg 1439
 Glu Phe Glu Thr Met Asp Lys Leu *
 465 470

ggggagtgag cggttgctgcg taaagctttc tccccagcct ttcgacttaa cctttcagga 1499

tttctgaatc atg agc atg aaa act ctg ccc aaa gag cgt cgt ttc gag 1548
 Met Ser Met Lys Thr Leu Pro Lys Glu Arg Arg Phe Glu
 475 480 485

act ttc tcg tac ctg cct ccc ctc agc gat cgc caa atc gct gca caa 1596
 Thr Phe Ser Tyr Leu Pro Pro Leu Ser Asp Arg Gln Ile Ala Ala Gln
 490 495 500

atc gag tac atg atc gag caa ggc ttc cac ccc ttg atc gag ttc aac 1644
 Ile Glu Tyr Met Ile Glu Gln Gly Phe His Pro Leu Ile Glu Phe Asn
 505 510 515

gag cac tcg aat ccg gaa gag ttc tac tgg acg atg tgg aag ctc ccc 1692
 Glu His Ser Asn Pro Glu Glu Phe Tyr Trp Thr Met Trp Lys Leu Pro
 520 525 530

ctg ttt gac tgc aag agc cct cag caa gtc ctc gat gaa gtg cgt gag 1740
 Leu Phe Asp Cys Lys Ser Pro Gln Gln Val Leu Asp Glu Val Arg Glu
 535 540 545

tgc cgc agc gaa tac ggt gat tgc tac atc cgt gtc gct ggc ttc gac 1788
 Cys Arg Ser Glu Tyr Gly Asp Cys Tyr Ile Arg Val Ala Gly Phe Asp
 550 555 560 565

aac atc aag cag tgc caa acc gtg agc ttc atc gtt cat cgt ccc ggt 1836
 Asn Ile Lys Gln Cys Gln Thr Val Ser Phe Ile Val His Arg Pro Gly
 570 575 580

cgc tac taa 1845
 Arg Tyr *

<210> SEQ ID NO 41
 <211> LENGTH: 472
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: F2A-10 rbcL

<400> SEQUENCE: 41

Met Pro Lys Thr Gln Ser Ala Ala Gly Tyr Lys Ala Gly Val Lys Asp
 1 5 10 15

Tyr Lys Leu Thr Tyr Tyr Thr Pro Asp Tyr Thr Pro Lys Asp Thr Asp
 20 25 30

Leu Leu Ala Ala Phe Arg Phe Ser Pro Gln Pro Gly Val Pro Ala Asp
 35 40 45

Glu Ala Gly Ala Ala Ile Ala Ala Glu Ser Ser Thr Gly Thr Trp Thr
 50 55 60

Thr Val Trp Thr Asp Leu Leu Thr Asp Met Asp Arg Tyr Lys Gly Lys
 65 70 75 80

Cys Tyr His Ile Glu Pro Val Gln Gly Glu Glu Asn Ser Tyr Phe Ala
 85 90 95

Phe Ile Ala Tyr Pro Leu Asp Leu Phe Glu Glu Gly Ser Val Thr Asn
 100 105 110

Ile Leu Thr Ser Ile Val Gly Asn Val Phe Gly Phe Lys Ala Ile Arg
 115 120 125

-continued

Ser Leu Arg Leu Glu Asp Ile Arg Phe Pro Val Ala Leu Val Lys Thr
 130 135 140
 Phe Gln Gly Pro Pro His Gly Ile Gln Val Glu Arg Asp Leu Leu Asn
 145 150 155 160
 Lys Tyr Gly Arg Pro Met Leu Gly Cys Thr Ile Lys Pro Lys Leu Gly
 165 170 175
 Leu Ser Ala Lys Asn Tyr Gly Arg Ala Val Tyr Glu Cys Leu Arg Gly
 180 185 190
 Gly Leu Asp Phe Thr Lys Asp Asp Glu Asn Ile Asn Ser Gln Pro Phe
 195 200 205
 Gln Arg Trp Arg Asp Arg Phe Leu Phe Val Ala Asp Ala Ile His Lys
 210 215 220
 Ser Gln Ala Glu Thr Gly Glu Ile Lys Gly His Tyr Leu Asn Val Thr
 225 230 235 240
 Ala Pro Thr Cys Glu Glu Met Met Lys Arg Ala Glu Phe Ala Lys Glu
 245 250 255
 Leu Gly Met Pro Ile Ile Met His Asp Phe Leu Thr Ala Gly Phe Thr
 260 265 270
 Ala Asn Thr Thr Leu Ala Lys Trp Cys Arg Asp Asn Gly Val Leu Leu
 275 280 285
 His Ile His Arg Ala Met His Ala Val Ile Asp Arg Gln Arg Asn His
 290 295 300
 Gly Ile His Phe Arg Val Leu Ala Lys Cys Leu Arg Leu Ser Gly Gly
 305 310 315 320
 Asp His Leu His Ser Gly Thr Val Val Gly Lys Leu Glu Gly Asp Lys
 325 330 335
 Ala Ser Thr Leu Gly Phe Val Asp Leu Met Arg Glu Asp His Ile Glu
 340 345 350
 Ala Asp Arg Ser Arg Gly Val Phe Phe Thr Gln Asp Trp Ala Ser Met
 355 360 365
 Pro Gly Val Leu Pro Val Ala Ser Gly Gly Ile His Val Trp His Met
 370 375 380
 Pro Ala Leu Val Glu Ile Phe Gly Asp Asp Ser Val Leu Gln Phe Gly
 385 390 395 400
 Gly Gly Thr Leu Gly His Pro Trp Gly Asn Ala Pro Gly Ala Thr Ala
 405 410 415
 Asn Arg Val Ala Leu Glu Ala Cys Val Gln Ala Arg Asn Glu Gly Arg
 420 425 430
 Asp Leu Tyr Arg Glu Gly Gly Asp Ile Leu Arg Glu Ala Gly Lys Trp
 435 440 445
 Ser Pro Glu Leu Ala Ile Ala Leu Asp Leu Trp Lys Glu Ile Lys Phe
 450 455 460
 Glu Phe Glu Thr Met Asp Lys Leu
 465 470

<210> SEQ ID NO 42
 <211> LENGTH: 111
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: F2A-10 rbcS

<400> SEQUENCE: 42

Met Ser Met Lys Thr Leu Pro Lys Glu Arg Arg Phe Glu Thr Phe Ser
 1 5 10 15

-continued

Tyr Leu Pro Pro Leu Ser Asp Arg Gln Ile Ala Ala Gln Ile Glu Tyr
 20 25 30
 Met Ile Glu Gln Gly Phe His Pro Leu Ile Glu Phe Asn Glu His Ser
 35 40 45
 Asn Pro Glu Glu Phe Tyr Trp Thr Met Trp Lys Leu Pro Leu Phe Asp
 50 55 60
 Cys Lys Ser Pro Gln Gln Val Leu Asp Glu Val Arg Glu Cys Arg Ser
 65 70 75 80
 Glu Tyr Gly Asp Cys Tyr Ile Arg Val Ala Gly Phe Asp Asn Ile Lys
 85 90 95
 Gln Cys Gln Thr Val Ser Phe Ile Val His Arg Pro Gly Arg Tyr
 100 105 110

<210> SEQ ID NO 43
 <211> LENGTH: 1845
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: F2A-16 rbcLS
 <220> FEATURE:
 <221> NAME/KEY: CDS
 <222> LOCATION: (1)...(1419)
 <223> OTHER INFORMATION: F2A-16 rbcL
 <220> FEATURE:
 <221> NAME/KEY: CDS
 <222> LOCATION: (1510)...(1845)
 <223> OTHER INFORMATION: F2A-16 rbcS

<400> SEQUENCE: 43

atg ccc aag acg caa tct gcc gca ggc tat aag gcc ggg gtg aag gac 48
 Met Pro Lys Thr Gln Ser Ala Ala Gly Tyr Lys Ala Gly Val Lys Asp
 1 5 10 15
 tac aaa ctc acc tat tac acc ccc gat tac acc ccc aaa gac act gac 96
 Tyr Lys Leu Thr Tyr Tyr Thr Pro Asp Tyr Thr Pro Lys Asp Thr Asp
 20 25 30
 ctg ctg gcg gct ttc cgc ttc agc cct cag ccg ggt gtc cct gct gac 144
 Leu Leu Ala Ala Phe Arg Phe Ser Pro Gln Pro Gly Val Pro Ala Asp
 35 40 45
 gaa gct ggt gcg gcg atc gcg gct gaa tct tcg acc ggt acc tgg acc 192
 Glu Ala Gly Ala Ala Ile Ala Ala Glu Ser Ser Thr Gly Thr Trp Thr
 50 55 60
 acc gtg tgg acc gac ttg ctg acc gac atg gat cgg tac aaa ggc aag 240
 Thr Val Trp Thr Asp Leu Leu Thr Asp Met Asp Arg Tyr Lys Gly Lys
 65 70 75 80
 tgc tac cac atc gag ccg gtg caa ggc gaa gag aac tcc tac ttt gcg 288
 Cys Tyr His Ile Glu Pro Val Gln Gly Glu Glu Asn Ser Tyr Phe Ala
 85 90 95
 ttc atc gct tac ccg ctc gac ctg ttt gaa gaa ggg tcg gtc acc aac 336
 Phe Ile Ala Tyr Pro Leu Asp Leu Phe Glu Glu Gly Ser Val Thr Asn
 100 105 110
 atc ctg acc tcg atc gtc ggt aac gtg ttt ggc ttc aaa gct atc cgt 384
 Ile Leu Thr Ser Ile Val Gly Asn Val Phe Gly Phe Lys Ala Ile Arg
 115 120 125
 tcg ctg cgt ctg gaa gac atc cgc ttc ccc gtc gcc ttg gtc aaa acc 432
 Ser Leu Arg Leu Glu Asp Ile Arg Phe Pro Val Ala Leu Val Lys Thr
 130 135 140
 ttc caa ggt cct ccc cac ggt atc caa gtc gag cgc gac ctg ctg aac 480
 Phe Gln Gly Pro Pro His Gly Ile Gln Val Glu Arg Asp Leu Leu Asn
 145 150 155 160
 aag tac ggc cgt ccg atg ctg ggt tgc acg atc aaa cca aaa ctc ggt 528
 Lys Tyr Gly Arg Pro Met Leu Gly Cys Thr Ile Lys Pro Lys Leu Gly

-continued

```

tttctgaatc atg agc atg aaa act ctg ccc aaa gag cgt cgt ttc gag      1548
      Met Ser Met Lys Thr Leu Pro Lys Glu Arg Arg Phe Glu
              475                      480                      485

act ttc tcg tac ctg cct ccc ctc agc gat cgc caa atc gct gca caa      1596
Thr Phe Ser Tyr Leu Pro Pro Leu Ser Asp Arg Gln Ile Ala Ala Gln
              490                      495                      500

atc gag tac atg atc gag caa ggc ttc cac ccc ttg atc gag ttc aac      1644
Ile Glu Tyr Met Ile Glu Gln Gly Phe His Pro Leu Ile Glu Phe Asn
              505                      510                      515

gag cac tcg aat ccg gaa gag ttc tac tgg acg atg tgg aag ctc ccc      1692
Glu His Ser Asn Pro Glu Glu Phe Tyr Trp Thr Met Trp Lys Leu Pro
              520                      525                      530

ctg ttt gac tgc aag agc cct cag caa gtc ctc gat gaa gtg cgt gag      1740
Leu Phe Asp Cys Lys Ser Pro Gln Gln Val Leu Asp Glu Val Arg Glu
              535                      540                      545

tgc cgc agc gaa tac ggt gat tgc tac atc cgt gtc gct ggc ttc gac      1788
Cys Arg Ser Glu Tyr Gly Asp Cys Tyr Ile Arg Val Ala Gly Phe Asp
550                      555                      560                      565

aac atc aag cag tgc caa acc gtg ggc ttc atc gtt cat cgt ccc ggc      1836
Asn Ile Lys Gln Cys Gln Thr Val Gly Phe Ile Val His Arg Pro Gly
              570                      575                      580

cgc tac taa      1845
Arg Tyr *
```

```

<210> SEQ ID NO 44
<211> LENGTH: 472
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: F2A-16 rbcL
```

```

<400> SEQUENCE: 44
```

```

Met Pro Lys Thr Gln Ser Ala Ala Gly Tyr Lys Ala Gly Val Lys Asp
 1                      5                      10                      15

Tyr Lys Leu Thr Tyr Tyr Thr Pro Asp Tyr Thr Pro Lys Asp Thr Asp
              20                      25                      30

Leu Leu Ala Ala Phe Arg Phe Ser Pro Gln Pro Gly Val Pro Ala Asp
              35                      40                      45

Glu Ala Gly Ala Ala Ile Ala Ala Glu Ser Ser Thr Gly Thr Trp Thr
 50                      55                      60

Thr Val Trp Thr Asp Leu Leu Thr Asp Met Asp Arg Tyr Lys Gly Lys
65                      70                      75                      80

Cys Tyr His Ile Glu Pro Val Gln Gly Glu Glu Asn Ser Tyr Phe Ala
              85                      90                      95

Phe Ile Ala Tyr Pro Leu Asp Leu Phe Glu Glu Gly Ser Val Thr Asn
              100                      105                      110

Ile Leu Thr Ser Ile Val Gly Asn Val Phe Gly Phe Lys Ala Ile Arg
              115                      120                      125

Ser Leu Arg Leu Glu Asp Ile Arg Phe Pro Val Ala Leu Val Lys Thr
              130                      135                      140

Phe Gln Gly Pro Pro His Gly Ile Gln Val Glu Arg Asp Leu Leu Asn
145                      150                      155                      160

Lys Tyr Gly Arg Pro Met Leu Gly Cys Thr Ile Lys Pro Lys Leu Gly
              165                      170                      175

Leu Ser Ala Lys Asn Tyr Gly Arg Ala Val Tyr Glu Cys Leu Arg Gly
              180                      185                      190

Gly Leu Asp Phe Thr Lys Asp Asp Glu Asn Ile Asn Ser Gln Pro Phe
```

-continued

195					200					205					
Gln	Arg	Trp	Arg	Asp	Arg	Phe	Leu	Phe	Val	Ala	Asp	Ala	Ile	His	Lys
210					215					220					
Ser	Gln	Ala	Glu	Thr	Gly	Glu	Ile	Lys	Gly	His	Tyr	Leu	Asn	Val	Thr
225					230					235					240
Ala	Pro	Thr	Cys	Glu	Glu	Met	Met	Lys	Arg	Ala	Glu	Phe	Ala	Lys	Glu
245					250					255					
Leu	Gly	Met	Pro	Ile	Ile	Met	His	Asp	Phe	Leu	Thr	Ala	Gly	Phe	Thr
260					265					270					
Ala	Asn	Thr	Thr	Leu	Ala	Lys	Trp	Cys	Arg	Asp	Asn	Gly	Val	Leu	Leu
275					280					285					
His	Ile	His	Arg	Ala	Met	His	Ala	Val	Ile	Asp	Arg	Gln	Arg	Asn	His
290					295					300					
Gly	Ile	His	Phe	Arg	Val	Leu	Ala	Lys	Cys	Leu	Arg	Leu	Ser	Gly	Gly
305					310					315					320
Asp	His	Leu	His	Ser	Gly	Thr	Val	Val	Gly	Lys	Leu	Glu	Gly	Asp	Lys
325					330					335					
Ala	Ser	Thr	Leu	Gly	Phe	Val	Asp	Leu	Met	Arg	Glu	Asp	His	Ile	Glu
340					345					350					
Ala	Asp	Arg	Ser	Arg	Gly	Val	Phe	Phe	Thr	Gln	Asp	Trp	Ala	Ser	Met
355					360					365					
Pro	Gly	Val	Leu	Pro	Val	Ala	Ser	Gly	Gly	Ile	His	Val	Trp	His	Met
370					375					380					
Pro	Ala	Leu	Val	Glu	Ile	Phe	Gly	Asp	Asp	Ser	Val	Leu	Gln	Phe	Gly
385					390					395					400
Gly	Gly	Thr	Leu	Gly	His	Pro	Trp	Gly	Asn	Ala	Pro	Gly	Ala	Thr	Ala
405					410					415					
Asn	Arg	Val	Ala	Leu	Glu	Ala	Cys	Val	Gln	Ala	Arg	Asn	Glu	Gly	Arg
420					425					430					
Asp	Leu	Tyr	Arg	Glu	Gly	Gly	Asp	Ile	Leu	Arg	Glu	Ala	Gly	Lys	Trp
435					440					445					
Ser	Pro	Glu	Leu	Ala	Ala	Ala	Leu	Asp	Leu	Trp	Lys	Glu	Ile	Lys	Phe
450					455					460					
Glu	Phe	Glu	Thr	Met	Asp	Lys	Leu								
465					470										

<210> SEQ ID NO 45

<211> LENGTH: 111

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: F2A-16 rbcS

<400> SEQUENCE: 45

Met	Ser	Met	Lys	Thr	Leu	Pro	Lys	Glu	Arg	Arg	Phe	Glu	Thr	Phe	Ser
1				5					10					15	
Tyr	Leu	Pro	Pro	Leu	Ser	Asp	Arg	Gln	Ile	Ala	Ala	Gln	Ile	Glu	Tyr
		20						25					30		
Met	Ile	Glu	Gln	Gly	Phe	His	Pro	Leu	Ile	Glu	Phe	Asn	Glu	His	Ser
		35				40						45			
Asn	Pro	Glu	Glu	Phe	Tyr	Trp	Thr	Met	Trp	Lys	Leu	Pro	Leu	Phe	Asp
	50					55					60				
Cys	Lys	Ser	Pro	Gln	Gln	Val	Leu	Asp	Glu	Val	Arg	Glu	Cys	Arg	Ser
65				70					75					80	
Glu	Tyr	Gly	Asp	Cys	Tyr	Ile	Arg	Val	Ala	Gly	Phe	Asp	Asn	Ile	Lys

-continued

										85											90											95											
										Gln	Cys	Gln	Thr	Val	Gly	Phe	Ile	Val	His	Arg	Pro	Gly	Arg	Tyr																			
										100					105					110																							
<210> SEQ ID NO 46																																											
<211> LENGTH: 1845																																											
<212> TYPE: DNA																																											
<213> ORGANISM: Artificial Sequence																																											
<220> FEATURE:																																											
<223> OTHER INFORMATION: F2A-20 rbcLS																																											
<220> FEATURE:																																											
<221> NAME/KEY: CDS																																											
<222> LOCATION: (1)...(1419)																																											
<223> OTHER INFORMATION: F2A-20 rbcL																																											
<220> FEATURE:																																											
<221> NAME/KEY: CDS																																											
<222> LOCATION: (1510)...(1845)																																											
<223> OTHER INFORMATION: F2A-20 rbcS																																											
<400> SEQUENCE: 46																																											
										atg	ccc	aag	acg	caa	tct	gcc	gca	ggc	tat	aag	gcc	ggg	gtg	aag	gac											48							
										Met	Pro	Lys	Thr	Gln	Ser	Ala	Ala	Gly	Tyr	Lys	Ala	Gly	Val	Lys	Asp																		
										1						5						10						15															
										tac	aaa	ctc	acc	tat	tac	acc	ccc	gat	tac	acc	ccc	aaa	gac	act	gac											96							
										Tyr	Lys	Leu	Thr	Tyr	Tyr	Thr	Pro	Asp	Tyr	Thr	Pro	Lys	Asp	Thr	Asp																		
															20						25						30																
										ctg	ctg	gcg	gct	ttc	cgc	ttc	agc	cct	cag	ccg	ggg	gtc	cct	gct	gac											144							
										Leu	Leu	Ala	Ala	Phe	Arg	Phe	Ser	Pro	Gln	Pro	Gly	Val	Pro	Ala	Asp																		
															35						40						45																
										gaa	gct	ggg	gcg	gcg	atc	gcg	gct	gaa	tct	tcg	acc	ggg	acc	tgg	acc											192							
										Glu	Ala	Gly	Ala	Ala	Ile	Ala	Ala	Glu	Ser	Ser	Thr	Gly	Thr	Trp	Thr																		
															50						55						60																
										acc	gtg	tgg	acc	gac	ttg	ctg	acc	gac	atg	gat	cgg	tac	aaa	ggc	aag											240							
										Thr	Val	Trp	Thr	Asp	Leu	Leu	Thr	Asp	Met	Asp	Arg	Tyr	Lys	Gly	Lys																		
															65						70						75						80										
										tgc	tac	cac	atc	gag	ccg	gtg	caa	ggc	gaa	gag	aac	tcc	tac	ttt	gcg											288							
										Cys	Tyr	His	Ile	Glu	Pro	Val	Gln	Gly	Glu	Glu	Asn	Ser	Tyr	Phe	Ala																		
															85						90						95																
										ttc	atc	gct	tac	ccg	ctc	gac	ctg	ttt	gaa	gaa	ggg	tcg	gtc	acc	aac											336							
										Phe	Ile	Ala	Tyr	Pro	Leu	Asp	Leu	Phe	Glu	Glu	Gly	Ser	Val	Thr	Asn																		
															100						105						110																
										atc	ctg	acc	tcg	atc	gtc	ggg	aac	gtg	ttt	ggc	ttc	aaa	gct	atc	cgt											384							
										Ile	Leu	Thr	Ser	Ile	Val	Gly	Asn	Val	Phe	Gly	Phe	Lys	Ala	Ile	Arg																		
															115						120						125																
										tca	ctg	cgt	ctg	gaa	gac	atc	cgc	ttc	ccc	gtc	gcc	ttg	gtc	aaa	acc											432							
										Ser	Leu	Arg	Leu	Glu	Asp	Ile	Arg	Phe	Pro	Val	Ala	Leu	Val	Lys	Thr																		
															130						135						140																
										ttc	caa	ggg	cct	ccc	cac	ggg	atc	caa	gtc	gag	cgc	gac	ctg	ctg	aac											480							
										Phe	Gln	Gly	Pro	Pro	His	Gly	Ile	Gln	Val	Glu	Arg	Asp	Leu	Leu	Asn																		
															145						150						155						160										
										aag	tac	ggc	cgt	ccg	atg	ctg	ggg	tgc	acg	atc	aaa	cca	aaa	ctc	ggg											528							
										Lys	Tyr	Gly	Arg	Pro	Met	Leu	Gly	Cys	Thr	Ile	Lys	Pro	Lys	Leu	Gly																		
															165						170						175																
										ctg	tcg	gcg	aaa	aac	tac	ggg	cgt	gcc	gtc	tac	gaa	tgt	ctg	cgc	ggc											576							
										Leu	Ser	Ala	Lys	Asn	Tyr	Gly	Arg	Ala	Val	Tyr	Glu	Cys	Leu	Arg	Gly																		
															180						185						190																
										ggg	ctg	gac	ttc	acc	aaa	gac	gac	gaa	aac	atc	aac	tcg	cag	ccg	ttc											624							
										Gly	Leu	Asp	Phe	Thr	Lys	Asp	Asp	Glu	Asn	Ile	Asn	Ser	Gln	Pro	Phe																		
															195						200						205																
										caa	cgc	tgg	cgc	gat	cgc	ttc	ctg	ttt	gtg	gct	gat	gca	atc	cac	aaa											672							
										Gln	Arg	Trp	Arg	Asp	Arg	Phe	Leu	Phe	Val	Ala	Asp	Ala	Ile	His	Lys																		
															210						215						220																

-continued

tcg caa gca gaa acc ggt gaa atc aaa ggt cac tac ctg aac gtg acc	720
Ser Gln Ala Glu Thr Gly Glu Ile Lys Gly His Tyr Leu Asn Val Thr	
225 230 235 240	
gcg ccg acc tgc gaa gaa atg atg aaa cgg gct gag ttc gct aaa gaa	768
Ala Pro Thr Cys Glu Glu Met Met Lys Arg Ala Glu Phe Ala Lys Glu	
245 250 255	
ctc ggc atg ccg atc atc atg cat gac ttc ttg acg gct ggt ttc acc	816
Leu Gly Met Pro Ile Ile Met His Asp Phe Leu Thr Ala Gly Phe Thr	
260 265 270	
gcc aac acc acc ttg gca aaa tgg tgc cgc gac aac ggc gtc ctg ctg	864
Ala Asn Thr Thr Leu Ala Lys Trp Cys Arg Asp Asn Gly Val Leu Leu	
275 280 285	
cac atc cac cgt gca atg cac gcg gtg atc gac cgt cag cgt aac cac	912
His Ile His Arg Ala Met His Ala Val Ile Asp Arg Gln Arg Asn His	
290 295 300	
ggg att cac ttc cgt gtc ttg gcc aag tgt ttg cgt ctg tcc ggt ggt	960
Gly Ile His Phe Arg Val Leu Ala Lys Cys Leu Arg Leu Ser Gly Gly	
305 310 315 320	
gac cac ctc cac tcc ggc acc gtc gtc ggc aaa ctg gaa ggc gac aaa	1008
Asp His Leu His Ser Gly Thr Val Val Gly Lys Leu Glu Gly Asp Lys	
325 330 335	
gct tcg acc ttg ggc ttt gtt gac ttg atg cgc gaa gac cac atc gaa	1056
Ala Ser Thr Leu Gly Phe Val Asp Leu Met Arg Glu Asp His Ile Glu	
340 345 350	
gct gac cgc agc cgt ggg gtc ttc ttc acc caa gat tgg gcg tcg atg	1104
Ala Asp Arg Ser Arg Gly Val Phe Phe Thr Gln Asp Trp Ala Ser Met	
355 360 365	
ccg ggc gtg ctg ccg gtt gct tcc ggt ggt atc cac gtg tgg cac atg	1152
Pro Gly Val Leu Pro Val Ala Ser Gly Gly Ile His Val Trp His Met	
370 375 380	
ccc gca ctg gtg gaa atc ttc ggt gat gac tcc gtt ctc cag ttc ggt	1200
Pro Ala Leu Val Glu Ile Phe Gly Asp Asp Ser Val Leu Gln Phe Gly	
385 390 395 400	
ggc ggc acc ttg ggt cac ccc tgg ggt aat gct cct ggt gca acc gcg	1248
Gly Gly Thr Leu Gly His Pro Trp Gly Asn Ala Pro Gly Ala Thr Ala	
405 410 415	
aac cgt gtt gcc ttg gaa gct tgc gtc caa gct cgg aac gaa ggt cgc	1296
Asn Arg Val Ala Leu Glu Ala Cys Val Gln Ala Arg Asn Glu Gly Arg	
420 425 430	
gac ctc tac cgt gaa ggc ggc gac atc ctt cgt gaa gct ggc aag tgg	1344
Asp Leu Tyr Arg Glu Gly Gly Asp Ile Leu Arg Glu Ala Gly Lys Trp	
435 440 445	
tcg cgt gaa ctg gct gct gcc ctc gac ctc tgg aaa gag atc aag ttc	1392
Ser Arg Glu Leu Ala Ala Ala Leu Asp Leu Trp Lys Glu Ile Lys Phe	
450 455 460	
gaa ttc gaa acg atg gac aag ctc taa ggagcctctg actatcgctg	1439
Glu Phe Glu Thr Met Asp Lys Leu *	
465 470	
ggggagtgag cggtgctgcg taaagctttc tccccagcct ttcgacttaa cctttcagga	1499
tttctgaatc atg agc atg aaa act ctg ccc aaa gag cgt cgt ttc gag	1548
Met Ser Met Lys Thr Leu Pro Lys Glu Arg Arg Phe Glu	
475 480 485	
act ttc tcg tac ctg cct ccc ctc agc gat cgc caa atc gct gca caa	1596
Thr Phe Ser Tyr Leu Pro Pro Leu Ser Asp Arg Gln Ile Ala Ala Gln	
490 495 500	
atc gag tac atg atc gag caa ggc ttc cac ccc ttg atc gag ttc aac	1644
Ile Glu Tyr Met Ile Glu Gln Gly Phe His Pro Leu Ile Glu Phe Asn	
505 510 515	
gag cac tcg aat ccg gaa gag ttc tac tgg acg atg tgg aag ctc ccc	1692

-continued

Ala Asn Thr Thr Leu Ala Lys Trp Cys Arg Asp Asn Gly Val Leu Leu
 275 280 285

His Ile His Arg Ala Met His Ala Val Ile Asp Arg Gln Arg Asn His
 290 295 300

Gly Ile His Phe Arg Val Leu Ala Lys Cys Leu Arg Leu Ser Gly Gly
 305 310 315 320

Asp His Leu His Ser Gly Thr Val Val Gly Lys Leu Glu Gly Asp Lys
 325 330 335

Ala Ser Thr Leu Gly Phe Val Asp Leu Met Arg Glu Asp His Ile Glu
 340 345 350

Ala Asp Arg Ser Arg Gly Val Phe Phe Thr Gln Asp Trp Ala Ser Met
 355 360 365

Pro Gly Val Leu Pro Val Ala Ser Gly Gly Ile His Val Trp His Met
 370 375 380

Pro Ala Leu Val Glu Ile Phe Gly Asp Asp Ser Val Leu Gln Phe Gly
 385 390 395 400

Gly Gly Thr Leu Gly His Pro Trp Gly Asn Ala Pro Gly Ala Thr Ala
 405 410 415

Asn Arg Val Ala Leu Glu Ala Cys Val Gln Ala Arg Asn Glu Gly Arg
 420 425 430

Asp Leu Tyr Arg Glu Gly Gly Asp Ile Leu Arg Glu Ala Gly Lys Trp
 435 440 445

Ser Arg Glu Leu Ala Ala Ala Leu Asp Leu Trp Lys Glu Ile Lys Phe
 450 455 460

Glu Phe Glu Thr Met Asp Lys Leu
 465 470

<210> SEQ ID NO 48
 <211> LENGTH: 111
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: F2A-20 rbcS

<400> SEQUENCE: 48

Met Ser Met Lys Thr Leu Pro Lys Glu Arg Arg Phe Glu Thr Phe Ser
 1 5 10 15

Tyr Leu Pro Pro Leu Ser Asp Arg Gln Ile Ala Ala Gln Ile Glu Tyr
 20 25 30

Met Ile Glu Gln Gly Phe His Pro Leu Ile Glu Phe Asn Glu His Ser
 35 40 45

Asn Pro Glu Glu Phe Tyr Trp Thr Met Trp Lys Leu Pro Leu Phe Asp
 50 55 60

Cys Lys Gly Pro Gln Gln Val Leu Asp Glu Val Arg Glu Cys Arg Ser
 65 70 75 80

Glu Tyr Gly Asp Cys Tyr Ile Arg Val Ala Gly Phe Asp Asn Ile Lys
 85 90 95

Gln Cys Gln Thr Val Ser Phe Ile Val His Arg Pro Gly Arg Tyr
 100 105 110

<210> SEQ ID NO 49
 <211> LENGTH: 1845
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: F2B-2 rbcLS
 <220> FEATURE:
 <221> NAME/KEY: CDS

-continued

```

<222> LOCATION: (1)...(1419)
<223> OTHER INFORMATION: F2B-2 rbcL
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1510)...(1845)
<223> OTHER INFORMATION: F2B-2 rbcS

<400> SEQUENCE: 49

atg ccc aag acg caa tct gcc gca ggc tat aag gcc ggg gtg aag gac      48
Met Pro Lys Thr Gln Ser Ala Ala Gly Tyr Lys Ala Gly Val Lys Asp
  1             5             10             15

tac aaa ctc acc tat tac acc ccc gat tac acc ccc aaa gac act gac      96
Tyr Lys Leu Thr Tyr Tyr Thr Pro Asp Tyr Thr Pro Lys Asp Thr Asp
             20             25             30

ctg ctg gcg gct ttc cgc ttc agc cct cag ccg ggt gtc cct gct gac      144
Leu Leu Ala Ala Phe Arg Phe Ser Pro Gln Pro Gly Val Pro Ala Asp
             35             40             45

gaa gct ggt gcg gcg atc gcg gct gaa tct tcg acc ggt acc tgg acc      192
Glu Ala Gly Ala Ala Ile Ala Ala Glu Ser Ser Thr Gly Thr Trp Thr
             50             55             60

acc gtg tgg acc gac ttg ctg acc gac atg gat cgg tac aaa ggc aag      240
Thr Val Trp Thr Asp Leu Leu Thr Asp Met Asp Arg Tyr Lys Gly Lys
             65             70             75             80

tgc tac cac atc gag ccg gtg caa ggc gaa gag aac tcc tac ttt gcg      288
Cys Tyr His Ile Glu Pro Val Gln Gly Glu Glu Asn Ser Tyr Phe Ala
             85             90             95

ttc atc gct tac ccg ctc gac ctg ttt gaa gaa ggg tcg gtc acc aac      336
Phe Ile Ala Tyr Pro Leu Asp Leu Phe Glu Glu Gly Ser Val Thr Asn
             100            105            110

atc ctg acc tcg atc gtc ggt aac gtg ttt ggc ttc aaa gct atc cgt      384
Ile Leu Thr Ser Ile Val Gly Asn Val Phe Gly Phe Lys Ala Ile Arg
             115            120            125

tcg ctg cgt ctg gaa gac atc cgc ttc ccc gtc gcc ctg gtc aaa acc      432
Ser Leu Arg Leu Glu Asp Ile Arg Phe Pro Val Ala Leu Val Lys Thr
             130            135            140

ttc caa ggt cct ccc cac ggt atc caa gtc gag cgc gac ctg ctg aac      480
Phe Gln Gly Pro Pro His Gly Ile Gln Val Glu Arg Asp Leu Leu Asn
             145            150            155            160

aag tac ggc cgt ccg atg ctg ggt tgc acg atc aaa cca aaa ctc ggt      528
Lys Tyr Gly Arg Pro Met Leu Gly Cys Thr Ile Lys Pro Lys Leu Gly
             165            170            175

ctg tcg gcg aaa aac tac ggt cgt gcc gtc tac gaa tgt ctg cgc ggc      576
Leu Ser Ala Lys Asn Tyr Gly Arg Ala Val Tyr Glu Cys Leu Arg Gly
             180            185            190

ggt ctg gac ttc acc aaa gac gac gaa aac atc aac tcg cag ccg ttc      624
Gly Leu Asp Phe Thr Lys Asp Asp Glu Asn Ile Asn Ser Gln Pro Phe
             195            200            205

caa cgc tgg cgc gat cgc ttc ctg ttt gtg gct gat gca atc cac aaa      672
Gln Arg Trp Arg Asp Arg Phe Leu Phe Val Ala Asp Ala Ile His Lys
             210            215            220

tcg caa gca gaa acc ggt gaa atc aaa ggt cac tac ctg aac gtg acc      720
Ser Gln Ala Glu Thr Gly Glu Ile Lys Gly His Tyr Leu Asn Val Thr
             225            230            235            240

gcg ccg acc tgc gaa gaa atg atg aaa ccg gct gag ttc gct aaa gaa      768
Ala Pro Thr Cys Glu Glu Met Met Lys Arg Ala Glu Phe Ala Lys Glu
             245            250            255

ctc ggc atg ccg atc atc atg cat gac ttc ttg acg gct ggt ttc acc      816
Leu Gly Met Pro Ile Ile Met His Asp Phe Leu Thr Ala Gly Phe Thr
             260            265            270

gcc aac acc acc ttg gca aaa tgg tgc cgc gac aac ggc gtc ctg ctg      864
Ala Asn Thr Thr Leu Ala Lys Trp Cys Arg Asp Asn Gly Val Leu Leu

```

-continued

275	280	285	
cac atc cac cgt gca atg cac gcg gtg atc gac cgt cag cgt aac cac His Ile His Arg Ala Met His Ala Val Ile Asp Arg Gln Arg Asn His 290 295 300			912
ggg att cac ttc cgt gtc ttg gcc aag tgt ttg cgt ctg tcc ggt ggt Gly Ile His Phe Arg Val Leu Ala Lys Cys Leu Arg Leu Ser Gly Gly 305 310 315 320			960
gac cac ctc cac tcc ggc acc gtc gtc ggc aaa ctg gaa ggc gac aaa Asp His Leu His Ser Gly Thr Val Val Gly Lys Leu Glu Gly Asp Lys 325 330 335			1008
gct tcg acc ttg ggc ttt gtt gac ttg atg cgc gaa gac cac atc gaa Ala Ser Thr Leu Gly Phe Val Asp Leu Met Arg Glu Asp His Ile Glu 340 345 350			1056
gct gac cgc aac cgt ggg gtc ttc ttc acc caa gat tgg gcg tcg atg Ala Asp Arg Asn Arg Gly Val Phe Phe Thr Gln Asp Trp Ala Ser Met 355 360 365			1104
ccg ggc gtg ctg ccg gtt gct tcc ggt ggt atc cac gtg tgg cac atg Pro Gly Val Leu Pro Val Ala Ser Gly Gly Ile His Val Trp His Met 370 375 380			1152
ccc gca ctg gtg gaa atc ttc ggt gat gac tcc gtt ctc cag ttc ggt Pro Ala Leu Val Glu Ile Phe Gly Asp Asp Ser Val Leu Gln Phe Gly 385 390 395 400			1200
ggc ggc acc ttg ggt cac ccc tgg ggt aat gct cct ggt gca acc gcg Gly Gly Thr Leu Gly His Pro Trp Gly Asn Ala Pro Gly Ala Thr Ala 405 410 415			1248
aac cgt gtt gcc ttg gaa gct tgc gtc caa gct cgg aac gaa ggt cgc Asn Arg Val Ala Leu Glu Ala Cys Val Gln Ala Arg Asn Glu Gly Arg 420 425 430			1296
gac ctc tac cgt gaa ggc ggc gac atc ctt cgt gaa gct ggc aag tgg Asp Leu Tyr Arg Glu Gly Gly Asp Ile Leu Arg Glu Ala Gly Lys Trp 435 440 445			1344
tcg cct gaa ctg gct gct gcc ctc gac ctc tgg aaa gag atc aag ttc Ser Pro Glu Leu Ala Ala Leu Asp Leu Trp Lys Glu Ile Lys Phe 450 455 460			1392
gaa ttc gaa acg atg gac aag ctc taa ggagcctctg actatcgctg Glu Phe Glu Thr Met Asp Lys Leu * 465 470			1439
ggggagtgag cgttgctgcg taaagctttc tccccagcct ttcgacttaa cctttcagga			1499
tttctgaatc atg agc atg aaa act ctg ccc aaa gag cgt cgt ttc gag Met Ser Met Lys Thr Leu Pro Lys Glu Arg Arg Phe Glu 475 480 485			1548
act ttc tcg tac ctg cct ccc ctc agc gat cgc caa atc gct gca caa Thr Phe Ser Tyr Leu Pro Pro Leu Ser Asp Arg Gln Ile Ala Ala Gln 490 495 500			1596
atc gag tac atg atc gag caa ggc ttc cac ccc ttg atc gag ttc aac Ile Glu Tyr Met Ile Glu Gln Gly Phe His Pro Leu Ile Glu Phe Asn 505 510 515			1644
gag cac tcg aat ccg gaa gag ttc tac tgg acg atg tgg aag ctc ccc Glu His Ser Asn Pro Glu Glu Phe Tyr Trp Thr Met Trp Lys Leu Pro 520 525 530			1692
ctg ttt gac tgc aag agc cct cag caa gtc ctc gat gaa gtg cgt gag Leu Phe Asp Cys Lys Ser Pro Gln Gln Val Leu Asp Glu Val Arg Glu 535 540 545			1740
tgc cgc agc gaa tac ggt gat tgc tac atc cgt gtc gct ggc ttc gac Cys Arg Ser Glu Tyr Gly Asp Cys Tyr Ile Arg Val Ala Gly Phe Asp 550 555 560 565			1788
aac atc aag cag tgc caa acc gtg agc ttc atc gtt cat cgt ccc ggc Asn Ile Lys Gln Cys Gln Thr Val Ser Phe Ile Val His Arg Pro Gly 570 575 580			1836

-continued

cgc tac taa
Arg Tyr *

1845

<210> SEQ ID NO 50
<211> LENGTH: 472
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: F2B-2 rbcL

<400> SEQUENCE: 50

Met	Pro	Lys	Thr	Gln	Ser	Ala	Ala	Gly	Tyr	Lys	Ala	Gly	Val	Lys	Asp	1	5	10	15
Tyr	Lys	Leu	Thr	Tyr	Tyr	Thr	Pro	Asp	Tyr	Thr	Pro	Lys	Asp	Thr	Asp	20	25	30	
Leu	Leu	Ala	Ala	Phe	Arg	Phe	Ser	Pro	Gln	Pro	Gly	Val	Pro	Ala	Asp	35	40	45	
Glu	Ala	Gly	Ala	Ala	Ile	Ala	Ala	Glu	Ser	Ser	Thr	Gly	Thr	Trp	Thr	50	55	60	
Thr	Val	Trp	Thr	Asp	Leu	Leu	Thr	Asp	Met	Asp	Arg	Tyr	Lys	Gly	Lys	65	70	75	80
Cys	Tyr	His	Ile	Glu	Pro	Val	Gln	Gly	Glu	Glu	Asn	Ser	Tyr	Phe	Ala	85	90	95	
Phe	Ile	Ala	Tyr	Pro	Leu	Asp	Leu	Phe	Glu	Glu	Gly	Ser	Val	Thr	Asn	100	105	110	
Ile	Leu	Thr	Ser	Ile	Val	Gly	Asn	Val	Phe	Gly	Phe	Lys	Ala	Ile	Arg	115	120	125	
Ser	Leu	Arg	Leu	Glu	Asp	Ile	Arg	Phe	Pro	Val	Ala	Leu	Val	Lys	Thr	130	135	140	
Phe	Gln	Gly	Pro	Pro	His	Gly	Ile	Gln	Val	Glu	Arg	Asp	Leu	Leu	Asn	145	150	155	160
Lys	Tyr	Gly	Arg	Pro	Met	Leu	Gly	Cys	Thr	Ile	Lys	Pro	Lys	Leu	Gly	165	170	175	
Leu	Ser	Ala	Lys	Asn	Tyr	Gly	Arg	Ala	Val	Tyr	Glu	Cys	Leu	Arg	Gly	180	185	190	
Gly	Leu	Asp	Phe	Thr	Lys	Asp	Asp	Glu	Asn	Ile	Asn	Ser	Gln	Pro	Phe	195	200	205	
Gln	Arg	Trp	Arg	Asp	Arg	Phe	Leu	Phe	Val	Ala	Asp	Ala	Ile	His	Lys	210	215	220	
Ser	Gln	Ala	Glu	Thr	Gly	Glu	Ile	Lys	Gly	His	Tyr	Leu	Asn	Val	Thr	225	230	235	240
Ala	Pro	Thr	Cys	Glu	Glu	Met	Met	Lys	Arg	Ala	Glu	Phe	Ala	Lys	Glu	245	250	255	
Leu	Gly	Met	Pro	Ile	Ile	Met	His	Asp	Phe	Leu	Thr	Ala	Gly	Phe	Thr	260	265	270	
Ala	Asn	Thr	Thr	Leu	Ala	Lys	Trp	Cys	Arg	Asp	Asn	Gly	Val	Leu	Leu	275	280	285	
His	Ile	His	Arg	Ala	Met	His	Ala	Val	Ile	Asp	Arg	Gln	Arg	Asn	His	290	295	300	
Gly	Ile	His	Phe	Arg	Val	Leu	Ala	Lys	Cys	Leu	Arg	Leu	Ser	Gly	Gly	305	310	315	320
Asp	His	Leu	His	Ser	Gly	Thr	Val	Val	Gly	Lys	Leu	Glu	Gly	Asp	Lys	325	330	335	
Ala	Ser	Thr	Leu	Gly	Phe	Val	Asp	Leu	Met	Arg	Glu	Asp	His	Ile	Glu	340	345	350	

-continued

Ala Asp Arg Asn Arg Gly Val Phe Phe Thr Gln Asp Trp Ala Ser Met
 355 360 365

Pro Gly Val Leu Pro Val Ala Ser Gly Gly Ile His Val Trp His Met
 370 375 380

Pro Ala Leu Val Glu Ile Phe Gly Asp Asp Ser Val Leu Gln Phe Gly
 385 390 395 400

Gly Gly Thr Leu Gly His Pro Trp Gly Asn Ala Pro Gly Ala Thr Ala
 405 410 415

Asn Arg Val Ala Leu Glu Ala Cys Val Gln Ala Arg Asn Glu Gly Arg
 420 425 430

Asp Leu Tyr Arg Glu Gly Gly Asp Ile Leu Arg Glu Ala Gly Lys Trp
 435 440 445

Ser Pro Glu Leu Ala Ala Ala Leu Asp Leu Trp Lys Glu Ile Lys Phe
 450 455 460

Glu Phe Glu Thr Met Asp Lys Leu
 465 470

<210> SEQ ID NO 51
 <211> LENGTH: 111
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: F2B-2 rbcS

<400> SEQUENCE: 51

Met Ser Met Lys Thr Leu Pro Lys Glu Arg Arg Phe Glu Thr Phe Ser
 1 5 10 15

Tyr Leu Pro Pro Leu Ser Asp Arg Gln Ile Ala Ala Gln Ile Glu Tyr
 20 25 30

Met Ile Glu Gln Gly Phe His Pro Leu Ile Glu Phe Asn Glu His Ser
 35 40 45

Asn Pro Glu Glu Phe Tyr Trp Thr Met Trp Lys Leu Pro Leu Phe Asp
 50 55 60

Cys Lys Ser Pro Gln Gln Val Leu Asp Glu Val Arg Glu Cys Arg Ser
 65 70 75 80

Glu Tyr Gly Asp Cys Tyr Ile Arg Val Ala Gly Phe Asp Asn Ile Lys
 85 90 95

Gln Cys Gln Thr Val Ser Phe Ile Val His Arg Pro Gly Arg Tyr
 100 105 110

<210> SEQ ID NO 52
 <211> LENGTH: 1845
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: F2B-3 rbcLS
 <220> FEATURE:
 <221> NAME/KEY: CDS
 <222> LOCATION: (1)...(1419)
 <223> OTHER INFORMATION: F2B-3 rbcL
 <220> FEATURE:
 <221> NAME/KEY: CDS
 <222> LOCATION: (1510)...(1845)
 <223> OTHER INFORMATION: F2B-3 rbcS

<400> SEQUENCE: 52

atg ccc aag acg caa tct gcc gca ggc tat aag gcc ggg gtg aag gac 48
 Met Pro Lys Thr Gln Ser Ala Ala Gly Tyr Lys Ala Gly Val Lys Asp
 1 5 10 15

tac aaa ctc acc tat tac acc ccc gat tac acc ccc aaa gac act gac 96

-continued

Tyr	Lys	Leu	Thr	Tyr	Tyr	Thr	Pro	Asp	Tyr	Thr	Pro	Lys	Asp	Thr	Asp		
			20					25					30				
ctg	ctg	gcg	gct	ttc	cgc	ttc	agc	cct	cag	ccg	ggt	gtc	cct	gct	gac	144	
Leu	Leu	Ala	Ala	Phe	Arg	Phe	Ser	Pro	Gln	Pro	Gly	Val	Pro	Ala	Asp		
		35					40					45					
gaa	gct	ggt	gcg	gcg	atc	gcg	gct	gaa	tct	tcg	acc	ggt	acc	tgg	acc	192	
Glu	Ala	Gly	Ala	Ala	Ile	Ala	Ala	Glu	Ser	Ser	Thr	Gly	Thr	Trp	Thr		
	50					55					60						
acc	gtg	tgg	acc	gac	ttg	ctg	acc	gac	atg	gat	cgg	tac	aaa	ggc	aag	240	
Thr	Val	Trp	Thr	Asp	Leu	Leu	Thr	Asp	Met	Asp	Arg	Tyr	Lys	Gly	Lys		
	65				70					75					80		
tgc	tac	cac	atc	gag	ccg	gtg	caa	ggc	gaa	gag	aac	tcc	tac	ttt	gcg	288	
Cys	Tyr	His	Ile	Glu	Pro	Val	Gln	Gly	Glu	Glu	Asn	Ser	Tyr	Phe	Ala		
				85					90					95			
ttc	atc	gct	tac	ccg	ctc	gac	ctg	ttt	gaa	gaa	ggg	tcg	gtc	acc	aac	336	
Phe	Ile	Ala	Tyr	Pro	Leu	Asp	Leu	Phe	Glu	Glu	Gly	Ser	Val	Thr	Asn		
			100					105					110				
atc	ctg	acc	tcg	atc	gtc	ggt	aac	gtg	ttt	ggc	ttc	aaa	gct	atc	cgt	384	
Ile	Leu	Thr	Ser	Ile	Val	Gly	Asn	Val	Phe	Gly	Phe	Lys	Ala	Ile	Arg		
		115					120					125					
tcg	ctg	cgt	ctg	gaa	gac	atc	cgc	ttc	ccc	gtc	gcc	ttg	gtc	aaa	acc	432	
Ser	Leu	Arg	Leu	Glu	Asp	Ile	Arg	Phe	Pro	Val	Ala	Leu	Val	Lys	Thr		
	130					135					140						
ttc	caa	ggt	cct	ccc	cac	ggt	atc	caa	gtc	gag	cgc	gac	ctg	ctg	aac	480	
Phe	Gln	Gly	Pro	Pro	His	Gly	Ile	Gln	Val	Glu	Arg	Asp	Leu	Leu	Asn		
	145				150					155					160		
aag	tac	ggc	cgt	ccg	atg	ctg	ggt	tgc	acg	atc	aaa	cca	aaa	ctc	ggt	528	
Lys	Tyr	Gly	Arg	Pro	Met	Leu	Gly	Cys	Thr	Ile	Lys	Pro	Lys	Leu	Gly		
				165					170					175			
ctg	tcg	gcg	aaa	aac	tac	ggt	cgt	gcc	gtc	tac	gaa	tgt	ctg	cgc	ggc	576	
Leu	Ser	Ala	Lys	Asn	Tyr	Gly	Arg	Ala	Val	Tyr	Glu	Cys	Leu	Arg	Gly		
			180					185					190				
ggt	ctg	gac	ttc	acc	aaa	gac	gac	gaa	aac	atc	aac	tcg	cag	ccg	ttc	624	
Gly	Leu	Asp	Phe	Thr	Lys	Asp	Asp	Glu	Asn	Ile	Asn	Ser	Gln	Pro	Phe		
		195						200				205					
caa	cgc	tgg	cgc	gat	cgc	ttc	ctg	ttt	gtg	gct	gat	gca	atc	cac	aaa	672	
Gln	Arg	Trp	Arg	Asp	Arg	Phe	Leu	Phe	Val	Ala	Asp	Ala	Ile	His	Lys		
	210					215					220						
tcg	caa	gca	gaa	acc	ggt	gaa	acc	aag	ggt	cac	tac	ctg	aac	gtg	acc	720	
Ser	Gln	Ala	Glu	Thr	Gly	Glu	Thr	Lys	Gly	His	Tyr	Leu	Asn	Val	Thr		
	225				230					235					240		
gcg	ccg	acc	tgc	gaa	gaa	atg	atg	aaa	cgg	gct	gag	ttc	gct	aaa	gaa	768	
Ala	Pro	Thr	Cys	Glu	Glu	Met	Met	Lys	Arg	Ala	Glu	Phe	Ala	Lys	Glu		
				245					250					255			
ctc	ggc	atg	ccg	atc	atc	atg	cat	gac	ttc	ttg	acg	gct	ggt	ttc	act	816	
Leu	Gly	Met	Pro	Ile	Ile	Met	His	Asp	Phe	Leu	Thr	Ala	Gly	Phe	Thr		
			260					265						270			
gcc	aac	acc	acc	ttg	gca	aaa	tgg	tgc	cgc	gac	aac	ggc	gtc	ctg	ctg	864	
Ala	Asn	Thr	Thr	Leu	Ala	Lys	Trp	Cys	Arg	Asp	Asn	Gly	Val	Leu	Leu		
		275					280					285					
cac	atc	cac	cgc	gct	atg	cac	gca	ggt	atc	gac	cgt	cag	cgt	aac	cac	912	
His	Ile	His	Arg	Ala	Met	His	Ala	Val	Ile	Asp	Arg	Gln	Arg	Asn	His		
	290					295					300						
ggg	att	cac	ttc	cgt	gtc	ttg	gcc	aag	tgt	ttg	cgt	ctg	tcc	ggt	ggt	960	
Gly	Ile	His	Phe	Arg	Val	Leu	Ala	Lys	Cys	Leu	Arg	Leu	Ser	Gly	Gly		
	305				310					315					320		
gat	cac	ctc	cac	tcc	ggc	acc	gtc	gtc	ggc	aaa	ctg	gaa	ggc	gac	aaa	1008	
Asp	His	Leu	His	Ser	Gly	Thr	Val	Val	Gly	Lys	Leu	Glu	Gly	Asp	Lys		
				325					330					335			

-continued

gct tcg acc ttg ggc ttt gtt gac ttg atg cgc gaa gac cac atc gaa Ala Ser Thr Leu Gly Phe Val Asp Leu Met Arg Glu Asp His Ile Glu 340 345 350	1056
gct gac cgc agc cgt ggg gtc ttc ttc acc caa gat tgg gcg tcg atg Ala Asp Arg Ser Arg Gly Val Phe Phe Thr Gln Asp Trp Ala Ser Met 355 360 365	1104
ccg ggc gtg ctg ccg gtt gct tcc ggt ggt atc cac gtg tgg cac atg Pro Gly Val Leu Pro Val Ala Ser Gly Gly Ile His Val Trp His Met 370 375 380	1152
ccc gca ctg gtg gaa atc ttc ggt gat gac tcc gtt ctc cag ttc ggt Pro Ala Leu Val Glu Ile Phe Gly Asp Asp Ser Val Leu Gln Phe Gly 385 390 395 400	1200
ggc ggc acc ttg ggt cac ccc tgg ggt aat gct cct ggt gca acc gcg Gly Gly Thr Leu Gly His Pro Trp Gly Asn Ala Pro Gly Ala Thr Ala 405 410 415	1248
aac cgt gtt gcc ttg gaa gct tgc gtc caa gct cgg aac gaa ggt cgc Asn Arg Val Ala Leu Glu Ala Cys Val Gln Ala Arg Asn Glu Gly Arg 420 425 430	1296
gac ctc tac cgt gaa ggc ggc gac atc ctt cgt gag gct ggc aag tgg Asp Leu Tyr Arg Glu Gly Gly Asp Ile Leu Arg Glu Ala Gly Lys Trp 435 440 445	1344
tcg cct gaa ctg gct gct gcc ctc gac ctc tgg aaa gag atc aag ttc Ser Pro Glu Leu Ala Ala Ala Leu Asp Leu Trp Lys Glu Ile Lys Phe 450 455 460	1392
gaa ttc gaa acg atg gac aag ctc taa ggagcctctg actatcgctg Glu Phe Glu Thr Met Asp Lys Leu * 465 470	1439
agggagtgag cggtgctgcg taaagccttc tccccagcct ttcgacttaa cctttcagga	1499
tttctgaatc atg agc atg aaa act ctg ccc aaa gag cgt cgt ttc gag Met Ser Met Lys Thr Leu Pro Lys Glu Arg Arg Phe Glu 475 480 485	1548
act ttc tcg tac ctg cct ccc ctc agc gat cgc caa atc gct gca caa Thr Phe Ser Tyr Leu Pro Pro Leu Ser Asp Arg Gln Ile Ala Ala Gln 490 495 500	1596
atc gag tac atg atc gag caa ggc ttc cac ccc ttg atc gag ttc aac Ile Glu Tyr Met Ile Glu Gln Gly Phe His Pro Leu Ile Glu Phe Asn 505 510 515	1644
gag cac tcg aat ccg gaa gag ttc tac tgg acg atg tgg aag ctc ccc Glu His Ser Asn Pro Glu Glu Phe Tyr Trp Thr Met Trp Lys Leu Pro 520 525 530	1692
ctg ttt gac tgc aag agc cct cag caa gtc ctc gat gaa gtg cgt gag Leu Phe Asp Cys Lys Ser Pro Gln Gln Val Leu Asp Glu Val Arg Glu 535 540 545	1740
tgc cgc agc gaa tac ggt gat tgc tac atc cgt gtc gct ggc ttc gac Cys Arg Ser Glu Tyr Gly Asp Cys Tyr Ile Arg Val Ala Gly Phe Asp 550 555 560 565	1788
aac atc aag cag tgc caa acc gtg ggc ttc atc gtt cat cgt ccc ggc Asn Ile Lys Gln Cys Gln Thr Val Gly Phe Ile Val His Arg Pro Gly 570 575 580	1836
cgc tac taa Arg Tyr *	1845

<210> SEQ ID NO 53

<211> LENGTH: 472

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: F2B-3 rbcL

<400> SEQUENCE: 53

-continued

Met	Pro	Lys	Thr	Gln	Ser	Ala	Ala	Gly	Tyr	Lys	Ala	Gly	Val	Lys	Asp	1	5	10	15
Tyr	Lys	Leu	Thr	Tyr	Tyr	Thr	Pro	Asp	Tyr	Thr	Pro	Lys	Asp	Thr	Asp	20	25	30	
Leu	Leu	Ala	Ala	Phe	Arg	Phe	Ser	Pro	Gln	Pro	Gly	Val	Pro	Ala	Asp	35	40	45	
Glu	Ala	Gly	Ala	Ala	Ile	Ala	Ala	Glu	Ser	Ser	Thr	Gly	Thr	Trp	Thr	50	55	60	
Thr	Val	Trp	Thr	Asp	Leu	Leu	Thr	Asp	Met	Asp	Arg	Tyr	Lys	Gly	Lys	65	70	75	80
Cys	Tyr	His	Ile	Glu	Pro	Val	Gln	Gly	Glu	Glu	Asn	Ser	Tyr	Phe	Ala	85	90	95	
Phe	Ile	Ala	Tyr	Pro	Leu	Asp	Leu	Phe	Glu	Glu	Gly	Ser	Val	Thr	Asn	100	105	110	
Ile	Leu	Thr	Ser	Ile	Val	Gly	Asn	Val	Phe	Gly	Phe	Lys	Ala	Ile	Arg	115	120	125	
Ser	Leu	Arg	Leu	Glu	Asp	Ile	Arg	Phe	Pro	Val	Ala	Leu	Val	Lys	Thr	130	135	140	
Phe	Gln	Gly	Pro	Pro	His	Gly	Ile	Gln	Val	Glu	Arg	Asp	Leu	Leu	Asn	145	150	155	160
Lys	Tyr	Gly	Arg	Pro	Met	Leu	Gly	Cys	Thr	Ile	Lys	Pro	Lys	Leu	Gly	165	170	175	
Leu	Ser	Ala	Lys	Asn	Tyr	Gly	Arg	Ala	Val	Tyr	Glu	Cys	Leu	Arg	Gly	180	185	190	
Gly	Leu	Asp	Phe	Thr	Lys	Asp	Asp	Glu	Asn	Ile	Asn	Ser	Gln	Pro	Phe	195	200	205	
Gln	Arg	Trp	Arg	Asp	Arg	Phe	Leu	Phe	Val	Ala	Asp	Ala	Ile	His	Lys	210	215	220	
Ser	Gln	Ala	Glu	Thr	Gly	Glu	Thr	Lys	Gly	His	Tyr	Leu	Asn	Val	Thr	225	230	235	240
Ala	Pro	Thr	Cys	Glu	Glu	Met	Met	Lys	Arg	Ala	Glu	Phe	Ala	Lys	Glu	245	250	255	
Leu	Gly	Met	Pro	Ile	Ile	Met	His	Asp	Phe	Leu	Thr	Ala	Gly	Phe	Thr	260	265	270	
Ala	Asn	Thr	Thr	Leu	Ala	Lys	Trp	Cys	Arg	Asp	Asn	Gly	Val	Leu	Leu	275	280	285	
His	Ile	His	Arg	Ala	Met	His	Ala	Val	Ile	Asp	Arg	Gln	Arg	Asn	His	290	295	300	
Gly	Ile	His	Phe	Arg	Val	Leu	Ala	Lys	Cys	Leu	Arg	Leu	Ser	Gly	Gly	305	310	315	320
Asp	His	Leu	His	Ser	Gly	Thr	Val	Val	Gly	Lys	Leu	Glu	Gly	Asp	Lys	325	330	335	
Ala	Ser	Thr	Leu	Gly	Phe	Val	Asp	Leu	Met	Arg	Glu	Asp	His	Ile	Glu	340	345	350	
Ala	Asp	Arg	Ser	Arg	Gly	Val	Phe	Phe	Thr	Gln	Asp	Trp	Ala	Ser	Met	355	360	365	
Pro	Gly	Val	Leu	Pro	Val	Ala	Ser	Gly	Gly	Ile	His	Val	Trp	His	Met	370	375	380	
Pro	Ala	Leu	Val	Glu	Ile	Phe	Gly	Asp	Asp	Ser	Val	Leu	Gln	Phe	Gly	385	390	395	400
Gly	Gly	Thr	Leu	Gly	His	Pro	Trp	Gly	Asn	Ala	Pro	Gly	Ala	Thr	Ala	405	410	415	
Asn	Arg	Val	Ala	Leu	Glu	Ala	Cys	Val	Gln	Ala	Arg	Asn	Glu	Gly	Arg				

-continued

420	425	430
Asp Leu Tyr Arg Glu Gly Gly Asp Ile Leu Arg Glu Ala Gly Lys Trp		
435	440	445
Ser Pro Glu Leu Ala Ala Ala Leu Asp Leu Trp Lys Glu Ile Lys Phe		
450	455	460
Glu Phe Glu Thr Met Asp Lys Leu		
465	470	

<210> SEQ ID NO 54
 <211> LENGTH: 111
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: F2B-3 rbcS

<400> SEQUENCE: 54

Met Ser Met Lys Thr Leu Pro Lys Glu Arg Arg Phe Glu Thr Phe Ser			
1	5	10	15
Tyr Leu Pro Pro Leu Ser Asp Arg Gln Ile Ala Ala Gln Ile Glu Tyr			
20	25	30	
Met Ile Glu Gln Gly Phe His Pro Leu Ile Glu Phe Asn Glu His Ser			
35	40	45	
Asn Pro Glu Glu Phe Tyr Trp Thr Met Trp Lys Leu Pro Leu Phe Asp			
50	55	60	
Cys Lys Ser Pro Gln Gln Val Leu Asp Glu Val Arg Glu Cys Arg Ser			
65	70	75	80
Glu Tyr Gly Asp Cys Tyr Ile Arg Val Ala Gly Phe Asp Asn Ile Lys			
85	90	95	
Gln Cys Gln Thr Val Gly Phe Ile Val His Arg Pro Gly Arg Tyr			
100	105	110	

<210> SEQ ID NO 55
 <211> LENGTH: 1845
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Codon Optimized F2A-10, rbcLS
 <220> FEATURE:
 <221> NAME/KEY: CDS
 <222> LOCATION: (1)...(1419)
 <223> OTHER INFORMATION: Codon Optimized F2A-10, rbcL
 <220> FEATURE:
 <221> NAME/KEY: CDS
 <222> LOCATION: (1510)...(1845)
 <223> OTHER INFORMATION: Codon Optimized F2A-10, rbcS

<400> SEQUENCE: 55

atg ccg aag act caa agc gcg gcg ggc tac aag gcc ggc gtt aaa gat	48		
Met Pro Lys Thr Gln Ser Ala Ala Gly Tyr Lys Ala Gly Val Lys Asp			
1	5	10	15
tac aag ttg act tat tat acc ccg gat tac act ccc aaa gac acg gac	96		
Tyr Lys Leu Thr Tyr Tyr Thr Pro Asp Tyr Thr Pro Lys Asp Thr Asp			
20	25	30	
ttg ctc gcc gca ttc cgc ttc agc cca caa ccc gga gtt cct gct gat	144		
Leu Leu Ala Ala Phe Arg Phe Ser Pro Gln Pro Gly Val Pro Ala Asp			
35	40	45	
gag gcg ggt gcc gcc atc gcg gca gag agt agt acc ggc acg tgg act	192		
Glu Ala Gly Ala Ala Ile Ala Ala Glu Ser Ser Thr Gly Thr Trp Thr			
50	55	60	
act gtg tgg act gat ctg ttg acc gat atg gac cgc tac aaa ggg aaa	240		
Thr Val Trp Thr Asp Leu Leu Thr Asp Met Asp Arg Tyr Lys Gly Lys			
65	70	75	80

-continued

tgc tac cat atc gaa ccc gtg cag ggc gaa gag aac tca tat ttt gcc	288
Cys Tyr His Ile Glu Pro Val Gln Gly Glu Glu Asn Ser Tyr Phe Ala	
85 90 95	
ttt ata gca tat ccg tta gat tta ttc gaa gaa gga tct gtt acc aac	336
Phe Ile Ala Tyr Pro Leu Asp Leu Phe Glu Glu Gly Ser Val Thr Asn	
100 105 110	
att ctc act tcg atc gtc ggt aat gta ttt ggc ttc aag gcc att cga	384
Ile Leu Thr Ser Ile Val Gly Asn Val Phe Gly Phe Lys Ala Ile Arg	
115 120 125	
agt cta agg ttg gaa gat atc cgc ttt ccg gtg gct ttg gtg aag act	432
Ser Leu Arg Leu Glu Asp Ile Arg Phe Pro Val Ala Leu Val Lys Thr	
130 135 140	
ttt cag ggc ccg ccg cat gga ata caa gtt gaa cgt gat ctc ttg aat	480
Phe Gln Gly Pro Pro His Gly Ile Gln Val Glu Arg Asp Leu Leu Asn	
145 150 155 160	
aag tac ggc cgt ccc atg ctc gga tgc aca att aag ccg aaa tta ggg	528
Lys Tyr Gly Arg Pro Met Leu Gly Cys Thr Ile Lys Pro Lys Leu Gly	
165 170 175	
ctg tcc gcc aag aac tac gga cga gct gtt tat gag tgt tta cgg ggg	576
Leu Ser Ala Lys Asn Tyr Gly Arg Ala Val Tyr Glu Cys Leu Arg Gly	
180 185 190	
gga ctg gac ttc act aag gat gac gag aat atc aac agc caa cca ttc	624
Gly Leu Asp Phe Thr Lys Asp Asp Glu Asn Ile Asn Ser Gln Pro Phe	
195 200 205	
caa cgc tgg cgc gat cga ttt ttg ttc gtg gcc gac gca atc cac aaa	672
Gln Arg Trp Arg Asp Arg Phe Leu Phe Val Ala Asp Ala Ile His Lys	
210 215 220	
tca cag gct gaa act ggc gag ata aag ggg cac tac tta aat gtt acc	720
Ser Gln Ala Glu Thr Gly Glu Ile Lys Gly His Tyr Leu Asn Val Thr	
225 230 235 240	
gct ccc acc tgt gaa gaa atg atg aag cgc gcc gaa ttt gcg aaa gaa	768
Ala Pro Thr Cys Glu Glu Met Met Lys Arg Ala Glu Phe Ala Lys Glu	
245 250 255	
tta ggg atg cca atc ata atg cat gat ttt ctt act gcc ggt ttt act	816
Leu Gly Met Pro Ile Ile Met His Asp Phe Leu Thr Ala Gly Phe Thr	
260 265 270	
gcc aat acg acc tta gcc aaa tgg tgc cga gac aac ggc gtg ctg ctg	864
Ala Asn Thr Thr Leu Ala Lys Trp Cys Arg Asp Asn Gly Val Leu Leu	
275 280 285	
cat att cat cgt gct atg cac gca gta att gat aga caa cgg aac cat	912
His Ile His Arg Ala Met His Ala Val Ile Asp Arg Gln Arg Asn His	
290 295 300	
gga att cat ttt aga gtg ctc gca aag tgt tta cgc ttg agt ggt gga	960
Gly Ile His Phe Arg Val Leu Ala Lys Cys Leu Arg Leu Ser Gly Gly	
305 310 315 320	
gat cat ttg cac agc ggg act gtc gtg ggc aag ttg gaa ggc gat aaa	1008
Asp His Leu His Ser Gly Thr Val Val Gly Lys Leu Glu Gly Asp Lys	
325 330 335	
gcg agt act ttg ggc ttt gtt gac tta atg cgt gag gat cat att gaa	1056
Ala Ser Thr Leu Gly Phe Val Asp Leu Met Arg Glu Asp His Ile Glu	
340 345 350	
gcg gac cgt tct ccg ggc gta ttc ttt act caa gac tgg gct agt atg	1104
Ala Asp Arg Ser Arg Gly Val Phe Phe Thr Gln Asp Trp Ala Ser Met	
355 360 365	
cca ggg gtc cta ccc gtg gct tcc ggg ggc atc cac gta tgg cat atg	1152
Pro Gly Val Leu Pro Val Ala Ser Gly Gly Ile His Val Trp His Met	
370 375 380	
ccg gcg ttg gtg gaa att ttt ggc gac gat agt gtg ttg caa ttt ggt	1200
Pro Ala Leu Val Glu Ile Phe Gly Asp Asp Ser Val Leu Gln Phe Gly	

-continued

385	390	395	400	
ggg ggt acc ctg ggt cac ccg tgg ggc aat gca ccg ggg gcc act gcc				1248
Gly Gly Thr Leu Gly His Pro Trp Gly Asn Ala Pro Gly Ala Thr Ala				
	405	410	415	
aac cgt gtg gct ctt gaa gcc tgc gtc cag gca aga aat gaa ggg agg				1296
Asn Arg Val Ala Leu Glu Ala Cys Val Gln Ala Arg Asn Glu Gly Arg				
	420	425	430	
gat tta tat cga gaa ggg ggg gat att ctg cgt gaa gct ggt aaa tgg				1344
Asp Leu Tyr Arg Glu Gly Gly Asp Ile Leu Arg Glu Ala Gly Lys Trp				
	435	440	445	
agc ccc gaa ttg gct att gct tta gat cta tgg aag gaa att aag ttt				1392
Ser Pro Glu Leu Ala Ile Ala Leu Asp Leu Trp Lys Glu Ile Lys Phe				
	450	455	460	
gag ttt gag acc atg gat aag cta taa ggagcctctg actatcgctg				1439
Glu Phe Glu Thr Met Asp Lys Leu *				
	465	470		
ggggagtgag cggttgctgcg taaagctttc tccccagcct ttcgacttaa cctttcagga				1499
tttctgaatc atg tcc atg aaa acc ttg ccc aaa gaa cgg cgg ttt gaa				1548
Met Ser Met Lys Thr Leu Pro Lys Glu Arg Arg Phe Glu				
	475	480	485	
acc ttt tcc tat ttg ccc ccc ttg tcc gat cgg caa att gcc gcc caa				1596
Thr Phe Ser Tyr Leu Pro Pro Leu Ser Asp Arg Gln Ile Ala Ala Gln				
	490	495	500	
att gaa tat atg att gaa caa ggc ttt cat ccc ttg att gaa ttt aat				1644
Ile Glu Tyr Met Ile Glu Gln Gly Phe His Pro Leu Ile Glu Phe Asn				
	505	510	515	
gaa cat tcc aat ccc gaa gaa ttt tat tgg acc atg tgg aaa ttg ccc				1692
Glu His Ser Asn Pro Glu Glu Phe Tyr Trp Thr Met Trp Lys Leu Pro				
	520	525	530	
ttg ttt gat tgt aaa tcc ccc caa caa gtg ttg gat gaa gtg cgg gaa				1740
Leu Phe Asp Cys Lys Ser Pro Gln Gln Val Leu Asp Glu Val Arg Glu				
	535	540	545	
tgt cgg tcc gaa tat ggc gat tgt tat att cgg gtg gcc gcc ttt gat				1788
Cys Arg Ser Glu Tyr Gly Asp Cys Tyr Ile Arg Val Ala Gly Phe Asp				
	550	555	560	565
aat att aaa caa tgt caa acc gtg tcc ttt att gtg cat cgg ccc gcc				1836
Asn Ile Lys Gln Cys Gln Thr Val Ser Phe Ile Val His Arg Pro Gly				
	570	575	580	
cggtat taa				1845
Arg Tyr *				

<210> SEQ ID NO 56

<211> LENGTH: 472

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: F2A-10 rbcL

<400> SEQUENCE: 56

Met Pro Lys Thr Gln Ser Ala Ala Gly Tyr Lys Ala Gly Val Lys Asp															
1			5					10						15	
Tyr Lys Leu Thr Tyr Tyr Thr Pro Asp Tyr Thr Pro Lys Asp Thr Asp															
			20					25					30		
Leu Leu Ala Ala Phe Arg Phe Ser Pro Gln Pro Gly Val Pro Ala Asp															
			35					40					45		
Glu Ala Gly Ala Ala Ile Ala Ala Glu Ser Ser Thr Gly Thr Trp Thr															
			50					55					60		
Thr Val Trp Thr Asp Leu Leu Thr Asp Met Asp Arg Tyr Lys Gly Lys															
			65					70					75		80

-continued

Cys Tyr His Ile Glu Pro Val Gln Gly Glu Glu Asn Ser Tyr Phe Ala
 85 90 95
 Phe Ile Ala Tyr Pro Leu Asp Leu Phe Glu Glu Gly Ser Val Thr Asn
 100 105 110
 Ile Leu Thr Ser Ile Val Gly Asn Val Phe Gly Phe Lys Ala Ile Arg
 115 120 125
 Ser Leu Arg Leu Glu Asp Ile Arg Phe Pro Val Ala Leu Val Lys Thr
 130 135 140
 Phe Gln Gly Pro Pro His Gly Ile Gln Val Glu Arg Asp Leu Leu Asn
 145 150 155 160
 Lys Tyr Gly Arg Pro Met Leu Gly Cys Thr Ile Lys Pro Lys Leu Gly
 165 170 175
 Leu Ser Ala Lys Asn Tyr Gly Arg Ala Val Tyr Glu Cys Leu Arg Gly
 180 185 190
 Gly Leu Asp Phe Thr Lys Asp Asp Glu Asn Ile Asn Ser Gln Pro Phe
 195 200 205
 Gln Arg Trp Arg Asp Arg Phe Leu Phe Val Ala Asp Ala Ile His Lys
 210 215 220
 Ser Gln Ala Glu Thr Gly Glu Ile Lys Gly His Tyr Leu Asn Val Thr
 225 230 235 240
 Ala Pro Thr Cys Glu Glu Met Met Lys Arg Ala Glu Phe Ala Lys Glu
 245 250 255
 Leu Gly Met Pro Ile Ile Met His Asp Phe Leu Thr Ala Gly Phe Thr
 260 265 270
 Ala Asn Thr Thr Leu Ala Lys Trp Cys Arg Asp Asn Gly Val Leu Leu
 275 280 285
 His Ile His Arg Ala Met His Ala Val Ile Asp Arg Gln Arg Asn His
 290 295 300
 Gly Ile His Phe Arg Val Leu Ala Lys Cys Leu Arg Leu Ser Gly Gly
 305 310 315 320
 Asp His Leu His Ser Gly Thr Val Val Gly Lys Leu Glu Gly Asp Lys
 325 330 335
 Ala Ser Thr Leu Gly Phe Val Asp Leu Met Arg Glu Asp His Ile Glu
 340 345 350
 Ala Asp Arg Ser Arg Gly Val Phe Phe Thr Gln Asp Trp Ala Ser Met
 355 360 365
 Pro Gly Val Leu Pro Val Ala Ser Gly Gly Ile His Val Trp His Met
 370 375 380
 Pro Ala Leu Val Glu Ile Phe Gly Asp Asp Ser Val Leu Gln Phe Gly
 385 390 395 400
 Gly Gly Thr Leu Gly His Pro Trp Gly Asn Ala Pro Gly Ala Thr Ala
 405 410 415
 Asn Arg Val Ala Leu Glu Ala Cys Val Gln Ala Arg Asn Glu Gly Arg
 420 425 430
 Asp Leu Tyr Arg Glu Gly Gly Asp Ile Leu Arg Glu Ala Gly Lys Trp
 435 440 445
 Ser Pro Glu Leu Ala Ile Ala Leu Asp Leu Trp Lys Glu Ile Lys Phe
 450 455 460
 Glu Phe Glu Thr Met Asp Lys Leu
 465 470

<210> SEQ ID NO 57

<211> LENGTH: 111

-continued

<212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: F2A-10 rbcS

<400> SEQUENCE: 57

```
Met Ser Met Lys Thr Leu Pro Lys Glu Arg Arg Phe Glu Thr Phe Ser
  1           5           10           15
Tyr Leu Pro Pro Leu Ser Asp Arg Gln Ile Ala Ala Gln Ile Glu Tyr
          20           25           30
Met Ile Glu Gln Gly Phe His Pro Leu Ile Glu Phe Asn Glu His Ser
          35           40           45
Asn Pro Glu Glu Phe Tyr Trp Thr Met Trp Lys Leu Pro Leu Phe Asp
          50           55           60
Cys Lys Ser Pro Gln Gln Val Leu Asp Glu Val Arg Glu Cys Arg Ser
          65           70           75           80
Glu Tyr Gly Asp Cys Tyr Ile Arg Val Ala Gly Phe Asp Asn Ile Lys
          85           90           95
Gln Cys Gln Thr Val Ser Phe Ile Val His Arg Pro Gly Arg Tyr
          100          105          110
```

<210> SEQ ID NO 58
 <211> LENGTH: 2354
 <212> TYPE: DNA
 <213> ORGANISM: Synechocystis sp. PCC6803
 <220> FEATURE:
 <221> NAME/KEY: misc_feature
 <222> LOCATION: (1) ... (2354)
 <223> OTHER INFORMATION: 5' sequence flanking rbcLS for vector pGR-2a

<400> SEQUENCE: 58

```
aaatcgacgc gtgttaccag attgcctaaa cccttagctc ccgtgggggc caaccttttt    60
tagattggca attgcgctat ctacaacagc agggttttcg gcgatcgctc ctttctacgg    120
gttatctggc agaaaaagtg gcggcctatg ctcaagatgc cgatattgtt gacatggcga    180
tcgcctgtgt ggcggaaatg gaaccgttgg gaacagcggg gggatttgtc aatgcggtta    240
atcaccatgg ttttagagaa ctaacaccgg ctggctcgtt gcttaacggc gactcgttaa    300
ttgtgacgga ttatcgggtt ctggttggcg agttagagga tgacagcgtt gatggggtaa    360
ttttggcgct tcatgtgcc gatgcttccc gttttggctc cttaaaggtt aatagtcaag    420
gggaattgct acaatttgca gaaaagcaag ccggagccgg cgtgattaat agtggggttt    480
atctccttgg cgatcgctg ttggcccggg ttcccgccca cagaccctta agttttgagt    540
atgatgtggt cccacattg ttggcccagg gagccaaaat caaagtccat gctgtggaag    600
ctcccttttt agatattggc accccgaaa cattagccca ggcgggggaa tttatccaat    660
ccctcggtag gttgaaccga attcaagacc tagacaaata gcttaaaatg agaagctaac    720
tgagaaatta actaagtttt gtaaattttg gtttgccggg gcgagcgtca cgatgggtaa    780
acggacaagg cggttttggg ctttagcttt ttctttgctg atggggggcc tgatttatct    840
gggcaataca ccgtcggcct tggttttcac cgaggaacaa aagctactgt tgcaatcctg    900
gcgtttggtc aaccaatcct atctcgatga aacctttaac catcaaaatt ggtggctggt    960
gcgggagaag tacgttaaac gtcccctccg gaaccgggaa gaaacctaca cggcgatcga   1020
agaaatgctc gctaccctgg atgaaccctt taccgctta ctgcgtccgg aacagtacgg   1080
caatctccag gtgaccacca ctggtgagct atcgggggta ggtctgcaaa tcaacatcaa   1140
ccctgaaacc aaccagttag aaattatggc cccctggcc ggttcccctg cggaggaggc   1200
```


-continued

```

cgggctgcaa ccccatgacc aaatTTTggc gatcgacggt gtagataccc aaaccctgag 1260
cttagacgaa gcagcggcca gaatgcgggg cccaaaaaac accaaagttt ccctggaaat 1320
tctgtcagcg ggcaccgaag taccCCAaga atttaccctg actcggcagt taatttccct 1380
cagtccggtg gcggcccaat tggacgattc ccgcccaggt caatcgggtg gttacattcg 1440
cctcagtcaa tttagtGCCa atgcctataa agaagtagcc cacgctctgc atcaacttga 1500
ggaacagggg gccgacggtt atatcTTgga tttgcgtaac aaccCCggtg gttactcca 1560
ggctggTatt gacattgctc ggttGTggtt accgGaaagc accattgtct acaccgTtaa 1620
tcgccaaggc acccaggaaa gtttCActgc caatggagaa gcggcgaccg atcgcccgtt 1680
ggtggtgTtg gtcaaccagg gtactGCCag tgccagcGaa atTTtagccg gagctTTgca 1740
ggataatcag cgggccactc tagtggggga aaaaacTTT ggtaagggtt tgattcaatc 1800
ctgtTTgaa ctatccgatg gggccggcat tgccgtcAcg gtggccaaat acgaaacCCC 1860
ccaacatcac gacatccata aactgggcat tatgcccgat gaagtggTgg agcaacCCct 1920
gattagcttt gcgGaaatta cttccccgc cgatgtGcaa taccaagccg ccttagattt 1980
gctcaccgga ggagtggcaa tcgcccataa atcttcttca attcccGca tggcaacggc 2040
tcacaagccc aactaatcac catttggaca aaacatcagg aattctaatt agaaagtcca 2100
aaaattgtaa tttaaaaaac agtcaatgga gagcattgcc ataagtaaag gcatcccctg 2160
cgtgataaga ttaccttCag aaaacagata gttgctgggt tatcgCagat ttttctcgca 2220
accaaataac tgtaataat aactgtctct gggcgacgg taggctttat attgccaat 2280
ttcggccgtg ggagaaagct aggtattca atgtttatgg aggactgatc tagacctgac 2340
cacgtacgt cagg 2354

```

<210> SEQ ID NO 59

<211> LENGTH: 2251

<212> TYPE: DNA

<213> ORGANISM: Synechocystis sp. PCC6803

<220> FEATURE:

<221> NAME/KEY: misc_feature

<222> LOCATION: (1) ... (2251)

<223> OTHER INFORMATION: 3' sequence flanking rbcLS for vector pGR-2a

<400> SEQUENCE: 59

```

gagctcgTtg gtaaattgga aggggaacgg ggtatcacca tgggcttCgt tgacctcatg 60
cgcgaaagatt acgttgagga agatcgctcc cggggTattt tcttCacca agactatgcc 120
tccatgcctg gcaccatgcc cgtagcttcc ggtggtatcc acgtatggca catgcccgcg 180
ttggtgGaaa tcttcggTga tgattcctgc ttacagtttG gtggtggtac tttgggtcac 240
ccctggggta atgctcccgg tgcaaccgct aaccgtgTtg ctttGgaagc ttgtgttcaa 300
gctcggaaag aaggtcGtaa cctggctcgc gaagGtaatg acgttatccg ggaagcctgt 360
cgttggTccc ctgagttggc cgccgcctgc gaactctgga aagagatcaa gtttgagttc 420
gaggccatgg atacccteta aaccggTggt tggattgtcg gagttgtact cgTccgTtaa 480
ggatgaacag ttcttcgggg ttgagtctgc taactaatta gccattaaca gcggcttaac 540
taacagTtag tcattggcaa ttgtcaaaaa attgttaatc agccaaaacc cactgcttac 600
tgatgttcaa cttcgacagc aatttaccAA ttaccgggta gagtgTtcat gcaactaag 660
cacatagctc aggcaacagt gaaagtactg caaagttacc tcacctacca agccgttctc 720
aggatccaga gtgaactcgg ggaaaccaac cctcccagG ccatttggTt aaaccagtat 780

```

-continued

ttagccagtc acagtattca aaatggagaa acgtttttga cggaactcct ggatgaaaat	840
aaagaactgg tactcaggat cctggcggta agggaagaca ttgccgaatc agtgtagat	900
tttttgcccg gtatgaccg gaatagctta gcggaatcta acatcgccca ccgcccgat	960
ttgcttgaac gtctgaccg taccgtagcc gaagtcgata atttccttc ggaaacctcc	1020
aacggagaat caaacaacaa cgattctccc ccgtcctaac gtagtcatca gcaaggaaaa	1080
cttttaaatc gatgaaaact ttacccaaag agcgcgcta cgaaacctt tcttacctgc	1140
ccccttaac cgatcaacag attgctaaac aggttgagtt tctgtagac cagggcttta	1200
ttcccggcgt ggaatttgaa gaagaccccc aaccgaaac ccacttctgg accatgtgga	1260
aactgcctt ctttgggtgt gccactgcca acgaagttct agccgaagta cgggaatgtc	1320
gttctgagaa tcccactgc tacattcggg tgattggtt cgacaatc aaacagtgc	1380
agactgtaag ctttattgtc cacaaacca accaaaacca aggccgttac taagttacag	1440
ttttggcaat tactaaaaa ctgacttcaa ttcaatgta gcccgctccc gcgggtttt	1500
tgttgctttt tcacagtgc tataggtaat cagcaacaca atacggcct gttctttgga	1560
cagttttgt ataagtga ccgcatcctg accggatttt ttatctaagt ggggaattgt	1620
caattgtcaa ttaaagctaa gtttactaa tgttttagaa ggcattgtcg attgaaaata	1680
agggttgaat ggagaaaatt ttgagccttt gtcaaagata aaaatttatt tcaacagttt	1740
tttaactagc cgaaccagag aatgaccag tggcgtgac tttgctccc agttttgtt	1800
agaaattacc ctcaagaagt aatctaataa taaacctaac cgaataattt cccaggggag	1860
tattccggaa aaccatggtt aaacttactt gccatcccc atggtaaaat tgcaacgatt	1920
ttgatcaaag tctaatttt tttgtaaagc ttttagtaat cttctgatt tcccatgaa	1980
gctcatgat tcccgtggca gaattttcgg catagtcagc ctgttgatc tgggggccc	2040
cttgatcacc ctcatgtag ctgtgggaat tttcgttctg ccgggcagtt ctggcaaaag	2100
cattcttgcc caagccaacg ccgcttccat tgaattgacg accattgtcc ggggattaaa	2160
cgtattagat ccccaggtgg tgctggatga gtttaaagcc gaaaaacca acatcattat	2220
tcgcaatcaa ccggctggcc agggcggccg c	2251

<210> SEQ ID NO 60

<211> LENGTH: 1594

<212> TYPE: DNA

<213> ORGANISM: Synechocystis sp. PCC 6803

<220> FEATURE:

<221> NAME/KEY: misc_feature

<222> LOCATION: (1)...(1594)

<223> OTHER INFORMATION: 5' sequence flanking rbcLS for vector pGR-2b

<400> SEQUENCE: 60

tttcgcgcta cgcgtgtaaa cggacaaggc ggttttgggc tttagctttt tctttgctga	60
tgggggccc gatttatctg ggcaatacac cgtcggcctt ggctttcacc gaggaacaaa	120
agctactggt gcaatcctgg cgtttggtca accaatccta tctcgatgaa acctttaacc	180
atcaaaattg gtggctgttg cgggagaagt acgttaaacy tcccctccgg aaccgggaag	240
aaacctacac ggcgatcgaa gaaatgctcg ctacctgga tgaaccctt acccgcttac	300
tgcgtccgga acagtacggc aatctccagg tgaccaccac tggtageta tgggggtag	360
gtctgcaaat caacatcaac cctgaaacca accagttaga aattatggcc cccctggccg	420
gttcccctgc ggaggaggcc gggctgcaac cccatgacca aattttggcg atcgacggtg	480
tagataccca aaccctgagc ttagacgaag cagcggccag aatgcggggc ccaaaaaaca	540

-continued

```

ccaaagtttc cctggaaatt ctgtcagcgg gcaccgaagt accccaagaa tttaccctga 600
ctcggcagtt aatttcctc agtccggtgg cggccaatt ggacgattcc cgcccaggtc 660
aatcgggtggg ttacattcgc ctcagtcaat ttagtgccaa tgcctataaa gaagtagccc 720
acgctctgca tcaacttgag gaacaggggg cgcagcggta tatcttggat ttgcgtaaca 780
accccgggtgg cttactccag gctgggtattg acattgctcg gttgtgggta ccggaaagca 840
ccattgtcta caccgttaat cgccaaggca cccaggaaag tttcactgcc aatggagaag 900
cggcgaccga tcgcccgttg gtgggtgttg tcaaccaggg tactgccagt gccagcgaaa 960
ttttagccgg agctttgcag gataatcagc gggccactct agtgggggaa aaaacctttg 1020
gtaagggttt gattcaatcc ttgtttgaac tatccgatgg ggccggcatt gccgtcacgg 1080
tggccaaata cgaaaccccc caacatcacg acatccataa actgggcatt atgcccgatg 1140
aagtgggtgga gcaaccctg attagctttg cgaaattac tcccccgcc gatgtgcaat 1200
accaagccgc cttagatttg ctcaccggag gagtggcaat cgcccataaa tcttcttcaa 1260
tccccgcat ggcaacggct cacaagccca actaatcacc atttggaaa aacatcagga 1320
attctaatta gaaagtccaa aaattgtaat ttaaaaaaca gtcaatggag agcattgcca 1380
taagtaaagg catcccctgc gtgataagat taccttcaga aaacagatag ttgctggggt 1440
atcgcagatt tttctcga ccaataact gtaataata actgtctctg gggcgacgg 1500
aggctttata ttgccaatt tcgcccgtgg gagaaagcta ggctattcaa tgtttatgga 1560
ggactgatct agatgtaca aagccaaagc aggg 1594

```

<210> SEQ ID NO 61

<211> LENGTH: 1624

<212> TYPE: DNA

<213> ORGANISM: *Synechocystis* sp. PCC6803

<220> FEATURE:

<221> NAME/KEY: misc_feature

<222> LOCATION: (1) ... (1624)

<223> OTHER INFORMATION: 3' sequence flanking rbcLS for vector pGR-3a

<400> SEQUENCE: 61

```

accttagagc tcataatggt gaccgcatcc tgaccggatt ttttatctaa gtggggaatt 60
gtcaattgtc aattaaagct aagttctact aatgttttag aaggcattgt cgattgaaaa 120
taagggttga atggagaaaa ttttgagcct ttgtcaaaga taaaaattta tttcaacagt 180
tttttaacta gccgaaccag agaatgacct agtggcgctg actttgctcc cgagtttttg 240
ttagaaatta ccctcaagaa gtaatctaata aataaaccta accgaataat tcccagggg 300
agtattccgg aaaacctagg ttaaaacttac ttgccatccc ccatggtaaa attgcaacga 360
ttttgatcaa agtcctaatt tttttgtaaa gcttttagta atccttctga ttttcccatg 420
aagctcatcg attcccgtgg cagaattttc ggcatagtea gcctgttggg tctggggggcc 480
gccttgatca tcctcatggt agctgtggga attttcgttc tgccgggcag ttctggcaaa 540
agcattcttg cccaagccaa cgccgcttcc attgaattga cgaccattgt ccggggatta 600
aacgtattag atcccaggt ggtgctggat gaggttaaag ccgaaaaaac caacatcatt 660
attcgcaatc aaccggctgg ccagggtggag gtagtgaatg tgcaggaact ccctcgcaat 720
ttagcagtgc cccagcctga tggttccgtc aaatctctgc cggatcctcg gccagagtct 780
aattacagcc gggatatgct cctgaccctc aaaggtaggg gggatttcac ctccaccggc 840
atggttttag ggggacaaaa ggtgaaaatt ggcacggttt tagaattaga aggcaaaaac 900

```


-continued

tataacttca atgccagtgt ggtgggcatc aatcaaccaa agtgaccaa gtattagatt	960
agtcgggccc ccgagaattg ctggtggctg cccaaagttt tgctgtaccc tgggtaaggg	1020
tgacagattt ggaaaaggta atggaatgga acgagagtct tctccggctc actggtgctt	1080
ttgtactggg atcgaccctg ggcattgaac ggcagtggcg ccaacggatg gcgggcttgc	1140
gtactaatac cttggtggcc attggagctg cattgtttgt gattgtttct gtctcacca	1200
atcatgacag cagtcccacc cgaattcctg cccaaattgt ctccggcatt ggttttctgg	1260
cggggggagt aattctcaag gaaggcttaa ctgtaaggg gctaaatag gcggcgaccc	1320
tctggtgttc agcggcggtg ggcaccctct gtggtcaagg gctgttttct gaggetgtgc	1380
ttggctcgat gatggttttg gtggccaaca ttgccctgcg gcctctgagc acgtttatta	1440
accaccaacc catgcatagc actgaattgg agtgccatta tctttgtcac ttggtatgtc	1500
ggggggatga ggagcgcaat gtgcgacgca ttttcttga ttccttagcg gaaataaaga	1560
atattaaatt acggtctttg cggagccatg atttagatga gtttaacctg cggccgcttc	1620
cctt	1624

What is claimed is:

1. An isolated or recombinant Rubisco large subunit polypeptide comprising an amino acid sequence that has at least 99% sequence identity-to SEQ ID NO: 11 and at least one of the following residues: (a) an isoleucine at position 454, (b) a valine at position 84, (c) a lysine at position 158, (d) a leucine at position 166, and (e) a methionine at position 317.

2. The isolated or recombinant polypeptide of claim 1, which comprises the amino acid sequence listed in SEQ ID NO: 11 or the amino acid sequence listed in SEQ ID NO:11 having conservative mutations at less than 1% of the positions.

3. The isolated or recombinant polypeptide of claim 1, wherein the amino acid sequence further comprises at least one amino acid residue selected from the group consisting of:

D at position 92; F at position 93; L at position 113; L at position 116; L at position 117; L at position 127; A at position 129; V at position 137; I at position 139; Y at position 141; L at position 142; S at position 149; G at position 154; M at position 209; Q at position 219; E at position 220; E at position 223; A at position 225; T at position 232; Q at position 246; E at position 249; A at position 252; I at position 257; T at position 259; G at position 269; S at position 276; Y at position 280; L at position 286; A at position 297; K at position 303; T at position 304; Q at position 322; T at position 325; R at position 336; Q at position 337; T at position 338; I at position 343; Q at position 345; L at position 346; S at position 349; F at position 350; P at position 352; E at position 353; N or T at position 356; N at position 359; D at position 362; G at position 366; F at position 372; A at position 373; A at position 389; I at position 415; and R at position 450.

4. The isolated or recombinant polypeptide of claim 1, wherein the amino acid sequence comprises at least two

25

amino acid residues selected from the group consisting of: V at position 84, K at position 158, L at position 166, M at position 317, and I at position 415.

5. An isolated polypeptide having Rubisco specific activity comprising the Rubisco large subunit polypeptide of claim 1, wherein the amino acid sequence has an isoleucine at position 454 and wherein the polypeptide is capable of a higher k_{cat} than the wild-type polypeptide encoded by SEQ ID NO:1.

6. An isolated polypeptide having Rubisco specific activity comprising the Rubisco large subunit polypeptide of claim 1, wherein the amino acid sequence has a valine at position 84 and wherein the polypeptide is capable of a lower K_M than the wild-type polypeptide encoded by SEQ ID NO:1.

7. An isolated polypeptide having Rubisco specific activity comprising the Rubisco large subunit polypeptide of claim 1, wherein the amino acid sequence has a lysine at position 158 and wherein the polypeptide is capable of a lower K_M than the wild-type polypeptide encoded by SEQ ID NO:1.

8. An isolated polypeptide having Rubisco specific activity comprising the Rubisco large subunit polypeptide of claim 1, wherein the amino acid sequence has a leucine at position 166 and wherein the polypeptide is capable of a lower K_M than the wild-type polypeptide encoded by SEQ ID NO:1.

9. An isolated polypeptide having Rubisco specific activity comprising the Rubisco large subunit polypeptide of claim 1, wherein the amino acid sequence has a valine at position 84 and wherein the polypeptide is capable of a lower K_M than the wild-type polypeptide encoded by SEQ ID NO:1.

* * * * *